APRIL 8-13

PROGRAM GUIDE

Continuing Medical Education Activity - AMA PRA Category 1 Credits™ available

AACR.ORG
#AACR22
JOIN US AT OUR EXHIBITOR SPOTLIGHT THEATER

Utilizing immunosequencing to study oncology targets and therapies

Monday, April 11 | 12:30-1:30pm
Theater B | Exhibit Hall
Ernest N. Morial Convention Center, New Orleans, LA

Join us and learn about:
• The principles behind the immunoSEQ technology
• Immuno-oncology target identification using coupled immunogenomics
• Transgenic T-cell receptor adoptive cell therapies: addressing epigenetic suppression & optimizing therapies with immunosequencing

PATRICK RABER, PhD
Director, Business Development, Adaptive Biotechnologies

KELLIE N. SMITH, PhD
Assistant Professor of Oncology Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine

THEODORE SCOTT NOWICKI, MD, PhD
Assistant Professor-in-Residence Pediatric Hematology/Oncology University of California Los Angeles

immunoSEQ.com
**TABLE OF CONTENTS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>WELCOME LETTER</td>
</tr>
<tr>
<td>2-21</td>
<td>COMMITTEES</td>
</tr>
<tr>
<td>2</td>
<td>Annual Meeting Program Committee</td>
</tr>
<tr>
<td>2</td>
<td>Scientific Program Subcommittee Members</td>
</tr>
<tr>
<td>5</td>
<td>Clinical Trials, Education, and Satellite Educational Symposia Committees</td>
</tr>
<tr>
<td>5</td>
<td>AACR Officers, Directors, and Foundation</td>
</tr>
<tr>
<td>6</td>
<td>Standing Committees</td>
</tr>
<tr>
<td>9</td>
<td>Specialty Award Committee</td>
</tr>
<tr>
<td>9</td>
<td>Scientific Achievement Awards Committees</td>
</tr>
<tr>
<td>12</td>
<td>Scientific Grant Review Committees</td>
</tr>
<tr>
<td>14</td>
<td>Specialty Groups and Committees</td>
</tr>
<tr>
<td>15</td>
<td>Scientific Task Forces</td>
</tr>
<tr>
<td>18</td>
<td>Scientific Working Groups</td>
</tr>
<tr>
<td>20</td>
<td>Constituency Groups</td>
</tr>
<tr>
<td>21</td>
<td>AACR 50-Year Members and Honorary Members</td>
</tr>
<tr>
<td>22-26</td>
<td>SUPPORTERS</td>
</tr>
<tr>
<td>22</td>
<td>Annual Meeting 2022 Supporters</td>
</tr>
<tr>
<td>23</td>
<td>The Scientific Program</td>
</tr>
<tr>
<td>23</td>
<td>AACR Awards and Lectureships</td>
</tr>
<tr>
<td>24</td>
<td>AACR Runners for Research 5K Run/Walk</td>
</tr>
<tr>
<td>24</td>
<td>AACR Travel Grants and Scholar Awards</td>
</tr>
<tr>
<td>25</td>
<td>Supporters</td>
</tr>
<tr>
<td>25</td>
<td>Research Grants and Fellowships</td>
</tr>
<tr>
<td>26</td>
<td>Special Conference Supporters for 2021-2022</td>
</tr>
<tr>
<td>26</td>
<td>Sustaining Members</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER IMAGE:**

*Images, clockwise:*
- A cancer survivor in treatment, nanotechnology (purple), a technician in the lab, cancer cell mitosis, tumor evolution (blue/red), a cancer survivor post-treatment, epigenetics (orange/yellow), a young investigator in the lab, animal models (white), a pediatric patient, drug development (green), a researcher in the lab, DNA/human genome (green/orange).

©2022 American Association for Cancer Research
TABLE OF CONTENTS (cont’d)

27-42 GENERAL INFORMATION

43-53 MAPS
43 New Orleans Marriott Second Floor
44 New Orleans Marriott Third Floor
45 New Orleans Marriott Fourth Floor
46 New Orleans Ernest N. Morial Convention Center Exhibit Floor

48 New Orleans Ernest N. Morial Convention Center First Floor
50 New Orleans Ernest N. Morial Convention Center Second Floor
52 New Orleans Ernest N. Morial Convention Center Third Floor

SCIENTIFIC ACHIEVEMENT AWARDS

AACR Award for Lifetime Achievement in Cancer Research
AACR Award for Outstanding Achievement in Basic Cancer Research
AACR Award for Outstanding Achievement in Blood Cancer Research
AACR Award for Outstanding Achievement in Chemistry in Cancer Research
AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research
AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
AACR Team Science Award
AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research

AACR-Irving Weinstein Foundation Distinguished Lectureship
AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research
AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship
AACR-Princess Takamatsu Memorial Lectureship
AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research
AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research
AACR-Women in Cancer Research Charlotte Friend Lectureship
Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
The Victoria’s Secret Global Fund for Women’s Cancers Meritorious Awards, In Partnership with Pelotonia & AACR
COVID-19 GUIDELINES

The safety of Annual Meeting attendees is the AACR’s highest priority. We are committed to providing a safe and comfortable environment for attendees to enjoy a week of great science and discussions. Therefore, a summary of the policies and mitigation measures that have been implemented for the AACR Annual Meeting 2022 are below.

Vaccinations
We require all attendees and exhibitors to be fully vaccinated and to submit proof of vaccination prior to entry into the convention center. A list of currently accepted COVID-19 vaccines can be found on the U.S. Center for Disease Control website. ([https://www.cdc.gov/coronavirus/2019-ncov/travelers/proof-of-vaccination.html#covid-vaccines](https://www.cdc.gov/coronavirus/2019-ncov/travelers/proof-of-vaccination.html#covid-vaccines)).

Mask Recommendation
We strongly recommend that all speakers, attendees, convention center personnel, vendors, and AACR employees wear a KN95 mask indoors for large gatherings, however, it is not required. Attendees will be provided with one KN95 mask with their registration materials.

Testing
Onsite testing is available in the lobby of Hall H. The cost is partially subsidized by the AACR. Appointments are recommended and walk-ins will be accepted. Please see AACR.org/AACR2022 for additional details.

Social Distancing
Session rooms, poster halls, and exhibit floors will be designed to allow for social distancing.

Cleaning
There will be 30-minute breaks between each session to allow for thorough cleaning of the rooms. There will be hourly cleaning of high touch areas and easy access to sanitizing stations throughout the convention center.
How are you unmasking tumor heterogeneity and tracing clonal evolution?

Visit booth 1910 or QR for presentation and poster details.
Your Trusted Supplier of in vivo MAbs

Accelerate your research from pilot to pre-clinical phases.
Rely on us to deliver the largest catalog of MAbs formulated specifically for in vivo use and provide customizable antibody production services - backed by 25 years of experience.

- Immune Checkpoint Inhibitors
- Mouse Cell Specific Depletion
- Cytokine Neutralization
- Biosimilar Antibodies
- Agonistic Antibodies
- Antibody Production Services

VISIT US AT
BOOTH #1353

SPIN TO WIN

bioxcell.com
Hope is where innovation meets determination.

City of Hope is advancing cancer treatment by utilizing our expertise in clinical research to develop life-saving therapies. With nearly 800 patients treated in immune effector therapy trials, including CAR T cell therapy, we continue to advance treatment possibilities to save the lives of more patients. **Hope is here.**

**Visit us at Booth #1801 to discover our leading-edge research and treatment options**

City of Hope physician Leo Wang, M.D., Ph.D.
Visit the Merck Booth and Learn More About KEYTRUDA

• Approved indications
• Resources for health care professionals
• The Merck Access Program
• KEY+YOU Patient Support Program
We offer products & services for:

Diagnostic Manufacturing
We have expertise in molecular diagnostics, antigen, and serologic testing.

Commercial Assay Development
Custom services with quality control & timely delivery of projects that cover a breadth of application areas.

Drug Discovery Research
We have an extensive portfolio of high quality antibodies and nanoparticles, as well as custom services to support your research.

Powered by our brands:

[Logos of BETHYL LABORATORIES, INC., nanoComposix, Empirical bioscience, and ARISTA BIOLOGICALS inc.]

Learn more: fortislife.com
SAVE THE DATE!

JOIN US IN ORLANDO
AACR ANNUAL MEETING
2023
APRIL 14-19

Robert H. Vonderheide, MD, DPhil
Director, Abramson Cancer Center
of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Chair, 2023 Program Committee

For more information as it becomes available, visit AACR.org

American Association for Cancer Research
Trusted and Timely Publication of Scientific Discoveries

PRIORITIZING AUTHOR AND READER NEEDS

NEW!

AACRJournals.org

American Association for Cancer Research®

AACRJournals.org
Dear Members and Friends of the AACR,

Whether you are joining us in person in New Orleans or participating virtually, we are excited to welcome you to the 113th Annual Meeting of the American Association for Cancer Research (AACR)! After two years of holding virtual Annual Meetings, we are thrilled to be in the vibrant city of New Orleans—a diverse city that represents the diverse community that we serve—to celebrate our return to an in-person meeting.

Through the hard work and expert guidance from members of our Annual Meeting Program Committee, Education Committee, and Clinical Trials Committee, we have developed a multidisciplinary program that embodies the theme of this year’s meeting—“Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.” This theme reflects our focus on the myriad of processes that contribute to cancer development and, in particular, how those processes vary from patient to patient depending on their environment, lifestyle, and germline genetics. Our concerted goal is to put patients at the center of the meeting’s content, to understand how diversity and cancer disparities across populations affect their outcomes, and to bring the best science to bear on transforming those outcomes into long-term survival. Our pursuit of that goal is supported by the participation and input of our patient advocate community, and we welcome those advocates who are in attendance.

The Opening Plenary Session will address the theme of the meeting and set the tone for a week of cutting-edge science. Daily plenary sessions will address critical topics in the field, including precancer discovery science, cancer health disparities, precision medicine for immuno-oncology, and tumor evolution and therapeutic resistance.

The scientific sessions, including the Educational Program, will be livestreamed to the virtual meeting platform, and in-person and virtual attendees are encouraged to submit questions to the speakers using the platform or the meeting App. We are thrilled to have leading experts from around the world join us in New Orleans to present the latest discoveries from across the continuum of basic, translational, clinical, prevention, and population research.

Significant progress has been made since last year’s meeting. A few sessions, including provocative forums, will focus on the impact of COVID-19 on cancer research, patient care, and clinical trials, discussing some of the lessons learned during the pandemic that may be applied to research and care as we move forward. Sessions will also highlight vital areas in immuno-oncology, drug discovery and development, and regulatory science and public policy. And on this 40th anniversary of the discovery of the first human oncogene, we will celebrate progress in the development of therapeutics for KRAS, which has previously been considered an undruggable target. Several of the major scientific sessions will showcase the work of the 2022 AACR NextGen Stars. A total of 14 emerging early-career scientists have been selected as NextGen Stars through a competitive application process, and we look forward to their presentations.

In addition to our return to an in-person meeting, this year also marks a major milestone in the history of our organization—the 115th anniversary of the founding of the AACR in 1907. Throughout the meeting we will be celebrating the rich history of progress in cancer research along with the AACR’s pivotal role at the forefront of every breakthrough against cancer. On Sunday, April 10, a video acknowledging the anniversary will be shown during our Opening Ceremony, and AACR Past President and AACR Academy President Charles L. Sawyers, MD, FAACR will deliver a special lecture on “The future of cancer research in transforming patient outcomes” during the Opening Plenary. We also invite you to walk through the Landmarks in Cancer Research 1907-2022 Exhibit in the Hall F lobby that chronicles the events and discoveries that have had a profound effect on advancing the knowledge of the causes, detection, diagnosis, treatment, and prevention of cancer throughout the rich history of the AACR.

We deeply appreciate the work done by members of the Scientific Program Committee who reviewed nearly 5,800 proffered papers that were submitted to the Annual Meeting and organized them into poster sessions and minisymposia. About 1,400 posters will be presented as posters only, but every one of the nearly 3,800 posters presented in person at the meeting will have a companion eposter presentation as well. These proffered papers include 237 clinical trials that will be presented in Clinical Trials Plenary Sessions, minisymposia, and poster sessions. During the Clinical Trials Plenary Sessions, trials will be paired with a presentation focusing on the science behind the trial and its implications for delivering improved care to patients.

Finally, we extend our gratitude to the corporations, organizations, and foundations that have provided generous support for the AACR Annual Meeting 2022. These valued partners enable us to host this critically important forum that lays the groundwork for fruitful collaborations and advances in cancer research. Their commitment also fosters the professional advancement of the next generation of leaders in cancer research through their support of numerous scientific sessions, research grants, scholar-in-training awards, and scientific merit awards.

Thank you for joining us! We look forward to an exciting week of spectacular scientific talks, stimulating discussions among colleagues, and innovative ideas about how to markedly decrease cancer incidence, morbidity, and mortality around the world. Please plan to attend the wrap-up Plenary Session on Wednesday, April 13, to hear about some of the highlights from the week. And if you miss anything on this huge program, recordings of the scientific and educational sessions may be viewed on our virtual meeting platform through July 13.

Sincerely,

Marcia R. Cruz-Correa, MD, PhD Chair, 2022 Program Committee
David A. Tuveson, MD, PhD, FAACR President, 2021-2022
Margaret Foti, PhD, MD (hc) Chief Executive Officer, AACR
COMMITTEES

Annual Meeting Program Committee

Chair
Marcia R. Cruz-Correa

Vice Chairs
Sarah-Jane Dawson
Kojo Elenitoba-Johnson
Daniel Gomez
Roy S. Herbst
Helen E. Heslop
Katherine A. Janeway
Carl H. June
Miriam Merad
Augusto C. Ochoa
Woong-Yang Park
Varda Rotter
Yu Shyr
Mariana C. Stern
Danny R. Welch
Cheryl L. Willman
Timothy A. Yap

Cochairs
Julie R. Brahmer
Jennifer A. Doherty
Jeffrey A. Engelman
Claudia Fischbach
Gregory R. Friberg
Kevin L. Gardner
Robert A. Gatenby
Masanori Hatakeyama
Trey Ideker
Catriona H.M. Jamieson
Philip Jones
Beth Y. Karlan
Edison T. Liu
Ghecemy Lopez
Beth A. McCormick
Nicholas McGranahan
Ruben A. Mesa
William Pao
Kornelia Polyak
Martine Roussel
Anil K. Rustgi
Barbara Segarra-Vázquez
Lillian L. Siu
Julie Sutcliffe
Bin Tean Teh
Hongyang Wang
Clayton C. Yates

Scientific Program Subcommittee Members

Bioinformatics, Convergence Science, and System Biology

Bioinformatics and Computational Biology
Linghua Wang, Chair
Sheng Li
Sorana Morrissy
Sylvia K. Plevritis
Peter K. Sorgner

Convergence Science and Systems Biology
Benjamin D. Greenbaum, Chair
Paul C. Boutros
Benjamin J. Raphael

Chemistry

Drug Discovery, Design, and Delivery
Methvin Isaac, Chair
Dennis Hu
Ingo Hartung
Zaneta Nikolaus-Koleska

Structure and Chemical Biology
Nathaneal S. Gray, Chair
Brenda A. Schulman

Proteomics and Mass Spectrometry
Ahmed M. Aman, Chair

Clinical Research

Translational Research – Molecular Biology in Clinical Oncology
E. Scott Kopetz, Chair
Trevor G. Bivona
Ursula A. Matulonis

Pediatric Cancer – Clinical Investigations
Steven DuBois, Chair
Yael P. Mosse

Clinical Research in the Elderly
Chanita Hughes-Halbert, Chair
Martine Extermann

Clinical Research in Racial and Ethnic Minorities and Other Medically Underserved Populations
Chanita Hughes-Halbert, Chair
Martine Extermann

Biostatistics in Clinical Trials
J. Jack Lee, Chair

Immuono-oncology
Sherene Loi, Chair
Sarah Adams
Samuel E. Adunyah
Kristen M. Hege
Gal Markel
Saul Priceman
Robert H. Vonderheide

Radiation Oncology
Alec C. Kimmelman, Chair
Alice Ho

Surgical Oncology
Tari A. King, Chair
Lisa A. Newman

Clinical Endocrinology
Matthew J. Ellis, Chair
Khandan Keyomarsi

Survivorship Research and Supportive Care
Leslie L. Robison, Chair
Joshua G. Cohen

Biomarkers
Irene M. Ghobrial, Chair
Jill Bargonetti
Sarah-Jane Dawson
Maximilian Diehn
Justin F. Gainor
Susan E. Hankinson

Kenneth P. Olive
Martin G. Pomper
Pasi A. Jänne
Daniel S. Tan
Jeanne Tie
Samra Turajlic

Clinical Outcomes Research
Leslie L. Robison, Chair
Joshua G. Cohen

Real-World Data and Real-World Evidence
Philippe L. Bedard, Chair
Geoffrey R. Oxnard
Takayuki Yoshino

Precision Oncology
Philippe L. Bedard, Chair
Geoffrey R. Oxnard
Takayuki Yoshino

Endocrinology
Molecular, Preclinical, and Clinical Endocrinology
Matthew J. Ellis, Chair
Khandan Keyomarsi

Experimental and Molecular Therapeutics
Drug Discovery
Bruce A. Chabner, Chair
James E. Bradner
James L. Chen
Moshe Giladi
Kevin J. Harrington
Victoria M. Richon
Xiaojing (Gina) Wang

Mechanisms of Drug Action
Par Nordlund, Chair
Ivan Cornella-Taracido
Jaqueline Smith

Drug Resistance
Johann de Bono, Chair
Ryan B. Corcoran
Jos Jonkers
Andriy Marusyk
Daniela E. Matei
Katerina A. Politi
Shobha Vasudevan

Molecular Targets
James E. Audia, Chair
Helen X. Chen
James G. Christensen
William C. Hahn
Gottfried E. Konceny

Pharmacology, Pharmacogenetics, and Pharmacogenomics
Udai Banerji, Chair
Cory Abate-Shen
Chris H. Takimoto

Small Molecule Therapeutic Agents
Manuel Hidalgo, Chair
Rima S. Al-awar
Justin Bower
Alexander E. Drilon
Daniel A. Harki
Gordon B. Mills
Kathleen N. Moore
Chudi Ndubaku

Biological Therapeutic Agents
David S. Hong, Chair
Paulo C. Rodriguez

Gene and Vector-Based Therapy
Masato Yamamoto, Chair
Stephen J. Russell

Preclinical Radiotherapeutics
Katherine A. Vallis, Chair
Theodore A. Lawrence

Immunology
Tumor Immunobiology
Guangyong Peng, Chair
Gregory L. Beatty
George Coukos
Guangyong Peng
Matthew H. Spitzer
Tonya J. Spitzer
E. John Wherry
Lili Yang
Benjamin A. Youngblood

Immunotherapy: Preclinical
Cassian Yee, Chair
Joshua D. Brody
Olivera J. Finn
Thomas F. Gajewski
Stephen Gottschalk
James L. Gulley
Marcela V. Maus
William J. Murphy
Avery D. Posey
Marco Ruella
Padmanee Sharma
Weiping Zou

Molecular/Cellular Biology and Genetics
Cell Growth Signaling Pathways
Irwin H. Gelman, Chair
Chiara Ambrogio
Julian Downward
Andrew D. Hollenbach
Nima Sharifi

Cell Death
Moshe Oren, Chair
Suzanne Cory
Aaron D. Schimmer

Oncogenes and Tumor Suppressor Genes
Adam J. Bass, Chair
James V. Degregori
Tomoo Iwakuma
Nikolaus Schultz

Gene Regulation and Transcription Factors
Daniel Geoffrey Tenen, Chair
Martin Eilers
Douglas R. Hurst
Hari K. Koul

Epigenetics and Epigenomics
Jonathan R. Whetstine, Chair
Jason Scott Carroll
Kenneth P. Nephew
Bodour Salhia
S. Stephen Yi
COMMITTEES

Scientific Program Subcommittee Members (cont’d)

Cell Cycle
Sandra S. McAllister, Chair
J. Alan Diehl
Geoffrey I. Shapiro

DNA Damage and Repair
Alan D. D’Andrea, Chair
Fiona Simpkins
Elizabeth M. Swisher

Metabolism and Cancer
Karen H. Vousden, Chair
Navdeep S. Chandel
Christine Chio
Kayvan R. Keshari
Michael N. Pollak
Matthew G. Vander Heiden

Genomics
Victor E. Velculescu, Chair
Alberto Bardelli
Hannah K. Carter
Christina Curtis
Benjamin Haibe-Kains
Francesca Menghi

MicroRNAs and Other Noncoding RNAs
Isidore Rigoutsos, Chair
Muller Fabbri
Kate Lawrenson
Takahiro Ochiya

Cellular Stress Responses
Christopher D. Willey, Chair
Andrei V. Gudkov
Jason Moffat

Prevention, Early Detection, and Interception
Preclinical Prevention, Early Detection, and Interception
Victoria L. Seewaldt, Chair
Adriana Albini
Andrew T. Chan
Brian M. Wolpin

Clinical Prevention, Early Detection, and Interception
Eva Szabo, Chair
Ethan Dmitrovsky
Maria E. Fernandez
Scott M. Lippman

Implementation Science
Eva Szabo, Chair
Ethan Dmitrovsky
Maria E. Fernandez
Scott M. Lippman

Population Sciences
Population Sciences
Jennifer J. Hu, Chair
Michele L. Cote
Jane C. Figueiredo
Sheetal Hardikar
Dawn L. Hershman
Shehnaz K. Hussain
Susan L. Neuhausen
Brandon L. Pierce
Edward J. Trapido

Regulatory Science Policy
Regulatory and Science Policy
Gilbert S. Ommen, Chair
Roy L. Herbst

Science and Health Policy
Science and Health Policy
Kenneth C. Anderson, Chair

Tumor Biology
Nonclinical Models of Cancer
David A. Largaespada, Chair
Nabeel M. Bardeesy
David W. Cescon
Hirosi Nakagawa
Alice Soragni
Karina J. Yoon

Stem Cell Biology
Jane E. Visvader, Chair
Leslie A. Crews
Linjing Li
Ulrich G. Steidl

Tumor Adhesion
Katherine C. Fuh, Chair
Richard O. Hynes

Metastasis
Cimona V. Hinton, Chair
Yibin Kang
Mythreye Karthikeyan
Anna C. Obenauf
Ann Marie Pendergast
Erik W. Thompson
Lalage M. Wakefield

Angiogenesis
Sandra W. Ryeom, Chair
Dineo Khabele
Douglas M. Noonan

Tumor Microenvironment
Valerie M. Weaver, Chair
Thomas R. Cox
Mikala Egeblad
Neta Erez
Sunil R. Hingorani
Pepper J. Schedin
M. Sharon Stack
Timothy C. Wang
Elizabeth D. Williams

In Vivo Imaging
Jason S. Lewis, Chair
Carolyn J. Anderson
Sridhar Nimmagadda
Erik Sahai

Pediatric Cancer – Basic Science
Kimberly Stegmaier, Chair
Vivian Y. Chang
Sharon E. Plon
Nancy Ratner

Radiation Science
Robert G. Bristow, Chair
David R. Gius
Suzanne E. Lapi
Lilie L. Lin
Tumor Evolution and Heterogeneity
Carlo C. Maley, Chair
Samuel Aparicio
Nicholas E. Navin
Charles Swanton

Carcinogenesis
Zigang Dong, Chair
Kangdong Liu
Celeste Leigh Pearce
Igor Puzanov

Clinical Trials, Education, and Satellite Educational Symposia Committees

Clinical Trials Committee

Cochairs
Julie R. Brahmer
Timothy A. Yap

Members
Nita Ahuja
Benedito A. Carneiro
Ezra E.W. Cohen
William S. Dalton
Ruggero De Maria
Patrick M. Forde
Marina Chiara Garassino
Marcus DaSilva Goncalves
Susan Halabi
Roy S. Herbst
Virginia G. Kaklamani
Steven K. Libutti
Wendy B. London
Robert G. Maki
Katherine K. Matthay
Ignacio Melero
Ruben A. Mesa
Edith P. Mitchell
Pamela N. Munster
D. William Parsons
Akash Patnaik
Martine J. Piccart
Katy Rezvani
Stephen C. Rubin
Stefania Scala
Howard I. Scher
Padmanee Sharma
Weijing Sun
Naoko Takebe
Beverly A. Teicher
Margaret A. Tempero
Sara M. Tolaney
Nicholas C. Turner
Zev A. Wainberg
Colin D. Weekes
Evan Y. Yu
Sohrab Shah
Gregory H. Sonnenberg
Jennifer Tsui
Víctor E. Velculescu
Jovanny Zabaleta

AACR Satellite Educational Symposia Committee

Chair
Nina Bhardwaj

Members
Ryan B. Corcoran
Steven M. Dubinett

Education Committee

Chair
Lillian L. Siu

Cochairs
Trey Ideker
Martine Roussel
Mariana C. Stern

Members
Rima S. Al-awar
Adriana Albini
Nadine J. Barrett
Nina Bhardwaj
Ranjit S. Bindra
Gautam Borthakur
Lisa M. Cossens
Daniel D. De Carvalho
Marcia C. Haigis
Pasi A. Jänne
Giedre Krenciute
Karen T. Liby
Massimo Loda
Sherene Loi
Christine M. Lovly
Shiva Malek
Martin McMahon
Atsushi Ohtsu
Klaus Pantel
Martin G. Pomper
Camille C.R. Ragin
Renee Reams
Chris Sander

AACR Officers, Directors, and Foundation

AACR Officers and Directors

President
David A. Tuveson

President-Elect
Lisa M. Coussens

Immediate Past President
Antoni Ribas

Treasurer
William Hait

Chief Executive Officer
Margaret Foti

Members
Nina Bhardwaj
John D. Carpten
Marcia R. Cruz-Correa
Luis A. Diaz, Jr.
Keith T. Flaherty
Silvia Chiara Formenti
Elaine Fuchs
Susan M. Galbraith
Roy S. Herbst
COMMITTEES

AACR Officers, Directors, and Foundation (cont’d)

Standing Committees

Bylaws Committee
Chair
Michael A. Caligiuri
Members
Dafna Bar-Sagi
Roy S. Herbst
Elizabeth A. Platz
Trevor J. Pugh

Continuing Medical Education Committee
Chair
Steven T. Rosen
Members
Sarki A. Abdulkadir
Antonio T. Fojo
Karen A. Gelmon
Daniel A. Laheru
Bora Lim
Jennifer W. Mack
Edith P. Mitchell
Jean L. Nakamura
Ruth M. O’Regan
Mark E. Robson
Anita Villani
Evan Y. Yu

Education and Training Committee
Chair
Elaine R. Mardis
Members
Kimlin T. Ashing
Chetan Bettegowda
Nina Bhardwaj
Marcia R. Cruz-Correa
Chi Van Dang
Johann S. de Bono
Silvia Chiara Formenti
Obi Lee Griffith
Nada Jabado

AACR Officers, Directors, and Foundation

Trustees
Christiana Bardon
James V. Buzzitta
Lisa M. Coussens
Lauretta Chrys
Nancy E. Davidson
Faye Florence
Cathy Fraser
Judy E. Garber
William N. Hait
Tonya Hallett
Richard A. Heyman
Eleanor D. Kress
John E. Leonard
Glady H. Monroy
Antoni Ribas
Anil K. Rustgi
Stephen D. Ryan
Ajit Singh
Nancy Staisey
Gary Steele
David A. Tuveson

AACR Foundation for the Prevention and Cure of Cancer
Raymond N. DuBois,
Chair and President
Margaret Foti,
Secretary-Treasurer and Chief Executive Officer
Bayard D. Clarkson,
Founding Chairman of the Board and President Emeritus

AACR Officers, Directors, and Foundation

Peter A. Jones
Yibin Kang
Michelle M. Le Beau
Massimo Loda
Patricia M. LoRusso
Scott W. Lowe
Hiroyuki Mano
Gabor T. Marth
Gerrit A. Meijer
Ira Mellman
Victoria M. Richon
Yu Shyr
Avrum Spira
José G. Treviño II
Daniel D. Von Hoff
Elizabeth M. Jaffee, ex officio

Executive Committee
David A. Tuveson, President
Lisa M. Coussens, President-Elect
Antoni Ribas, Immediate Past President
William N. Hait, Treasurer
Margaret Foti, Chief Executive Officer

Exhibits Committee
Chair
Edward Chu
Members
Elana J. Fertig
Ajay Goel
Esther A. Obeng
Feyruz V. Rassool
Goli Samimi
Gina M. Sizemore
Rachel M. Syme
Ruoning Wang
Iain D.G. Watson
Additional appointments pending
Finance and Audit Committee

Chair
Cheryl L. Willman

Members
Alan Ashworth
Anna D. Barker
Michael A. Caligiuri
H. Shelton Earp III
Silvia Chiara Formenti
Charles S. Fuchs
Philip D. Greenberg
Eleanor D. Kress
John E. Leonard
Lisa A. Newman
Victoria M. Richon
Raphaël F. Rousseau
Stephen D. Ryan
Lillian L. Siu
John H. Stewart IV
Louis M. Weiner
Lisa M. Coussens, ex officio
William N. Hait, ex officio
David A. Tuveson, ex officio

International Affairs Committee

Chair
Elizabeth M. Jaffee

Members
Lewis C. Cantley
John D. Carpten
Susan M. Galbraith
Thomas W. Kensler
Patricia M. LoRusso
Antoni Ribas
Edison T. Liu
Elaine R. Mardis
Hitoshi Nakagama
Lillian L. Siu

Africa Regional Advisory Group

Chair
Lisa A. Newman

Members
Ernest Adjei
Francis Ali-Osman
Zodwa Dlamini
T. Peter Kingham
Frank McCormick
Miriam Mutebi
Hawa Nalwoga
Robert Newton
Ramou Njie
Folakemi T. Odedina
Kunle Odunsi
Timothy R. Rebbeck

India Regional Advisory Group

Chair
Anil K. Rustgi

Members
Varsha Gandhi
Aniruddha Ganguly
Pramod Garg
Indranil Mallick
Rita Mulherkar
Senthil K. Muthuswamy
Ashok K Saluja
Manish A. Shah
Anil Suri
Additional appointments pending

Latin America Regional Advisory Group

Chair
Eduardo M. Sotomayor

Members
Silvina Arrossi
Brady Beltran
Roger Chammas
Catterina Ferreccio

Southeast Asia Regional Advisory Group

Chair
Edison T. Liu

Members
Wee Joo Chng
Wen Son Hsieh
Tran Thanh Huong
Fuad Ismail
Kyaw Kan Kaung
Cecilia Ladines-Llave
Dan Laheru
Patrick Tan
Soo-Hwang Teo
Sumitra Thongprasert
Ashok Venkitaraman

Nominating Committee

Chair
Elizabeth M. Jaffee

Members
Dafna Bar-Sagi
Mary C. Beckerle
Michael A. Caligiuri
Michael B. Kastan
Pamela S. Ohashi
Jennifer A. Pietenpol
Valerie M. Weaver

Maria Romina Girotti
Luis Alonso Herrera
Vilma R. Martins
Raúl Murillo Moreno
Gabriel Rabinovich
Additional appointments pending

Maria Romina Girotti
Luis Alonso Herrera
Vilma R. Martins
Raúl Murillo Moreno
Gabriel Rabinovich
Additional appointments pending
## COMMITTEES

### Publications Committee

**Chair**
Victor E. Velculescu

**Members**
Adriana Albini  
Laura Fejerman  
Masanori Hatakeyama  
Catriona H.M. Jamieson  
Jos Jonkers  
Virginia G. Kaklamani  
Andrew Kung  
Jonathan D. Licht  
Ira Mellman  
Gordon B. Mills  
Kunle Odunsi  
Kenneth J. Pienta  
Joshua D. Rabinowitz  
Timothy R. Rebbeck  
David L. Rimm  
Mack Roach III  
Sheila K. Singh  
Sheila A. Stewart  
Miguel A. Villalona-Calero  

Additional appointments pending

### Science Education and Career Advancement Committee

**Chair**
Kathleen W. Scotto

**Members**
Miguel A. Villalona-Calero  

Additional appointments pending

### Science Policy and Government Affairs Committee

**Chair**
George D. Demetri

**Members**
Kenneth C. Anderson  
Anna D. Barker  
Smita Bhatia  
Michael A. Caligiuri  
Gerardo Colón-Otero  
Marcia R. Cruz-Correa  
Nancy E. Davidson  
B. Mark Evers  
David E. Fisher  
Lee M. Greenberger  
Roy S. Herbst  
Bianca N. Islam  
Elizabeth M. Jaffee  
Roy A. Jensen  
Judith S. Kaur  
Peter F. Lebowitz  
Steven K. Libutti  
Quynh-Thu Le  
Mia A. Levy  
Christine M. Lovly  
Ruben A. Mesa  
Stephen D. Nimer  
Gilbert S. Omenn  
Steven R. Patierno  
Raphael E. Pollock  
Brian M. Rivers  
Anil K. Rustgi  
Ellen V. Sigal  
Patricia Spears BS  
Sheila A. Stewart  
Alejandro Sweet-Cordero  
Cornelia M. Ulrich  
Robert H. Vonderheide  
George J. Weiner  
Cheryl L. Willman  
Robert A. Winn  
Douglas Yee  
Lisa M. Coussens, ex officio  
Antoni Ribas, ex officio  
David A. Tuveson, ex officio  

### Health Policy Subcommittee

**Chair**
Gilbert S. Omenn

**Members**
Karen H. Antman  
William S. Dalton  
Mark A. Israel  
Richard E. Kouri  
Thomas J. Lynch, Jr.  
Peter J. Neumann  
Steven R. Patierno  
Scott D. Ramsey  

### Tobacco and Cancer Subcommittee

**Chair**
Roy S. Herbst

**Members**
Christopher I. Amos  
Barbara A. Burtness  
Paul M. Cinciripini  
Maciej L. Goniewicz  
Dorothy K. Hatsukami  

### Regulatory Science and Policy Subcommittee

**Chair**
Kenneth C. Anderson

**Members**
James L. Abbruzzese  
Chris Boshoff  
William S. Dalton  
Raymond N. DuBois  
Susan M. Galbraith  
Judy E. Garber  
Levi A. Garraway  
Richard B. Gaynor  
Eric B. Haura  
Roy S. Herbst  
Pasi A. Jänne  
Chitkala Kalidas  
Peter F. Lebowitz  
John E. Leonard  
Thomas J. Lynch, Jr.  
Elaine R. Mardis  
David M. Reese  
Eric H. Rubin  
Charles L. Sawyers  
Mehdi Shahidi  
Howard I. Scher  
Ellen V. Sigal  
Suzanne L. Topalian  
Laura J. van ’t Veer  
Victor E. Velculescu

Mark E. Robson  
Deborah Schrag  
Ellen V. Sigal  
Sean R. Tunis
Suchitra Krishnan-Sarin
Scott J. Leischow
Timothy R. Rebbeck
Nancy A. Rigotti
Peter G. Shields
Avrum E. Spira
Benjamin A. Toll
Karismayajula Viswanath
Wendell Gray Yarbrough
Brian King, ex officio
Stephanie R. Land, ex officio

**AACR Tellers Committee**

**Chair**
René Bernards

**Members**
Theodore S. Lawrence
Elizabeth A. Platz
Shelley S. Tworoger

**Special Conferences Committee**

**Cochairs**
Dafna Bar-Sagi
Roy S. Herbst

**Members**
Hans Clevers
Christina Curtis
Riccardo Dalla-Favera
Chi Van Dang
Johann S. de Bono
James V. DeGregori
Kevin L. Gardner
David Hyman
Quynh-Thu Le
Massimo Loda
William G. Nelson
Pamela S. Ohashi
Klaus Pantel
Elizabeth A. Platz
Peter K. Sorger
Avrum Spira
Louis M. Staudt
Kimberly Stegmaier
Alejandro Sweet-Cordero
Jane E. Visvader
Jennifer A. Wargo
Danny R. Welch
Anna M. Wu

**Scientific Achievement Awards Committees**

**AACR Award for Lifetime Achievement in Cancer Research Committee**

**Chair**
Hans Clevers

**Members**
Richard B. Gaynor
Luisa Iruela-Arispe
Guillermina Lozano
Pamela S. Ohashi
Moshe Oren
William Pao
Brian M. Rivers
Martine F. Roussel
Anil K. Rustgi
Saraswati Sukumar
Karen H. Vousden

**June L. Biedler Prize for Cancer Journalism Judging Panel**

**Chair**
Clifton Leaf

**Vice Chair**
Ron Winslow

**Members**
David Boardman
Lecia Bushak
Antonio T. Fojo
Carey Goldberg
Ellen L. Goode
Adam Hayden
Roy S. Herbst
Patrick Hwu
Stefanie Joho
Esther Landhuis
Donna M. Ludwinski
Adam Piore
Cynthia Ryan
Mariana C. Stern
Ashani Weeraratna
Kari L. Whitehead
James E. Williams, Jr.
Swagata Yadavar

**AACR Award for Outstanding Achievement in Blood Cancer Research**

**Chair**
Catherine J. Wu

**Members**
Rajesh Chopra
Faith E. Davies
Christopher R. Flowers
Larry W. Kwak
Mignon Lee-Cheun Loh
Ravi Majeti
Emmanuelle Passegüe
Feyruz V. Rassool
Kerry J. Savage
Andrei Thomas-Tikhonenko
AACR Award for Outstanding Achievement in Chemistry in Cancer Research Committee

Chair
Mary M. Mader

Members
Natalie G. Ahn
Rima S. Al-awar
Sara J. Buhrlage
Gunda I. Georg
Amanda B. Hummon
Allan M. Jordan
Charles Lin
John E. Moses

AACR Award for Outstanding Achievement in Pediatric Cancer Research Committee

Chair
Susan L. Cohn

Members
Lisa R. Diller
Maryam Fouladi
A. Lindsay Frazier
Annie A. Huang
Mignon Lee-Cheun Loh
Sheila K. Singh
Gilles Vassal

AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research Committee

Chair
Louis M. Weiner

Members
Alex A. Adjei
Edward Chu
Karyn A. Goodman
Manuel Hidalgo
W. Kimryn Rathmell
Meredith M. Regan
Yu Shyr
Charles R. Thomas, Jr.
Miguel A. Villalona-Calero

AACR Distinguished Lectureship in Breast Cancer Research Committee

Chair
Alana L. Welm

Members
Jill Bargonetti
Roger A. Greenberg
Luisa Iruela-Arispe
Jos Jonkers
Pepper Jo Schedin
Naoto T. Ueno
Carlos L. Arteaga, ex officio

AACR Distinguished Lectureship on the Science of Cancer Health Disparities Committee

Chair
Rick A. Kittles

Members
Jennifer Beebe-Dimmer
Roshan Bastani
Gerardo Colón-Otero
Robin P. Farias-Eisner
Laura Fejerman
Steven R. Patierno
Gloria M. Petersen
Lewis R. Roberts

AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research Committee

Chair
Massimo Loda

Members
Yuan Chang
Kathleen R. Cho
Kojo Elenitoba-Johnson
Celina G. Kleer
Gerrit A. Meijer
Andrea L. Richardson
David L. Rimm
Sabina Signoretti
Poul H. B. Sorensen
Christian Steidl
Melissa A. Troester

AACR Laboratory Research Awards Committee
Chair
Sheila A. Stewart

Members
Hannah K. Carter
Ryan B. Corcoran
Cyrus M. Ghajar
Shehnaz K. Hussain
Chuan-Yuan Li
Maureen E. Murphy
John H.J. Petrini
Lewis R. Roberts
Takemasa Tsuji
Bradley G. Wouters

AACR Outstanding Investigator Award for Breast Cancer Research Committee
Chair
Lisa A. Carey

Members
Virginia F. Borges
Abenaa M. Brewster
Joann G. Elmore
Maryam B. Lustberg
Linda T. Vahdat MBA
Stephen T. Wong
Carlos L. Arteaga, ex officio

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research Committee
Chair
Anna D. Barker

Members
Marcia R. Cruz-Correa
Riccardo Dalla-Favera
Jennifer Rubin Grandis
Roy S. Herbst
Elizabeth M. Jaffee
Edison T. Liu
Patricia LoRusso
Lisa A. Newman
Brian M. Rivers
Suzanne L. Topalian
Paul Workman

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology Committee
Chair
Jedd D. Wolchok

Members
Nina Bhardwaj
Selina Chen-Kiang
Greg M. Delgoffe
Iqbal S. Grewal
Amanda W. Lund

AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship Committee
Chair
Folakemi T. Odedina

Members
Sarki A. Abdulkadir
Nadine J. Barrett
Lorraine T. Dean
Sophia H.L. George
Worta McCaskill-Stevens
William G. Nelson
Amelie G. Ramirez
Lorna Rodriguez-Rust
Javier F. Torres-Roca

AACR-Princess Takamatsu Memorial Lectureship Committee
Chair
Elaine R. Mardis

Members
Shelley L. Berger
Paolo Boffetta
Tak W. Mak
Hiroyuki Mano
Louis M. Staudt
Thea Dorothy Tlsty
Suzanne L. Topalian
Nikhil Wagle
Susumu Nishimura, ex officio
Takao Sekiya, ex officio

Gal Markel
Kunle Odunsi
Andrea Schietinger
COMMITTEES

AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research Committee

Chair
Edward S. Kim

Members
Lauren A. Byers
Maura L. Gillison
Roger S. Lo
Grace X. Ma
Katerina A. Politi
David B. Solit
Anne S. Tsao
Ignacio I. Wistuba

AACR-Women in Cancer Research Charlotte Friend Lectureship Committee

Chair
Caroline Dive

Members
Nita Ahuja
Nadine J Barrett
Emily Bernstein
Heather R. Christofk
Francesca M. Gany
Shiva Malek
Sumithra J. Mandrekar
Leslie L. Robison
Douglas Yee

Pezzoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research Committee

Chair
Lisa M. Coussens

Members
Anton J.M. Berns
Fabrizio d’Adda di Fagagna
Mariam Jamal-Hanjani
Ricky W. Johnstone
Yibin Kang
Crystal L. Mackall
Lisa A. Newman
Gabriella Sozzi

AACR Basic Cancer Research Grants Scientific Review Committee

Chair
Kenneth J. Pienta

Members
Viktor A. Adalsteinsson
Ana Aparicio
Sand Deep Burma
Janai R. Carr-Ascher
Nicholas C. Denko
Dean W. Felsher
Hani Goodarzi
Matthew M. Gubin
Annie A. Huang
Sophia C. Kamran
Jan Karlseder
Solange Landreville
Hui-Kuan Lin
Jun Luo
Nora M. Navone
Shyam Nyati
Bogdan Pasaniuc
Avery D. Posey, Jr.
Nilay Shah
Mario L. Suvà
Edward William Tate
Anna Woloszynska
Binhua Peter Zhou

AACR-AstraZeneca Career Development Award for Physician-Scientists in Honor of José Baselga Scientific Committee

Chair
Luis A. Diaz

Members
Javier Cortés
Sara A. Hurvitz
Patrick Hwu
Cigall Kadoch
Anthony G. Letai
Roger S. Lo
Gordon B. Mills
Jorge J. Nieva
Trevor J. Pugh
Lajos Pusztai
Jorge S. Reis-Filho
Hope S. Rugo
Violeta Serra
Christos Sotiriou

Scientific Grant Review Committees

AACR-AstraZeneca Career Development Award for Physician-Scientists in Honor of José Baselga Scientific Committee

Chair
Luis A. Diaz

Members
Javier Cortés
Sara A. Hurvitz
Patrick Hwu
Cigall Kadoch
Anthony G. Letai
Roger S. Lo
Gordon B. Mills
Jorge J. Nieva
Trevor J. Pugh
Lajos Pusztai
Jorge S. Reis-Filho
Hope S. Rugo
Violeta Serra
Christos Sotiriou

AACR-AORTIC-NCI Beginning Investigator Grants for Catalytic Research (BIG Cat) Steering Committee

Co-Chairs
James R. Alaro
Lisa A. Newman
Solomon O. Rotimi

Members
Susan Citonje
Msadabwe-Chikuni
Yixian (John) Zhang
Sam M. Mbulaiteye
AACR Breast Cancer Research Grants Scientific Review Committee

Chair
Massimo Cristofanilli

Members
Samuel Aparicio
Banu Arun
Kimlin T. Ashing
Kristy A. Brown
Anuradha Chakravarthy
Justin A. Colacino
Fergus J. Couch
Chad Creighton
Camila O. dos Santos
Douglas Easton
Joann G. Elmore
Sarah-Maria Fendt
Patricia A. Ganz
Antonio Giordano
Roger A. Greenberg
James B. Hicks
Luisa Iruela-Arispe
Benita S. Katzenellenbogen
Celina G. Kleer
Nancy U. Lin
Maryam B. Lustberg
Cynthia X. Ma
Dario Marchetti
Jaime L. Matta
Sandra S. McAllister
Steffi Oesterreich
Nick Orr
Violeta Serra
Daniel P. Silver
Joseph A. Sparano
Tiffany A. Traina
Joanne B. Weidhaas
Siyuan Zhang

Members
Jennifer Beebe-Dimmer
Patricia Chalela
Michael G. Goggins
Theresa A. Hastert
Folakemi T. Odedina
Julie R. Palmer
Rena J. Pasick
Sandi L. Pruitt
Camille C.R. Ragin
Melissa A. Simon
Melissa Troester

AACR Cancer Disparities Research Grants Scientific Review Committee

Chair
Scarlett L. Gomez

Members
Jennifer Beebe-Dimmer
Patricia Chalela
Michael G. Goggins
Theresa A. Hastert
Folakemi T. Odedina
Julie R. Palmer
Rena J. Pasick
Sandi L. Pruitt
Camille C.R. Ragin
Melissa A. Simon
Melissa Troester

AACR Immuno-oncology Research Grants Scientific Review Committee

Chair
Caroline Robert

Members
Samuel E. Adunyah
Djordje Atanackovic
Naomi S. Balzer-Haas
Julie E. Bauman
Ivan M. Borrello
Renier J. Brentjens
Carlos A. Casiano
Esteban Celis
Christopher H. Contag
Sandra P. D’Angelo
Daniel D. De Carvalho
Leisha A. Emens
Lawrence H. Fong
Terry J. Fry
Wendy S. Garrett
Sergei I. Grivennikov
Peixuan Guo
Kevin J. Harrington
Alex Yee-Chen Huang
Richard C. Koya
Peter P. Lee
Gerald P. Linette
Jason J. Luke
Marcela V. Maus
Pamela N. Munster
Smita Kesavan Nair
Jorge J. Nieva
Pierluigi Porcu
Jeffrey C. Rathmell
Elizabeth A. Repasky
Nadeem Riaz
Andrea Schietinger
Stephen P. Schoenberger
Vivek Subbiah
COMMITTEES

AACR-Lobular Breast Cancer Alliance
Invasive Lobular Carcinoma Research Grants Scientific Review Committee

Chair
Nancy E. Davidson

Members
Janice Axelrod
Christine Desmedt
Sophia H.L. George
Hans H. Kreipe
Megan L. Kruse
Christopher I. Li
Ingrid A. Mayer
Rita Nanda
Barbara Neilsen
Steffi Oesterreich
Ann H. Partridge
Roberto Salgado
Wendy A. Woodward
Gabriele M. Zoppoli

AACR-MPM Transformative Cancer Research Grants Scientific Review Committee

Chair
H. Robert Horvitz

Members
Joan S. Brugge
William C. Hahn
Helen E Heslop
David P. Ryan
Louis M. Weiner

AACR Pediatric Cancer Research Grants Scientific Review Committee

Chair
Richard G. Gorlick

Members
Claudia A. Benavente
Jonathan E. Constance
Klaus-Michael Debatin
Noah C. Federman
Cynthia E. Hawkins
Selene C. Koo
Patrick J. Leavey
David Liebner
Troy A. McEachron
Rayne H. Rouce
David Solomon
Jeffrey A. Toretsky
Brian Andrew Van Tine

Lustgarten Foundation-AACR Pancreatic Cancer Research Grants Scientific Review Committee

Chair
Elizabeth M. Jaffee

Members
Dafna Bar-Sagi
Gregory L. Beatty
Channing J. Der
Brian C. Lewis
Anirban Maitra
Peter J. O'Dwyer
Gloria M. Petersen

AACR-Pediatric Cancer Research Grants Scientific Review Committee

Chair
Richard G. Gorlick

Members
Claudia A. Benavente
Jonathan E. Constance
Klaus-Michael Debatin
Noah C. Federman
Cynthia E. Hawkins
Selene C. Koo
Patrick J. Leavey
David Liebner
Troy A. McEachron
Rayne H. Rouce
David Solomon
Jeffrey A. Toretsky
Brian Andrew Van Tine

Lustgarten Foundation-AACR Pancreatic Cancer Research Grants Scientific Review Committee

Chair
Elizabeth M. Jaffee

Members
Dafna Bar-Sagi
Gregory L. Beatty
Channing J. Der
Brian C. Lewis
Anirban Maitra
Peter J. O'Dwyer
Gloria M. Petersen

AACR Cancer Progress Report Steering Committee

Chair
David A. Tuveson

Specialty Groups and Committees

AACR Cancer Disparities Progress Report Steering Committee

Chair
Lisa A. Newman

Cochairs
Scarlett Lin Gomez
Steven R. Patierno
Mariana Stern
Cheryl L. Willman
Robert A. Winn

Members
Madina Agenor
Smita Bhatia
John D. Carpten
Kevin Cassel
Gerardo Colon-Otero
Melissa B. Davis
Carmen E. Guerra
Chanita Hughes-Halbert
Kevin Kalinsky
Patricia LoRusso
Edith P. Mitchell
Electra D. Paskett
Sandi L. Pruitt
Sanya A. Springfield
Lori Wilson

AACR Cancer Progress Report Steering Committee

Chair
David A. Tuveson
Members
Christine B. Ambrosone
A. William Blackstock, Jr.
Jacqueline S. Casillas
Jeffrey W. Clark
Christina Curtis
Luis A. Diaz, Jr.
Katherine W. Ferrara
Ramaswamy Govindan
Helen E. Heslop
Christopher S. Lathan
Raphael E. Pollock
Louis M. Staudt
George J. Weiner

Margaret Foti
Benjamin Haibe-Kains
William N. Hait
David G. Huntsman
Nada Jabado
Stephen Robbins
Lillian L. Siu
Bradly G. Wouters
Keith Thomas Flaherty
Patricia M. LoRusso
Elaine R. Mardis
Louis M. Staudt

AACR Governance Committee
James V. Buzzitta
Bayard D. Clarkson
Raymond N. DuBois
Faye Florence
Stephen D. Ryan

AACR History Project Advisory Committee
Members
Anna D. Barker
Elizabeth H. Blackburn
Michael A. Caligiuri
Raymond N. DuBois
William N. Hait
Elizabeth M. Jaffee
Peter A. Jones
Elaine R. Mardis
Olufunmilayo I. Olopade
Timothy R. Rebbeck
Daniel D. Von Hoff

AACR International-Canada Board of Directors
Chair
David A. Tuveson

Members
Lisa M. Coussens

Scientific Task Forces

AACR COVID-19 and Cancer
Chair
Antoni Ribas

Members
Dafna Bar-Sagi
John M. Carethers
Melissa Cushing
Gypsamber D’Souza
Keith T. Flaherty
Susan M. Galbraith
Elizabeth M. Jaffee
Karen E. Knudsen
Jean-Charles Soria
Avrum E. Spira
David A. Tuveson
E. John Wherry
Helen X. Chen, ex officio
James H. Doroshow, ex officio
Marc Theoret, ex officio
Margaret Foti, ex officio

AACR Exploratory IND/Phase 0 Clinical Trials Task Force
Chair
Patricia M. LoRusso

Vice Chair
David A. Tuveson

Members
Anna D. Barker
Nina Bhardwaj
Gideon M. Blumenthal
William S. Dalton
COMMITTEES

Johann S. de Bono
Caroline Dive
James H. Doroshow
Kojo Elenitoba-Johnson
Laura J. Esserman
Keith T. Flaherty
James L. Gulley
Priti Hegde
David M. Hyman
Elizabeth M. Jaffee
Oliver Jonas
Shivaani Kummar
Anthony G. Letai
Ignacio Melero
Ira Mellman
Ruben A. Mesa
Nickolas Papadopoulos
Emanuel F. Petricoin III
Gary K. Schwartz
Mirat Shah
Padmanee Sharma
Yu Shyr
Lillian L. Siu
Jean-Charles Soria
Avrum Spira
Jeff L. Summers
Timothy A. Yap

AACR Hematologic Malignancies Task Force

Chair
Jonathan D. Licht

Members
Kenneth C. Anderson
Scott A. Armstrong
P. Leif Bergsagel
Michael A. Caligiuri
Rajesh Chopra
Riccardo Dalla-Favera
Faith E. Davies
John E. Dick
Yusri A. Elsayed
Maria Eugenia Figueroa
Steven D. Gore
Ricky W. Johnstone
Carl H. June
Thomas J. Kipps
Toshio Kitamura
Michelle M. Le Beau
Ronald Levy
Mignon L. Loh
Ravi Majeti
Ari M. Melnick
Ruben A. Mesa
Phuong Khanh Morrow
Charles G. Mullighan
Bertrand Nadel
Lilli Petruzzelli
Stephen J. Schuster
Eduardo M. Sotomayor
Louis M. Staudt
Kimberly Stegmaier
Jeffrey W. Tyner
Nancy K. Valente
Cheryl L. Willman

AACR AI and Computational Pathology Subcommittee

Chair
Anil V. Parwani

Members
Andrew H. Beck
Thomas J. Fuchs
Felice Giangaspero
Hugo M. Horlings
Benjamin Liechty
Gerrit A. Meijer
Francesco Pezzella
Jorge S. Reis-Filho
David L. Rimm
Jeroen van der Laak
Paul J. van Diest
Ignacio I. Wistuba

AACR Communication Education and Training Subcommittee

Chair
Robin G. Lorenz

Members
Jayanta Debnath
Jiaoti Huang
Michael M. Ittmann
Annette S. Kim
Tamara L. Lotan
Richard N. Mitchell
Andrea L. Richardson

David L. Rimm
Mark A. Rubin
Lawrence D. True
Ignacio I. Wistuba

AACR Pathology in Cancer Research Task Force

Chair
Massimo Loda

Members
Andrew H. Beck
Carolyn C. Compton
Angelo M. De Marzo
Jayanta Debnath
Kojo Elenitoba-Johnson
Michelangelo Fiorentino
Chris A. French
Thomas J. Fuchs
Felice Giangaspero
Jiaoti Huang
A. John Iafrate
Michael M. Ittmann
Roy A. Jensen
Annette S. Kim
Michael Kluk
Robin G. Lorenz
Tamara L. Lotan
Anirban Maitra
Gerrit A. Meijer
Richard N. Mitchell
Anil V. Parwani
Francesco Pezzella
Eli Pikarsky
Jorge S. Reis-Filho
Andrea L. Richardson
AACR Molecular Pathology and Precision Medicine Subcommittee

Chair
Jorge S. Reis-Filho

Members
Angelo M. De Marzo
Kojo Elenitoba-Johnson
Michelangelo Fiorentino
Jiaoti Huang
A. John Iafrate
Annette S. Kim
Michael Kluk
Liudmila L. Kodach
Tamara L. Lotan
Anirban Maitra
Eli Pikarsky
Mark A. Rubin
Ignacio I. Wistuba

AACR Perspectives and Commentaries Subcommittee

Chair
Lawrence D. True

Members
Carolyn C. Compton
Keith D. Eaton
Chris A. French
Felicie Giangaspero
Jiaoti Huang
Roy A. Jensen
Robin G. Lorenz
Anil V. Parwani

AACR Precision Combination Therapies Task Force

Chair
Elizabeth M. Jaffee

Cochairs
Jennifer Rubin Grandis
Albert C. Koong
Patricia M. LoRusso
Antoni Ribas

Members
Alex A. Adjei
Kenneth C. Anderson
Anna D. Barker
Peter L. Choyke
Marcia R. Cruz-Correa
Sandra Demaria
James H. Doroshow
Laura J. Esserman
Katherine W. Ferrara
Silvia Chiara Formenti
Thomas J. Kipps
Massimo Loda
Crystal L. Mackall
Rita Nanda
Robert S. Negrin
Lisa A. Newman
Kunle Odunsi
Anil V. Parwani
Mary W. Redman
Kurt A. Schalper
Yu Shyr
Louis M. Staudt
Charles Swanton
Marc R. Theoret
David A. Tuveson
Eliezer M. Van Allen
Jennifer A. Wargo
Timothy A. Yap

AACR Aging Stress and Cancer Task Force

Chair
David A. Tuveson

Members
Adriana Albini
Gideon M. Blumenthal
Judith Campisi
Lewis C. Cantley
John D. Carpten
Alan D. D'Andrea
James V. DeGregori
Marcia Haigis
Pitri Hegde

AACR Racial Inequities in Cancer Research

Cochairs:
John M. Carethers
Melissa B. Davis

Members:
Michael A. Caligiuri
Luis G. Carvajal-Carmona
Kevin D. Cassel
Marcia R. Cruz-Correa
Lola A. Fashoyin-Aje
Rodney C. Haring
Christopher I. Li
Folasade P. Mayil
Lisa A. Newman
Steven R. Patierno
Avery D. Posey, Jr.
Antoni Ribas
Brian M. Rivers
Sanya A. Springfield
Mariana C. Stern
Karriem S. Watson
Ashani T. Weeraratna
Cheryl L. Willman
Robert A. Winn
John D. Carpten,
MICR Immediate Past-Chair
Gerardo Colon-Otero,
MICR Chair
Clayton C. Yates,
MICR Chair-Elect

Melissa M. Hudson
David M. Hyman
Michael R. Irwin
Juan Carlos Izpisúa Belmonte
Scott W. Lowe
Lydia Lynch
Masashi Narita
Anna Karolina Palucka
Electra D. Paskett
Emanuel F. Petricoin
Sheila A. Stewart
Cornelia M. Ulrich
Jennifer A. Wargo
Ashani Weeraratna
Robert A. Winn
E. John Wherry
COMMITTEES

AACR Trust in Science Task Force

Chair
William S. Dalton

Members
Stacey J. Adam
J. Carl Barrett
Arthur Caplan
Lisa M. Coussens
Lee M. Ellis
Cimona V. Hinton
Melissa M. Hudson
Fabian McCartney Johnston
Jesse Nodora
Edward Sanghyun Kim
James W. Lillard
Tracy G. Lively
Ira Mellman
Charles M. Perou
Martine J. Piccart
Debra Patt
Patricia Spears
Javier F. Torres-Roca
Eric H. Rubin
David A. Tuveson
Cheryl L. Willman
Robert A. Winn

Steering Committee

Members
M. William Audeh
Alberto Bardelli
Michael C. Campbell
Peter J. Campbell
Christina Curtis
James V. DeGregori
Robert A. Gatenby
Marco Gerlinger
Michael A. Gillette
Robert J. Gillies
Trevor Graham
Henry H. Q. Heng
Giulia C. Kennedy
Carlo C. Maley
Perry S. Marshall
Andriy Marusyk
Nicholas McGranahan
Franziska Michor
Paul S. Mischel
Nicholas E. Navin
Serena Nik-Zainal
Larry Norton
Elizabeth O’Day
Azra Raza
Andrea Sottoriva
Jonathan Weissman
Danny R. Welch

Scientific Working Groups

AACR Cancer Evolution Working Group (CEWG)

Executive Committee

Cochairs
Frank H. Laukien
Charles Swanton

Cochair-Elects
Anna D. Barker
Jeffrey P. Townsend

AACR Cancer Immunology Working Group (CIMM)

Steering Committee

Chair
Sandra Demaria

Chair-Elect
Kunle Odunsi

Members
Djordje Atanackovic
Lisa H. Butterfield
Alessandra Cesano
Kavita Dhodapkar
Leisha A. Emens
Helen E. Heslop
Richard C. Koya
Marcela V. Maus
Elizabeth A. Mittendorf
Paul M. Sondel
Eduardo M. Sotomayor
Takemasa Tsuji

AACR Cancer Prevention Working Group (CPWG)

Steering Committee

Chair
Adriana Albini

Members
Melissa L. Bondy
Philip E. Castle
Andrea De Censi
Zigang Dong
G. Paolo Dotto
Raymond N. DuBois
Stephen S. Hecht
Lee W. Jones
Suchitra Krishnan-Sarin
Stephen Lam
J. Jack Lee
Christopher I. Li
Karen T. Liby
William G. Nelson
Klaus Pantel
Michael N. Pollak
Timothy R. Rebbeck
Leslie L. Robison
Anil K. Rustgi
Victoria L. Seewaldt
Melissa A. Simon
Avrum Spira
Mariana C. Stern
Eva Szabo
Kenneth Kenji Tanabe
Cornelia M. Ulrich
Kala Visvanathan
AACR Chemistry in Cancer Research Working Group (CICR)

Steering Committee

Chair
Joachim Rudolph

Chair-Elect
Mary M. Mader

Immediate Past Chair
Philip Jones

Members
Rima Al-awar
Michelle Arkin
James E. Audia
Ivan Cornella-Taracido
Laura Akullian D'Agostino
Benjamin L. Ebert
Adrian L. Gill
Ingo Hartung
David Millan
Christopher Nasveschuk
Chudi O. Ndubaku
Zoran Rankovic
Xiaojing (Gina) Wang

AACR-CICR Award Nominating Committee

Chair
Mary M. Mader

Members
James E. Audia
Laura D'Agostino
Ingo Hartung
Chris Nasveschuk
Xiaojing Wang

AACR-CICR Chair-Elect Nominating Committee

Chair
Laura D'Agostino

Members
Zoran Rankovic
Philip Jones
Andrew J. Phillips
Joachim Rudolph

AACR-CICR Communications Subcommittee

Chair
Keith R. Hornberger

Chair-Elect
Martin E. Swarbrick

Immediate Past Chair
Iain D.G. Watson

Members
Barbara Czako
Adrian Gill
Dennis X. Hu
Lyn Howard Jones
Laetitia Martin

AACR Population Sciences Working Group (PSWG)

Steering Committee

Chair
Andrew T. Chan

Chair-Elect
Lorelei A. Mucci

Immediate Past Chair
Jennifer A. Doherty

Members
Peter T. Campbell
Michele L. Cote
Jason Diaz
Jane C. Figueiredo
Sophia H.L. George
Shehnaz K. Hussain
Shannon M. Lynch
Maria Elena Martinez
Leah E. Mechanic
Neil Murphy

AACR Pediatric Cancer Working Group (PCWG)

Steering Committee

Chair
Katherine Janeway

Immediate Past Chair
Kimberly Stegmaier

Members
Julia L. Glade Bender
Olivier Delattre
Steven Dubois
Maryam Fouladi
Elizabeth Fox
Alejandro Gutierrez
Meredith S. Irwin
Mark W Kieran
Leona Knox
Mignon Loh
Yael Mosse
Paul A. Northcott
Charles W.M. Roberts

AACR-PCWG Chair-Elect Nominating Committee

Chair
Smita Bhatia

Members
Lee J. Helman
Katherine A. Janeway
Troy A. McEachron
Kimberly Stegmaier
AACR Radiation Science and Medicine Working Group (RSM)

Steering Committee

Chair
Silvia Chiara Formenti

Immediate Past Chair
Mary-Helen Barcellos-Hoff

Members
Carmen Bergom
Eric Chuang
Theodore L. DeWeese
Amato Giaccia
Daphne Haas-Kogan
Alice Y. Ho
Isabel Lauren Jackson
Verena Jendrossek
Billy W. Loo, Jr.
Marc Mendonca
Charles R. Thomas, Jr.
Phuoc Tran
Joanne Weidhaas
Julia White
David S. Yu

AACR-RSM Chair-Elect Nominating Committee

Chair
Wendy A. Woodward

Members
Mary Helen Barcellos-Hoff
Roberto Diaz
Silvia Chiara Formenti
Dörthe Schaue

AACR Tumor Microenvironment Working Group (TME)

Steering Committee

Chair
Theresa A. Guise

Chair-Elect
Mikala Egeblad

Members
Adrienne Boire
Leah M. Cook
Karin E. de Visser
Cyrus M. Ghajar
Sergei I. Grivennikov
Xin Lu
Ilaria Malanchi
Florencia McAllister
Jeffrey W. Pollard
Ashani T. Weeraratna
Alana L. Weilm
Julio A. Aguirre-Ghiso

Constituency Groups

AACR Associate Member Council (AMC)

Chair
Kristin G. Anderson

Chair-Elect
Francesco Caiazza

Past Chair
Maeve Mullooly

Members
Kristin A. Atlwegg
Katie Campbell
Peter F. DelNero
James SeongJun Han
Bianca N. Islam
Sunil K. Joshi
Russell J. Ledet
Golnaz Morad
Margaret S. Pichardo
Caroline N. Smith
Erica S. Tsang

AACR Minorities in Cancer Research (MICR) Council

Chair
Gerardo Colón-Otero

Chair-Elect
Clayton C. Yates

Past Chair
John D. Carpten

Members
Sarki A. Abdulkadir
Lourdes Baezconde-Garbanati
Nadine J. Barrett
Melissa B. Davis
Luis A. Diaz, Jr.
Martin Mendoza
Lisa A. Newman
Folakemi T. Odedina
Camille C.R. Ragin
Dorothy A. Rhoades
Sanya A. Springfield

AACR Women in Cancer Research (WICR) Council

Chair
Amelie G. Ramirez

Chair-Elect
Sheila K. Singh

Past Chair
Marcia R. Cruz-Correa

Members
Abenaa M. Brewster
Karen A. Gelmon
Andrea A. Hayes Jordan
Nada Jabado
Johanna A. Joyce
Beverly D. Lyn-Cook
Shiva Malek
Lilli Petruzzelli
Victoria L. Seewaldt
**AACR 50-Year Members and Honorary Members**

Newly Inducted AACR 50-Year Members
It is the AACR’s privilege to honor those scientists who have reached the milestone of 50 years of AACR membership. The AACR Board of Directors would like to extend their sincere thanks and appreciation to these members for their dedication to cancer research and continued participation in and support of the AACR’s activities and programs.

- Rolf F. Barth
- Gerald L. Bartlett
- Miguel A. Basombrio
- Ulrich Batzdorf
- Irwin D. Bernstein
- Bruce C. Casto
- Howard L. Elford
- Curtis C. Harris
- Samuel Hellman
- Lawrence Nelson Quakertown
- Henry Hennings
- Brian L. Hillcoat
- William M. Hryniuk
- Loren J. Humphrey
- Norman Jaffe
- Charles B. Kasper
- Amanullah Khan
- Marvin A. Kirschner
- Mortimer J. Lacher
- Hsiu-san Lin
- Martin Lubin Hanover
- Danuta Malejka-Giganti Eagan
- Hans W.J. Marquardt
- Nis I. Nissen
- Jorge A. Ortega
- James F. Perdue
- Anthony J. Piro
- Thomas G. Pretlow
- David Schottenfeld
- Raymond J. Shamberger
- Roland T. Skeel
- Lewis M. Slater
- William D. Terry
- Jan Vaage
- Frederick A. Valeriote
- James D. Watson

**AACR Honorary Members**

The AACR is extremely pleased to recognize AACR’s Honorary Members. The AACR Board of Directors wish to convey their heartfelt thanks to the following individuals who have made extraordinary contributions to the advancement of cancer research, either through outstanding personal scientific activity or exceptional leadership in cancer research.

- HRH Princess Chulabhorn
- Joseph F. Fraumeni, Jr.
- Susan Band Horwitz
- Hon. Connie Mack
- Hon. John Edward Porter
- James D. Watson
- Harald zur Hausen
Annual Meeting 2022 Supporters

AACR gratefully acknowledges the generous support of individuals and organizations whose funding has made the AACR Annual Meeting 2022 possible.

Special Thanks to Distinguished Supporters of AACR Annual Meeting 2022

### Cure Level

- AstraZeneca
- Bristol Myers Squibb
- Daiichi Sankyo

### Progress Level

- AbbVie, Inc.
- Lilly Oncology

### Promise Level

- American Brain Tumor Association
- American Cancer Society
- American Chemical Society
- Amgen, Inc.
- Beigene
- Breast Cancer Research Foundation
- Cancer Research Institute
- Doreen J. Putrah Cancer Research Foundation
- Exelixis, Inc.
- Genentech, A Member of the Roche Group
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Incyte Corporation
- Irving Weinstein Foundation
- John and Elizabeth Leonard Family Foundation
- Ludwig Cancer Research
- Merck & Co., Inc.
- Novartis
- Novocure
- Pezcoller Foundation
- Pfizer Oncology
- Prostate Cancer Foundation
- Societa Italiana di Cancerologia (Italian Cancer Society)
- St. Baldrick’s Foundation
- Taiho Oncology
The Scientific Program

Advances in Diagnostics and Therapeutics
AstraZeneca

Advances in Prevention Research
Ludwig Cancer Research

Advances in the Science of Cancer Health Disparities
AstraZeneca

Forum
Dharma Master Jiantai Forum on Advances in Lung Cancer

Major Symposia
AstraZeneca
Dharma Master Jiantai Symposium in Biomarkers
Dharma Master Jiantai Symposium in Targeted Therapy

Opening Plenary:
Decoding Cancer Complexity, Integrating Science, Transforming Patient Outcomes
AstraZeneca

Regulatory Science and Policy Track
Bristol Myers Squibb

AACR Awards and Lectureships

AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
American Cancer Society

AACR Award for Lifetime Achievement in Cancer Research
American Association for Cancer Research

AACR Award for Outstanding Achievement in Basic Cancer Research
American Association for Cancer Research

AACR Award for Outstanding Achievement in Blood Cancer Research
American Association for Cancer Research

AACR Award for Outstanding Achievement in Chemistry in Cancer Research
American Association for Cancer Research

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Cancer Research Institute

AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
American Association for Cancer Research

AACR Gertrude B. Elion Cancer Research Award
GlaxoSmithKline

AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research
Lilly Oncology

AACR-Irving Weinstein Foundation Distinguished Lectureship
Irving Weinstein Foundation

AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research
Bristol Myers Squibb

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
American Association for Cancer Research
SUPPORTERS

AACR-Minorities in Cancer Research
Jane Cooke Wright Lectureship
American Association for Cancer Research

AACR Princess Takamatsu Memorial Lectureship
Princess Takamatsu Cancer Research Fund

AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research
St. Baldrick’s Foundation

AACR Team Science Award
Lilly Oncology

AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research
The Bosarge Family Foundation
Waun Ki Hong Endowment Fund

AACR-Women in Cancer Research Charlotte Friend Lectureship
American Association for Cancer Research

Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
Pezcoller Foundation

The Victoria’s Secret Global Fund for Women’s Cancers Meritorious Awards, In Partnership with Pelotonia & AACR
Victoria’s Secret Global Fund for Women’s Cancers

AACR Runners for Research 5K Run/Walk
Presenting Sponsor
AstraZeneca
Elite Sponsor
Sidney Kimmel Cancer Center-Jefferson Health

AACR Travel Grants and Scholar Awards

AACR Margaret Foti Undergraduate Prizes in Cancer Research
The Margaret Foti Foundation

AACR Minority Scholar in Cancer Research Awards
NCI-Center to Reduce Cancer Health Disparities
Merck & Co., Inc.

AACR Minority and Minority-Serving Institution Faculty Scholar Awards
NCI-Center to Reduce Cancer Health Disparities

AACR Undergraduate Scholar Awards
American Association for Cancer Research

AACR Women in Cancer Research Scholar Awards
American Association for Cancer Research

AACR Travel Grants and Scholar-in-Training Awards
American Association for Cancer Research
American Brain Tumor Association
Breast Cancer Research Foundation in Memory of Rebecca Scheinkman
Bristol Myers Squibb
Doreen J. Putrah Cancer Research Foundation
Heyman Family Fund
John and Elizabeth Leonard Family Foundation
Pezcoller Foundation
Prostate Cancer Foundation

Confirmed supporters as of February 23, 2022
Syngnature Discovery in Association with the CICR Working Group
The Estate of Dr. June L. Biedler
James V. Buzzitta, MD Family Fund
The Margaret Foti Foundation
The John and Joe Warner Fund
WuXi AppTec in Association with the CICR Working Group

**AAACR Scientific Working Groups**

**AACR Cancer Immunology Working Group**
Bristol Myers Squibb

**AACR Chemistry in Cancer Research Working Group**
American Chemical Society

**Supporters**

**AACR Advocacy Partners’ Pavilion**
Pfizer Oncology

**AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research Reception**
Lilly Oncology

**Charging Stations/Lounges**
Daiichi Sankyo

**Exhibit Hall Coffee Breaks**
NeoGenomics

**Fellows of the AACR Academy Induction Ceremony and Celebration Dinner**
Gilead Sciences, Inc.

**Hand Sanitizer Stations**
Roche Sequencing & Life Sciences

**Headshot Lounge**
Bristol Myers Squibb

**Hotel Key Cards**
AstraZeneca

**Online Proceedings and Itinerary Planner**
Novartis

**Posters and ePosters**
Bristol Myers Squibb
Merck & Co., Inc.
Daiichi Sankyo

**Professional Educational Grants**
AbbVie
Amgen
AstraZeneca
Beigene
Bristol Myers Squibb
Daiichi-Sankyo
Gilead/Kite Pharma Inc.
GlaxoSmithKline
Genmab
Incyte
Jazz Pharmaceuticals
Lilly
Novocure
Novartis
Pfizer
Taiho Oncology

**Scientist↔Survivor Program**
Bristol Myers Squibb
Exelixis, Inc.
Lilly Oncology
Merck & Co., Inc.
Novartis

**Shuttle Buses**
Daiichi Sankyo

**Research Grants and Fellowships**
AbbVie, Inc.
Amgen, Inc.
AstraZeneca
Bayer
Breast Cancer Research Foundation
Bristol Myers Squibb
Conquer Cancer Foundation
Day One Biopharmaceuticals
Debbie’s Dream Foundation
Exelixis, Inc.
Genentech, A Member of the Roche Group
SUPPORTERS

Confirmed Supporters as of March 5, 2019.

Genmab
GlaxoSmithKline
Incyte Corporation
Johnson & Johnson
Lobular Breast Cancer Alliance
Lustgarten Foundation
Merck & Co., Inc.
Mirati Therapeutics, Inc.
MPM Oncology Charitable Foundation
Novocure
Ocular Melanoma Foundation
Pelotonia
Pfizer Oncology
Takeda Oncology
The WWWW Foundation
Triple Negative Breast Cancer
St. Baldrick’s Foundation
Victoria’s Secret Global Fund
for Women’s Cancers
The Bosarge Family Foundation

Special Conference Supporters for 2021-2022

AbbVie, Inc.
Adaptimmune Ltd.
Astellas
AstraZeneca
Burroughs Wellcome Fund
Daiichi Sankyo
GlaxoSmithKline
Ipsen Biopharmaceuticals, Inc.
Lobular Breast Cancer Alliance
Lustgarten Foundation
Merck & Co., Inc.
Mirati Therapeutics, Inc.
Mission Bio
Novocure
Olympus
Pancreatic Cancer Action Network
Pfizer Oncology
Reaction Biology Corporation
Rivkin Center for Ovarian Cancer
Servier
Verastem Oncology

Sustaining Members

Leadership Sustaining Members
Amgen, Inc.
AstraZeneca
Bayer
Bristol Myers Squibb
Genentech, A Member of the Roche Group
Merck & Co., Inc.
Novocure
Pfizer Oncology
Takeda Oncology

Strategic Sustaining Members
Eisai Inc.
GlaxoSmithKline
Incyte Corporation
Lilly Oncology
Novartis
Pharmacyclics, an AbbVie Company

Major Sustaining Members
Astex Pharmaceuticals, Inc.
Daiichi Sankyo
Exelixis, Inc.
Fondazione Pezcoller
Genmab
Janssen Research & Development, LLC
Karyopharm Therapeutics
Kite, A Gilead Company
Nektar Therapeutics
Prelude Therapeutics
Regeneron
Sanofi GENZYME

Associate Sustaining Members
Mirati Therapeutics, Inc.
Verastem Oncology
# GENERAL INFORMATION

<table>
<thead>
<tr>
<th>Room Name</th>
<th>Location</th>
<th>Opens</th>
<th>Phone #</th>
</tr>
</thead>
<tbody>
<tr>
<td>AACR Office</td>
<td>238</td>
<td>Thursday, 6:00 a.m.</td>
<td>504-670-6704</td>
</tr>
<tr>
<td>AACR Exhibit Booth (AACR Central)</td>
<td>Exhibit Hall, Booth 1636</td>
<td>Sunday, 1:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Amphitheater</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associate Member Resource and Career Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minorities in Cancer Research (MICR) Networking and Resource Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women in Cancer Research (WICR) Networking and Resource Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AACR Publications Booth</td>
<td>Exhibit Hall, Booth 2101</td>
<td>Sunday, 1:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>CancerCareers.org Center</td>
<td>260 Foyer</td>
<td>Sunday, 9:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>CME Booth</td>
<td>Hall E Lobby</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Information Booth</td>
<td>Hall G Lobby</td>
<td>Friday, 12:00 p.m.</td>
<td>504-670-6700</td>
</tr>
<tr>
<td>Coat, Package, and Luggage Check</td>
<td>Hall I-1</td>
<td>Friday, 2:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>COVID-19 Testing</td>
<td>Hall H Lobby</td>
<td>Friday, 2:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Exhibit Management Office</td>
<td>Halls H</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Exhibitor Lounge</td>
<td>Halls H</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Housing Booth (CMR)</td>
<td>Hall E Lobby</td>
<td>Friday, 12:00 p.m.</td>
<td>504-670-6701</td>
</tr>
<tr>
<td>First Aid Stations</td>
<td>Hall D Lobby, Hall H Lobby</td>
<td>Thursday, 7:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>Membership Booth</td>
<td>Hall E Lobby</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Membership Hub</td>
<td>260 Foyer</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>NCI/NIH Meeting Room</td>
<td>297</td>
<td>Sunday, 9:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>Nursing Suite</td>
<td>Hall H Lobby, Hall B-1 Lobby</td>
<td>Friday, 2:30 p.m.</td>
<td></td>
</tr>
<tr>
<td>Prayer Room</td>
<td>201</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Press Office</td>
<td>255-257</td>
<td>Friday, 12:00 p.m.</td>
<td>504-670-6715 504-670-6716</td>
</tr>
<tr>
<td>Registration</td>
<td>Hall E Lobby</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Scientist↔Survivor Program Room</td>
<td>230</td>
<td>Sunday, 6:30 a.m.</td>
<td></td>
</tr>
<tr>
<td>Speaker Preparation Room</td>
<td>275-277</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

Registration
Registration will be located in Hall E Lobby on the following schedule:

- **Friday, April 8**: 12:00 p.m.-7:00 p.m.
- **Saturday, April 9**: 7:00 a.m.-6:00 p.m.
- **Sunday, April 10**: 6:30 a.m.-6:00 p.m.
- **Monday, April 11**: 6:30 a.m.-6:00 p.m.
- **Tuesday, April 12**: 6:30 a.m.-6:00 p.m.
- **Wednesday, April 13**: 6:30 a.m.-12:00 p.m.

Exhibit Hall
The Exhibit Hall is located in Halls D-I. Exhibit hours are:

- **Sunday, April 10**: 1:00 p.m.-5:00 p.m.
- **Monday, April 11**: 9:00 a.m.-5:00 p.m.
- **Tuesday, April 12**: 9:00 a.m.-5:00 p.m.
- **Wednesday, April 13**: 9:00 a.m.-12:30 p.m.

Housing
The AACR Housing Desk (CMR) will be available in the Hall D Lobby for individuals who need assistance with their accommodations. The Housing Desk will be open during the following hours:

- **Friday, April 8**: 3:00 p.m.-7:00 p.m.
- **Saturday, April 9**: 7:00 a.m.-6:00 p.m.
- **Sunday, April 10**: 6:30 a.m.-6:00 p.m.
- **Monday, April 11**: 6:30 a.m.-6:00 p.m.
- **Tuesday, April 12**: 6:30 a.m.-6:00 p.m.
- **Wednesday, April 13**: 6:30 a.m.-10:00 a.m.

Membership
With over 50,000 members in over 129 countries, the AACR comprises leaders and future leaders focused on every aspect of high-quality innovative cancer research. We firmly believe that our members play an integral part in achieving our mission.

Annual Meeting participants are invited to visit the Membership Information Hub, the Membership Center (located in AACR Central), and the Membership Booth (Registration) to learn more about membership and the exclusive benefits available to members, join one or more association groups within the AACR, update contact information, pay membership dues, and more. AACR Dedicated Member mementos are also available on a first-come, first-served basis.

Membership Information Hub
The Membership Information Hub is a home base for AACR members to refresh, connect, and learn more about AACR’s events, programs, and activities, during the meeting. Attendees are encouraged to engage with colleagues from around the world, join Association Groups, become more involved in AACR programs and activities, and share member experiences. Not a member? Stop by the Hub and join!

Membership for Early-Career Trainees and Students
The AACR is committed to the education, training, and professional development of early-career researchers, trainees, and students. Membership is FREE for graduate students, medical students, residents, postdoctoral or clinical fellows, undergraduate students, and high school students who are enrolled in education or training programs that could lead to a career in cancer research. Visit the
Membership Information Hub, Membership Center at AACR Central, or Membership Booth (Registration) to learn more about this amazing opportunity to join our esteemed association.

**AACR New Member Networking Mixer**
The AACR is extremely pleased to host a New Member Networking Mixer each year to welcome newly elected members into the association and provide them with an opportunity to meet and interact with the AACR leadership, network with colleagues and forge new relationships, and learn more about exclusive member benefits and how to get involved in the association. Visit the Membership Information Hub for more information.

**Member Appreciation Breakfast: Celebrating AACR Long-Term Members**
The AACR is extremely pleased to recognize those scientists who have been long-term members of the association for 25 years and more. The AACR board of directors extends its sincere and heartfelt thanks to these members for their devotion to cancer research and long participation in and support of the AACR. Visit the Membership Information Hub for more information.

**Meet the 2022-2023 AACR President, Lisa M. Coussens, PhD, FAACR**
The Meet the 2022-2023 AACR President event provides an opportunity for AACR members and Annual Meeting attendees to meet informally with the 2022-2023 AACR President, Dr. Lisa Coussens, to congratulate her on her presidency and ask general questions. Join us Tuesday, April 12, in the AACR Central Amphitheater (Exhibit Booth 1636).

**Professional Advancement Series**
Professional Advancement Series of sessions are organized to provide important skills to investigators at all levels, from junior faculty to high school students. These sessions are an exclusive benefit for AACR members. For all Professional Advancement Sessions, attendance is free for members with your Annual Meeting registration. The Professional Advancement Series of sessions are organized in a collaborative effort between the Associate Member Council (AMC), Minorities in Cancer Research (MICR) Council, Women in Cancer Research (WICR) Council, and the AACR Science Education and Career Advancement Committee.

Participation by AACR members for all sessions—except Personalized Career Conversations and Not Your Mother’s Typical Grant Writing Session—I Promise! which require advance registration—is on a first-come, first-served basis, as space is limited.

**The Dos and Don’ts for Graduate and Professional Students in Cancer Research**
Friday, April 8 • 1:00 p.m.-2:30 p.m. Room 260-262, New Orleans Ernest N. Morial Convention Center

In recognition of Graduate and Professional Student Appreciation Week (April 4-8, 2022), this session will address important strategies and skills that undergraduate and graduate students, medical students and residents, and clinical and postdoctoral fellows need to have a successful career in cancer research.
Not Your Mother’s Typical Grant Writing Session – I Promise!
Important Tips for Success from Experienced Scientists
Saturday, April 9 • 9:00 a.m.-12:00 p.m.
Bissonet, New Orleans Marriott

This session aims to provide new investigators (postdoctoral fellows and new faculty) with practical tools to write competitive grants. Focus is placed on how to write when writing isn’t your top skill-set (or even if you hate writing), how to structure an aims page to make help the reviewer “get” all the information you want them to “get” and also to help them think you are well organized and smart, and how to write an aims page that makes a reviewer excited about your grant. Here we will focus on crafting an aims page, show how to set up a crowdsourcing group over Zoom (with the help of 3-4 scientific friends and one senior person), and unveil the mysteries of the NIH “pink sheet.” Pre-registration is required to participate in this session.

17th Annual Undergraduate Student Caucus and Poster Competition
Saturday, April 9 • 9:30 a.m.-3:30 p.m.
Acadia, New Orleans Marriott

The Undergraduate Student Caucus Poster Competition continues to be the premier event for undergraduate students attending the AACR Annual Meeting. Now in its 17th year, this session gives undergraduates the opportunity to learn more about current research in the cancer field, hear from investigators about educational pathways and career development, explore career options in the cancer field, and compete for monetary prizes while presenting research. Undergraduates at all levels are welcome to participate and will receive complimentary registration.

Personalized Career Conversations
Sunday, April 10 • 5:30 p.m.-7:30 p.m.
Mardi Gras Salon D-E, New Orleans Marriott

This session provides a unique opportunity for early-career AACR Associate members to be paired with two world-renowned distinguished cancer researchers for a 15-minute one-on-one conversation with each to discuss science and obtain personal career advice. Session chairs will lead an informal panel discussion on various career development topics in the general session room while participants wait for their one-on-one conversations. Pre-registration is required to participate in this session.

How to Design a Successful Career Path in Cancer Research: The Dos and Don’ts for Early-Stage Investigators
Sunday, April 10 • 5:30 p.m.-7:00 p.m.
Carondelet, New Orleans Marriott

This session is intended for early-stage investigators to acquire skills and develop key strategies to avoid “pitfalls” and develop “alternative” tactics to enhance the probability of success in their first independent leadership position. We have recruited an expert panel of established investigators with invaluable experience on “how to” navigate a successful career in cancer research. This session is designed specifically for those who have already made the transition from trainee to the next career stage inside and outside of academia. This is an absolute must-attend session for all early-stage investigators.

Productive Peer Review: Improving Science while Avoiding Pitfalls
Monday, April 11 • 5:30 p.m.- 7:00 p.m.
Mardi Gras Salon FGH, New Orleans Marriott

Moderated by Dr. Chi Van Dang and Dr. Christine Lovly, this Professional Advancement Session will focus on how to become a proficient reviewer and how to effectively respond to reviewers’ comments. The Editors will share examples and tips for
communication, and lead discussion with the session participants.

Navigating the Path to a Successful Career in Cancer Research
Monday, April 11 • 7:00 p.m.-9:00 p.m. Acadia, New Orleans Marriott

This exciting and interactive roundtable session and networking reception provides a forum in which students, early-career researchers, and early-stage investigators can discuss critical career development topics and survival skills with established researchers from a variety of sectors, including academia, government, and industry. This session is a must for all individuals pursuing careers in cancer research or other biomedical sciences.

Building an Effective Mentorship Team: Essential Strategies at Every Stage in Your Career
Tuesday, April 12 • 5:30 p.m.-7:00 p.m. Carondelet, New Orleans Marriott

Navigating a successful career in cancer research, whether in academia, industry or government, can be daunting. Establishing a team of mentors to guide you along the way is an essential step as you begin your journey. This session features cancer researchers with a strong commitment to mentoring and supporting the professional development of cancer research investigators. Hear their stories and learn how to build and take full advantage of an effective mentoring team, whether you are a trainee, an early-stage investigator or a later stage investigator considering a career change.

AACR Annual Meeting Information Booth
The AACR Annual Meeting Information Booth is located in the Hall F-G Foyer. It will be open during session hours to provide information about the AACR, the AACR Annual Meeting, and the city of New Orleans. Staff members will be available to assist you with city and convention center maps, shuttle bus schedules, and information on AACR’s programs.

Speaker Preparation Room
Speakers should visit the Speaker Preparation Room (Room 275-277, New Orleans Convention Center) at least four hours before their sessions begin to test their presentations. The Speaker Preparation Room will be open on Friday, April 8, from 12:00 p.m. to 6:30 p.m., daily during the meeting from 6:30 a.m. to 6:30 p.m., and will close on Wednesday, April 13, at 12:00 p.m. Please note: Speakers in sessions located in hotels should not check in at the Speaker Preparation Room. Speakers in hotel sessions should arrive at the session room 30 minutes prior to the start of the session and check in with the AV technician to upload and test presentations. Speakers cannot use personal laptops in any session rooms.
Press Relations

The AACR Press Office is located in Room 255-257 of the New Orleans Convention Center. It will be open from 12:00 p.m. to 6:00 p.m., Friday, April 8; 7:30 a.m. to 6:00 p.m., Saturday, April 9 through Tuesday, April 12; and 7:30 a.m. to 12:00 p.m., Wednesday, April 13. The AACR’s press contacts are Julia Gunther, Associate Director of Public Relations, 770-403-7690, julia.gunther@aacr.org; and Rick Buck, Senior Director of Communications and Public Relations, 856-562-5668, rick.buck@aacr.org.

Nursing Mothers Suite

Annual Meeting participants who are also nursing mothers will find the Nursing Mothers Suite to be a private, comfortable, and secure environment. AACR-Women in Cancer Research (WICR) is pleased to sponsor this important service again in 2022. There are two Nursing Mother Suites, one located in in Hall H Lobby and one in Hall B-1 Lobby. Please note that no children under the age of 5 years of age are permitted in the center. Children must be fully vaccinated and confirmed through the vaccination verification process when entering the center.

Satellite Educational Symposia

The Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information can be found at the specially marked counter located in the Registration area.

To view more information or register for any of these symposia, visit AACR.org/satellite22.

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
Saturday, April 9 • 6:30 p.m.-9:30 p.m.
Grand Ballroom DE, Sheraton New Orleans Hotel, 500 Canal Street, New Orleans

Expanding Innovation in NSCLC Through Biomarker Testing and Efforts to Target KRAS G12C
Saturday, April 9 • 6:30 p.m.-9:30 p.m.
Grand Ballroom AB, Sheraton New Orleans, 500 Canal Street, New Orleans

HER2, HER3 and TROP2: An Update on Novel Treatments for Key Targets
Sunday, April 10 • 6:30 p.m.-9:30 p.m.
Grand Ballroom, Sheraton New Orleans Hotel, 500 Canal Street, New Orleans

Biomarker-Driven NSCLC Care: The Precision Medicine Model for Today and the Future
Monday, April 11 • 6:30 p.m.-9:30 p.m.
Grand Ballroom, Sheraton New Orleans Hotel, 500 Canal Street, New Orleans
Guide to Poster Sessions and Exhibits

Limited quantities of the Guide to Poster Sessions and Exhibits will be distributed at the entrances to the Poster and Exhibit Hall. Pick up a copy to locate posters, browse poster session topics, and learn about exhibiting companies and the products and services they offer.

Exhibitor Spotlight Theaters

Located in the Exhibit Hall, the Exhibitor Spotlight Theaters have been reserved by exhibiting companies to present special one-hour sessions during exhibit hours. For a full list of presentations taking place in Spotlight Theaters A, B, C and D, please refer to the Guide to Poster Sessions and Exhibits and the Annual Meeting App.

Explore!

Explore! is a fun way attendees can interact with exhibitors while entering a drawing for $250 Amazon gift cards. Download the AACR Annual Meeting App. Scan the QR codes when visiting participating exhibitors and special locations for a chance to win, courtesy of the AACR. Get out there, visit the exhibitors, and Explore! Winners will be notified after the meeting and prizes will be mailed shortly thereafter.

Headshot Lounge

Need a new headshot? Don’t forget to stop by the BMS Headshot Lounge, located in the Exhibit Hall. Professional photographers will be available to provide you with the perfect headshot for your next business card, resume, etc. Kiosks will be set up, which will display your photos and allow you to choose at least three that will be emailed directly to you.

Charging Lounges

Located in the back of the Exhibit Hall and in various areas of the convention center, these Daiichi Sankyo charging lounges provide attendees ample opportunity to charge their devices and take a well-deserved break during the meeting.

Exhibitor-Hosted Refreshment Breaks

Don’t miss the Exhibitor-Hosted Refreshment Breaks in the Exhibit Hall on Monday, April 11 and Tuesday, April 12, starting at 1:30 p.m. Light snacks will be available, compliments of the AACR exhibitors. Strategically located food and beverage stations are the ideal platform for interaction between attendees and exhibitors.

Food Court and Coffee Breaks

NeoGenomics is supporting the coffee breaks located throughout the Exhibit Hall. Additionally, in the back of the exhibit hall, you will find concession stands and a food court, with ample seating. Take a break during the meeting. A variety of good food will be available for purchase.
Landmarks in Cancer Research 1907-2022 Exhibit
Located in Hall F Lobby
Stop by this immersive experience that chronicles the events and discoveries that had a profound effect on advancing the knowledge of the causes, detection, diagnosis, treatment, and prevention of cancer throughout our rich history. In recognition of the 115th Anniversary of the AACR, and the impact it has made in the global cancer community, the Landmarks in Cancer Research exhibit is a living testament to those who strive to understand and eliminate the more than 200 diseases collectively known as cancer. It offers a tribute to the past and inspiration for the future.

AACR 115th Anniversary Shop
Located in Hall F Lobby
Located across from the Landmarks in Cancer Research exhibit, stop by the AACR 115th Anniversary Shop! The hours are:

- Sunday, April 10: 1:00 p.m.-5:00 p.m.
- Monday, April 11: 9:00 a.m.-5:00 p.m.
- Tuesday, April 12: 9:00 a.m.-5:00 p.m.
- Wednesday, April 13: 9:00 a.m.-12:30 p.m.

AACR Central
AACR Central serves as a hub for information and services for attendees and also as an event space for various programs. Open during Exhibit Hall hours, AACR Central is located centrally in the Exhibit Hall and is home to the Amphitheater, Membership Center, MICR Networking and Resource Center, WICR Networking and Resource Center, and information kiosks covering: Scientific Meetings and Workshops; AACR Foundation; AACR Publications; Scientific Review and Grants Administration; Science Policy and Advocacy; and much more.

At AACR Central, attendees can:
- Apply for AACR membership, learn more about AACR member benefits, and check on the status of membership.
- Participate in events organized by the Associate Member Council (AMC), Minorities in Cancer Research (MICR), Women in Cancer Research (WICR), the Science Education and Career Advancement Committee, and others.
- Find additional information on AACR’s conferences, award programs, advocacy efforts, and the AACR Foundation.
- Pick up copies of Cancer Today, AACR’s peer-reviewed journals, the AACR Cancer Progress Report, the AACR Cancer Disparities Progress Report, and Leading Discoveries magazine.

CancerCareers.org Center
Visit the CancerCareers.org Center to create your free jobseeker profile account to search for positions, post your CV/resume, and create job alerts.
CancerCareers is located on level 2, 260 Foyer of the Convention Center and is open during the following hours:
- Saturday, April 9: 9:00 a.m.-5:00 p.m.
- Sunday, April 10: 9:00 a.m.-5:00 p.m.
- Monday, April 11: 9:00 a.m.-5:00 p.m.
- Tuesday, April 12: 9:00 a.m.-5:00 p.m.
- Wednesday, April 13: 9:00 a.m.-1:00 p.m.
**Associate Member Meet and Greet**

**Sunday, April 10 • 8:00 p.m.-9:30 p.m.**
**Salon A, Hilton New Orleans Riverside**

Hosted by the AACR Associate Member Council (AMC), join fellow Associate members for an informal meet and greet and network with other early-career attendees; obtain information about programs, events, and initiatives specifically for Associate members both at the conference and throughout the year; and meet with those representatives who are advocating to the AACR on behalf of the needs and concerns of graduate students, medical students and residents, and clinical and postdoctoral fellows. Take advantage of some exciting promotions that will be available only for those who stop by this informal pop-up space and connect with other early-career attendees throughout the reception!

9:00 a.m. to 5:00 p.m. Sunday through Tuesday and from 9:00 a.m. until 12:00 p.m. on Wednesday.

**NCI/NIH Meeting Room**

The NCI/NIH Meeting Room, located in Room 297 of the Convention Center, provides researchers with the opportunity to interact with NCI and NIH Program Staff. Program and Review staff from the NCI as well as Review staff from CSR attend the Annual Meeting and can be available at the Meeting Room for discussions and consultation throughout the conference. Researchers interested in speaking with their Program Directors should contact them ahead of AACR to arrange a time to meet at the NCI Meeting Room. Conferences can be scheduled to discuss individual grant/review questions. New investigators are especially encouraged to meet with Program staff handling grant portfolios in their area of scientific interest. The Meeting Room will be open from

**Scientist↔Survivor Program®**

This unique international educational program provides an opportunity for cancer survivors, patient advocates, and scientists to share perspectives and discuss the latest findings in cancer research, regulatory science, and health policy. Led by Anna Barker, PhD, the curriculum is designed to build enduring partnerships among leaders in the scientific, cancer survivor, and patient advocacy communities.

The 5-day program provides patient advocates with an opportunity to attend special scientific sessions in plain language, present a poster highlighting their advocacy work, and network with leading cancer researchers and patient advocates. Participating scientists gain a better understanding of cancer’s impact on patients, are exposed to the key concerns of patients with cancer; and, explore the evolving role patient advocates play to support and advance cancer research. Promoting the exchange of information on key aspects of cancer research, survivorship, advocacy, and public policy strengthens communication and enhances efforts to accelerate progress in the fight against cancer.

To learn more about patient advocacy in cancer research, please visit the Scientist↔Survivor Program® Poster Sessions on April 11, from 1:30 p.m. to 5:00 p.m. and April 12, from 9:00 a.m. to 12:30 p.m. in the Poster and Exhibit Hall. To learn more about the AACR Scientist↔Survivor Program®, please visit [AACR.org](http://AACR.org) or email ssprogram@aacr.org.
AACR Advocacy Partners’ Pavilion

Visit the Advocacy Partners’ Pavilion, supported by Pfizer Oncology, located in the front of Exhibit Hall G, to learn more about nonprofit patient advocacy organizations focused on supporting patients with cancer and meet patient advocates who are leading the fight against cancer.

AACR Foundation

Join us for the 2022 AACR Runners for Research 5K Run/Walk on Saturday, April 9. Each year, our signature event kicks-off the AACR Annual Meeting, bringing together a community of scientists, patient advocates, healthcare professionals, and others to support the AACR’s mission to prevent and cure cancer. We hope that you will join us with your friends, family, and colleagues; it is a great way to engage in a healthy lifestyle activity while supporting cancer research.

This year’s 5K Run/Walk will take place along the scenic Crescent Park Riverfront. This beautiful course is part of the French Market District with breathtaking views of the riverfront and the city of New Orleans.

To register and learn more about this event, visit AACR.org/5K.

To learn about all the AACR Foundation activities and how you can get involved, stop by the AACR Foundation kiosk located in AACR Central in the Exhibit Hall.

Online Itinerary Planner and AACR Annual Meeting App

The Annual Meeting program is subject to change. Updates will be available in the online Itinerary Planner and the Annual Meeting App, along with full session details, including complete titles, author listings, and text for abstracts in poster sessions and minisymposia. To access the Itinerary Planner and download the Annual Meeting App, visit AACR.org/AACR2022.

Virtual Meeting Platform

Both in-person and virtual registration packages for the AACR Annual Meeting 2022 include access to live sessions, Q&A, networking, CME/MOC credits, and more. In-person registrants also receive complimentary access to the virtual meeting platform. Sessions that take place in hotels will not be included on the virtual meeting platform. Access to the virtual meeting will begin on April 8, 2022, and will run through July 13, 2022. For more information and to access the virtual meeting platform, visit AACR.org/AACR2022.
Coat and Luggage Check
Coat, package, and luggage check service will be available in Hall I-1 Lobby on the following schedule:

- **Friday, April 8**: 2:00 p.m.-7:00 p.m.
- **Saturday, April 9**: 6:30 a.m.-7:00 p.m.
- **Sunday, April 10**: 6:30 a.m.-8:30 p.m.
- **Monday, April 11**: 6:30 a.m.-8:30 p.m.
- **Tuesday, April 12**: 6:30 a.m.-8:30 p.m.
- **Wednesday, April 13**: 6:30 a.m.-3:00 p.m.

Special Accommodations for Attendees
The American Association for Cancer Research recognizes the importance of making its educational activities available to all interested participants of the professional medical community. This AACR educational activity is designed to accommodate all attendees and fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Registrants in need of auxiliary learning aids or special requirements for hotel accommodations, transportation, or other facilities connected with this meeting should contact the AACR Office in Room 238-239 of the Convention Center.

Code of Conduct, Policies, and Procedures
The AACR Annual Meeting 2022 will bring together academics, scientists, pharmaceutical industry representatives, and others from across the globe. In order for all participants to have the opportunity to gain the most benefit from this conference, the AACR is committed to providing a safe and secure environment. Please review the following policies and procedures for conference participants. By registering for the AACR Annual Meeting 2022, you agree to the following terms:

- All in person attendees must abide by the AACR Safety Guidelines and Procedures, which include but are not limited to the following:
  
  - Show proof of vaccination through the CrowdPass app or present your vaccination card and ID upon entering the Convention Center.
  
  - If you feel sick, please report to the first aid office and take a COVID test (testing is available on site at the Convention Center); should the test be positive, you must return to your hotel and quarantine.

- The AACR prohibits intimidating, threatening, or harassing conduct of any kind during this program. This applies to all participants—attendees, presenters, exhibitors, staff, vendors, etc.

- The AACR is committed to a safe, hospitable, and productive environment for all participants of this program, regardless of age, disability, ethnicity, gender, religion, or sexual orientation.
GENERAL INFORMATION

• The AACR expects all participants to communicate professionally and constructively, handling dissent and disagreement with courtesy, dignity, and an open mind, being respectful when providing feedback and being open to alternate points of view.

• Children under 5 years of age are not permitted in the Convention Center at any time. Children 5 years of age and older must be fully vaccinated and show proof of vaccination. Children under 12 years of age are not permitted in any scientific session, poster session, the exhibit hall, or any official event taking place at this program at any time. Children cannot be left unattended or unsupervised in the Convention Center.

• Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session. Participants should step out of session rooms to make calls or send emails or texts as the back lighting on electronic devices is distracting to other participants.

• The AACR expects participants to share information about this program responsibly and clearly distinguish individual opinion from fact.

• Participants must obey all applicable laws and regulations of the relevant government authorities while attending this program. Participants must comply with all applicable safety guidelines related to the conference venue.

• If a session room becomes too crowded, the AACR asks you to follow instructions provided by the AACR staff, Convention Center staff, or security. Instructions may include not standing against the walls, not blocking the aisles or doors, or being denied entry if the room becomes too crowded. The AACR and all participants are obligated to abide by the guidelines established by the Fire Marshal in the Convention Center. If a room reaches full capacity and there is not full cooperation, the Fire Marshal has the authority to delay or terminate the conference.

• The AACR encourages responsible drinking for those drinking alcohol. Beer and wine will be offered at some official events throughout this program. Alcohol will not be served to anyone under the age of 21. Alcoholic beverages are allowed in specific areas and must not be taken out of these areas.

COVID-19 Policy/Summary

Vaccination Verification
All attendees must be fully vaccinated. AACR is using the definition of “fully vaccinated” as established by the CDC. While we are not requiring that AACR Annual Meeting attendees receive a booster vaccine, we strongly encourage all attendees to be boosted.

All individuals who enter the convention center will access the venue through controlled access points where vaccination status will be verified. No attendee will be able pick up their badge without submitting proof of vaccination status.

Visit AACR.org/AACR2022 for more information.

Onsite Testing
There will be onsite testing in the Ernest N. Morial Convention Center located in Hall H Lobby.

Appointments are strongly encouraged and may be made online. Walk-in appointments will be available. Visit AACR.org/AACR2022 for more information.
The hours for testing are:

- Friday, April 8: 2:30 p.m.-5:30 p.m.
- Saturday, April 9: 12:00 p.m.-3:00 p.m.
- Sunday, April 10: 12:00 p.m.-3:00 p.m.
- Monday, April 11: 11:00 a.m.-5:00 p.m.
- Tuesday, April 12: 9:00 a.m.-6:00 p.m.
- Wednesday, April 13: 9:00 a.m.-12:00 p.m.

The AACR subsidizes the cost for this testing service. The final cost to the attendee will be $25 for a rapid antigen test, and $70 for a rapid PCR test.

**Photography and Social Media Policies**

**Photography.** Conference attendees may take photographs during oral or poster presentations provided that the photographs are strictly for personal, noncommercial use and are not to be published in any form. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience.

**Social Media.** Conference attendees may share information from presentations on social media provided that they respect the wishes of presenters. Oral presenters may label any or all slides in their presentations with “DO NOT POST.” Similarly, poster presenters may label their posters with “DO NOT POST.” Attendees must respect the presenters’ requests in these instances and refrain from posting any images from these designated slides or posters on social media.

**Emergency Response Procedures**

There are two first aid offices located in the Ernest N. Morial Convention Center in the Lobby of Hall D and the Lobby of Hall H. If you are displaying COVID symptoms, please go directly to onsite testing located in Hall H Lobby. Hours for testing are listed under COVID Policy.

If an emergency occurs, immediately call the Ernest N. Morial Convention Center Security at 504-582-3040 (or 3040 from a house phone). They will contact the New Orleans Police Department at the 9-1-1 Center via their direct line. Do not contact 9-1-1 yourself.

**No Smoking Regulation**

Smoking is prohibited in all areas of the Convention Center and at sessions and social events held in other venues.

**Notice of Photographer and Videographer on Premises**

A professional photographer and videographer may be on-site to document AACR Annual Meeting events and activities between April 8 and 13, 2022. Photographs and video footage are the sole property of AACR. By registering for and attending these events, attendees understand that AACR may use their likenesses for future promotional purposes. If you do not wish to be photographed, please notify the photographer and/or videographer on site.
Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
AACR has designated the AACR Annual Meeting 2022 live activity for a maximum of 398 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit
Credit survey
All individuals requesting continuing medical education credits must complete a CME Request for Credit Survey. The Request for Credit Survey will be accessible by logging into the AACR Annual Meeting 2022 Program Planner and via email. Registrants log on using their registration number and last name.

General instructions for claiming CME/CE credit
If you built a “My Itinerary" schedule, from “My Itinerary" click on “Add all eligible Sessions to Credit Cart”.
If you did not build a “My Itinerary" schedule, add the sessions you attended by browsing sessions by day, by session category, or by session. Click the “Add to Cart” icon to the right of each CME eligible session. (Note: non -CME sessions will not have this “Add to Cart” option.)

Print CME Certificate
Print your CME Certificate by clicking “CME Certificates” on the menu at right.

ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 398 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must complete all questions in the CME Request for Credit Survey and claim CME credit hours. Please then select “Request MOC Points Here” on the bottom right side of the screen. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives
The fight against cancer is rapidly progressing with the accelerating pace of discoveries in the basic, translational, and clinical sciences. This is due in large part to the advent of new technologies, such as advanced live imaging techniques and liquid biopsies, and our increased understanding of the importance of harnessing the power of the immune system to develop new
immunotherapies. However, understanding and combating the processes of cancer initiation, progression, and response to treatment require a multidisciplinary approach. The AACR Annual Meeting brings together cancer biologists, clinical oncologists, and population scientists with engineers, computational biologists, and physical scientists to develop quantitative approaches and ask new questions to develop better strategies for curing cancer. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Further, facilitating the interface between physicians and scientists increases the contributions of laboratory research to drug development as well as patient care, transforms the design and conduct of clinical research protocols, and creates an avenue for the rapid translation of laboratory research findings from “bench-to-bedside” for the benefit of improving patient outcomes. This meeting also acts as a forum to discuss cancer health disparities and help ensure that all patients benefit from emerging breakthroughs in research and cancer treatment.

Despite the tremendous progress in the field, cancer continues to be a global public health challenge, accounting for 1,670 deaths per day around the world. In the United States (U.S.) alone, it is predicted that 608,570 people will die from some form of cancer in 2021, making it the second most common cause of death after heart disease. One of the challenges we face is that cancer comprises more than 200 different diseases. For many of the most commonly diagnosed cancers in the U.S.—including lung, thyroid, bladder, ovarian, and colorectal cancer—incidence has been declining for more than a decade. However, incidence of other forms of cancer—including breast, renal pancreatic, endometrial, liver, and melanoma—has been on the rise. Incidence, diagnosis, access to treatment, and survival rates are also impacted by the cancer health disparities that exist in certain segments of the U.S. population, with older and underprivileged populations often witnessing higher incidences of cancer and mortality.

This conference will bring together investigators from the basic, translational, and clinical disciplines and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations. To provide the most advanced technologies and treatments, it is critical to bridge the gap between physicians who are answering fundamental questions about cancer biology and clinicians who are applying the latest diagnostic and treatment advances to patient care. As the incidence of cancer continues to increase, the fields of cancer prevention and early interception offer unprecedented opportunities to decrease the worldwide burden of cancer.

After participating in this CME activity, physicians should be able to:

1. Assess the technological advances and tools, such as liquid biopsies, being used to accelerate progress in cancer research and improve early detection and early interception, with the ultimate goal of extending patients’ lives and improving their quality of life.

2. Articulate how advances in precision cancer medicine are leading to improved patient outcomes.

3. Incorporate the latest research findings regarding therapies and treatment options, including immunotherapy and combination therapies, in a variety of cancer types to improve patient outcomes.
GENERAL INFORMATION

4. Formulate new strategies integrating multidisciplinary scientific and clinical research efforts towards the prevention, early detection, and interception of cancer.

5. Identify factors that impact the diagnosis, treatment, and prevention of various forms of cancers in patients from diverse populations.

6. Develop collaborations among physicians, researchers, and clinician-scientists to advance approaches for cancer treatment and prevention.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated. This disclosure information will be made available in the itinerary planner and the website of this conference.

Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants and will be disclosed at the activity.

Questions about CME?
Please contact the Office of CME at 215-440-9300 or cme@aacr.org.
New Orleans Marriott
Fourth Floor
FRIDAY, APRIL 8*

Professional Advancement Session • 1:00 p.m.-2:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room 260-262, Convention Center
The Dos and Don’ts for Graduate and Professional Students
Cochairs: Kathleen W. Scotto, New Brunswick, NJ; Augusto C. Ochoa, New Orleans, LA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.

Educational Sessions • 3:00 p.m.–4:30 p.m.
Great Hall BC, Convention Center
Cancer Dormancy and Immune Regulation
Chair: Maria Soledad Sosa, New York, NY
3:00 p.m. Elucidating the biology of disseminated tumor cell. Maria Soledad Sosa, New York, NY
3:30 p.m. The function of immune cells in residual disease and cancer recurrence. James V. Alvarez, Seattle, WA
4:00 p.m. Immune regulation of dormancy. Mikala Egeblad, Cold Spring Harbor, NY

New Orleans Theater C, Convention Center
Cancer Target Validation Using Chemical Probes
Chair: Cheryl H. Arrowsmith, Toronto, ON, Canada
3:00 p.m. Probing the cancer (epi)genome and transcriptome for therapeutic opportunities. Cheryl H. Arrowsmith, Toronto, ON, Canada
3:30 p.m. How to choose and use chemical probes for target validation: Help is at hand. Paul Workman, London, United Kingdom
4:00 p.m. Development of chemical probes for target validation in hematologic cancers. Jolanta E. Grembecka, Ann Arbor, MI
Room 243-245, Convention Center

**Degrading Undruggable Targets in Pediatric Cancer**

**Chair:** Nathanael S. Gray, Stanford, CA

3:00 p.m. **Targeted protein degradation: Current state-of-the-art.** Nathanael S. Gray, Stanford, CA

3:30 p.m. **Targeted degradation of mSWI/SNF chromatin remodeling complex components in human cancer.** Cigall Kadoch, Boston, MA

4:00 p.m. **Targeted protein degradation to drug and study tumorigenic chromatin regulation.** Michael A. Erb, La Jolla, CA

New Orleans Theater B, Convention Center

**Diet, Microbiota, and Cancer Immunotherapies**

**Chair:** Kathy McCoy, Calgary, AB, Canada

3:00 p.m. **The microbiome, diet, and immune response: From observation to intervention.** Jennifer McQuade, Houston, TX

3:30 p.m. **Microbiota-specific T cells support tertiary lymphoid structure formation and anti-colorectal cancer immunity.** Timothy Hand, Pittsburgh, PA

4:00 p.m. **Microbial-derived metabolites and their role in anti-tumor immunity.** Kathy McCoy, Calgary, AB, Canada

La Nouvelle Orleans C, Convention Center

**Epigenetics in Cancer**

**Chair:** Nada Jabado, Montréal, QC, Canada

3:00 p.m. **SWI/SNF (BAF) complex mutations in cancer: Mechanisms and vulnerabilities.** Charles W.M. Roberts, Memphis, TN

3:30 p.m. **Mechanisms of malignant transformation of the immune system.** Ari M. Melnick, New York, NY

4:00 p.m. **Deciphering oncohistone pathogenicity and exquisite vulnerabilities.** Nada Jabado, Montréal, QC, Canada
**FRIDAY, APRIL 8**

**New Orleans Theater A, Convention Center**

**Introduction to AI/ML in Cancer Genomics and Imaging**

**Chair:** Trey Ideker, La Jolla, CA

3:00 p.m.  **Quantifying tumor heterogeneity with single-cell and spatial sequencing technologies.** Benjamin J. Raphael, Princeton, NJ

3:30 p.m.  **Multi-modal and multi-scale modeling of glioma patients.** Olivier Gevaert, Stanford, CA

4:00 p.m.  **Identifying cancer drivers across scales: From mutations to genes to protein complexes and beyond.** Trey Ideker, La Jolla, CA

**Room 265-268, Convention Center**

**Regulatory Science and Policy Session**

**Using Patient-Generated Data to Optimize the Dose for Oncology Drugs**

**Moderator:** Mirat Shah, Silver Spring, MD

**Speaker titles to be announced.**

3:00 p.m.  Mirat Shah, Silver Spring, MD

3:10 p.m.  Paul G. Kluetz, Silver Spring, MD

3:20 p.m.  Vishal Bhatnagar, Silver Spring, MD

3:30 p.m.  Jeanne Fourie Zirkelbach, Olney, MD

3:40 p.m.  Mallorie Fiero, Silver Spring, MD

3:50 p.m.  Serban Ghiorghiu, Cambridge, United Kingdom

4:00 p.m.  Gita Thanarajasingam, Rochester, MN

4:10 p.m.  Karen E. Arscott, Scranton, PA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
**Methods Workshop • 3:00 p.m.–4:30 p.m.**

La Nouvelle Orleans A-B, Convention Center  
**Liquid Biopsy: From Biology to Clinical Use**

**Chair:** Catherine Alix-Panabieres, Montpellier, France

3:00 p.m.  
*Circulating tumor cells: A key biomarker in cancer patients and for the comprehension of the metastatic cascade.*  
Catherine Alix-Panabieres, Montpellier, France

3:30 p.m.  
*Considerations for bringing exosome and CTC technologies from the bench to the clinic.*  
Shannon L. Stott, Charlestown, MA

4:00 p.m.  
*Elaborating efficient ctDNA-based strategies for cancer patient follow-up: From development to clinical validation.*  
Valerie Taly, Paris, France

**Educational Sessions • 5:00 p.m.–6:30 p.m.**

New Orleans Theater A, Convention Center  
**Advances in Ligand Discovery Against Poorly Tractable Targets**

**Chair:** Mary M. Mader, Indianapolis, IN

5:00 p.m.  
*Introduction.*  
Mary M. Mader, Indianapolis, IN

5:01 p.m.  
*Chemical biology platforms to drug the undruggable.*  
Brandon Turunen, Collegeville, PA

5:30 p.m.  
*Targeted protein degradation: Access to new medicines by drugging challenging targets.*  
Christopher Nasveschuk, Stoneham, MA

6:00 p.m.  
*Enabling the discovery of new ligands for poorly tractable targets via DNA encoded libraries.*  
Katelyn Billings, Cambridge, MA

Great Hall BC, Convention Center  
**Increasing Diverse Participation in Biomedical Cancer Research: Best Practices and Innovation**

**Chair:** Clayton C. Yates, Tuskegee, AL

5:00 p.m.  
*Engagement strategies to increase diversity in the biomedical workforce.*  
Clayton C. Yates, Tuskegee, AL

5:30 p.m.  
*Triple-negative breast cancer: A clinical case for ancestry as the foundation to addressing cancer disparities.*  
Windy Dean-Colomb, Mobile, AL

6:00 p.m.  
*Transitioning from a basic science Ph.D. to a translational postdoctoral fellowship.*  
Jelani C. Zarif, Baltimore, MD
FRIDAY, APRIL 8

New Orleans Theater B, Convention Center
Predictive Biomarkers for Adjuvant Immunotherapy

Chair: Janis Marie Taube, Baltimore, MD

5:00 p.m.  Introduction to biomarkers in the adjuvant setting: Predictive vs prognostic.  
David L. Rimm, New Haven, CT

5:30 p.m.  Tissue-based biomarkers in the neoadjuvant/adjuvant setting.  
Janis Marie Taube, Baltimore, MD

6:00 p.m.  Peripheral blood ‘omics’ in the adjuvant setting.  
Tomas Kirchoff, New York, NY

La Nouvelle Orleans C, Convention Center
The Science Behind Cytokine Release Syndrome

Chair: Daniel W. Lee, Charlottesville, VA

5:00 p.m.  Title to be announced.  
Carl H. June, Philadelphia, PA

5:30 p.m.  Recognizing and managing cytokine release syndrome across T-cell therapeutics.  
Daniel W. Lee, Charlottesville, VA

6:00 p.m.  Title to be announced.  
Martin Hutchings, Copenhagen, Denmark

New Orleans Theater C, Convention Center
Understanding Cell Death in Cancer Therapy

Chair: Boyi Gan, Houston, TX

5:00 p.m.  Venetoclax plus hypomethylating agents in AML: From bedside to bench.  
Aaron Schimmer, Toronto, ON, Canada

5:30 p.m.  Ferroptosis: Mechanisms and implications for cancer therapy.  
Xuejun Jiang, New York, NY

6:00 p.m.  Targeting disulfide stress-induced cell death in cancer.  
Boyi Gan, Houston, TX

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Methods Workshops • 5:00 p.m.–6:30 p.m.

Room 243-245, Convention Center

Biobanks: Why You Need Them in Your Cancer Research Program

Chair: Mingyang Song, Boston, MA

5:00 p.m. Population biobanks in cancer epidemiology research. Mingyang Song, Boston, MA

5:30 p.m. Biobank in Africa: Strategies and possibilities. Olusegun Alatise, Ile-Ife, Nigeria

6:00 p.m. Expanding clinical trial biorepositories to improve multi-omic translational cancer research. David A. Drew, Boston, MA

La Nouvelle Orleans A-B, Convention Center

Spatial Transcriptomics and Cellular Imaging Analysis of the Tumor Microenvironment

Chair: Elana Judith Fertig, Baltimore, MD

5:00 p.m. Machine learning for pattern detection of spatial molecular data of cancer immunotherapy. Elana Judith Fertig, Baltimore, MD

5:30 p.m. Building a multiplexed imaging atlas of TiME in PDAC for advancing discovery and immune monitoring. Courtney Betts, Lake Oswego, OR

6:00 p.m. Spatially resolved multi-omics sequencing at genome scale and cellular level. Rong Fan, New Haven, CT
SUNDAY, APRIL 9*

**Educational Sessions • 8:00 a.m.–9:30 a.m.**
Room 220-222, Convention Center

**Cancer Survivorship**
*Chair: Smita Bhatia, Birmingham, AL*
8:00 a.m. **Landscape of cancer survivorship.** Smita Bhatia, Birmingham, AL
8:30 a.m. **Inequities in breast cancer survivorship.** Adana Llanos, New York, NY
9:00 a.m. **Models of care of cancer survivors.** Kevin C. Oeffinger, Durham, NC

Great Hall BC, Convention Center

**Chemistry to the Clinic, Part 1 of 3: Targeting RAS beyond KRASG12C**
*Co-chairs: Adrian L. Gill, Redwood City, CA; Kevan Michael Shokat, San Francisco, CA*
8:00 a.m. **Introduction.** Kevan Michael Shokat, San Francisco, CA
8:10 a.m. **Targeting oncogenic KRAS: Recent advances and opportunities for the future.** Piro Lito, New York, NY
8:35 a.m. **The beginning of the end for KRAS cancers.** Norbert Kraut, Ingelheim, Germany
9:00 a.m. **Discovery and development of RAS(ON) inhibitors beyond KRASG12C.** Elena S. Koltun, Redwood City, CA

La Nouvelle Orleans A-B, Convention Center

**Defining Cancer Evolution Types and Their Impact on Cancer**
*Chair: Henry Heng, Detroit, MI*
8:00 a.m. **Understanding cancer development through the lens of evolution.** Jamie Blundell, Cambridge, United Kingdom
8:30 a.m. **Genome chaos: Creating new genomic information essential for cancer evolution.** Henry Heng, Detroit, MI
9:00 a.m. **Polyploid giant cancer cells: Towards understanding the evil roots of evolution in cancers.** Jinsong Liu, Houston, TX

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers*
Room 353-355, Convention Center
Developing Replicable Genomic Classifiers of Cancer

Chair: Rob Scharpf, Baltimore, MD

8:00 a.m.  Applications of machine learning in cancer genomics. Rob Scharpf, Baltimore, MD
8:30 a.m.  Cross-study replicability of predictions in cancer: Challenges and opportunities. Giovanni Parmigiani, Boston, MA
9:00 a.m.  Translation of omics predictors to clinically useful tests: Avoiding the pitfalls and paving the way to success. Lisa M. McShane, Bethesda, MD

Room 356-357, Convention Center
Regulatory Science and Policy Session
Dose Optimization for Antibody-Drug Conjugates

Moderator: Mirat Shah, Silver Spring, MD
Speakers to be announced.

Room 265-268, Convention Center
The Evolving Crosstalk in the Cancer Stem Cell Niche

Chair: Naoki Oshimori, Portland, OR

8:00 a.m.  Cancer stem cell-driven signaling loop for the niche formation. Naoki Oshimori, Portland, OR
8:30 a.m.  Spatio-temporal tug-of-war for cytokines shapes the self-organization of leukocytes into inflammatory niches. Grégoire Altan-Bonnet, Bethesda, MD
9:00 a.m.  Cancer stem cell shapes the niche for supporting its survival, proliferation, and immune suppression. Linheng Li, Kansas City, MO
Room 243-245, Convention Center
**Novel Strategies to Target Cell Cycle and Transcriptional Cyclin-Dependent Kinases**

**Chair:** Geoffrey I. Shapiro, Boston, MA

- **8:00 a.m.** Building on the success of CDK4/6 inhibitors in HR+ breast cancer. Fabrice Andre, Villejuif, France
- **8:30 a.m.** Overcoming CDK4/6 inhibitor resistance: Targeting CDK2 and CDK6. Geoffrey I. Shapiro, Boston, MA
- **9:00 a.m.** Derailing the Pol II transcription cycle in cancer with CDK inhibitors. Robert P. Fisher, New York, NY

Room 343-345, Convention Center
**Pathology for Cancer Researchers**

**Chair:** Jiaoti Huang, Durham, NC

- **8:00 a.m.** Tumor pathology: Diagnosis, classification, grading and staging. Jiaoti Huang, Durham, NC
- **8:30 a.m.** PathOMICS: Next generation pathology for cancer research. Beatrice S. Knudsen, Salt Lake City, UT
- **9:00 a.m.** How molecular pathology tools lead to novel insights and inform tissue based genomics in cancer. Angelo Michael De Marzo, Baltimore, MD

New Orleans Theater B, Convention Center
**Precision Strategies for Cancer Risk Reduction**

**Chair:** Neil Mukund Iyengar, New York, NY

- **8:00 a.m.** Improving risk stratification to advance breast cancer precision prevention by optimizing data usage. Graham A. Colditz, Saint Louis, MO
- **8:30 a.m.** Prevention: From preclinical testing to high-risk populations. Florencia McAllister, Houston, TX
- **9:00 a.m.** Development of precision lifestyle interventions for cancer risk reduction. Neil Mukund Iyengar, New York, NY

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers*
Room 208-210, Convention Center

**Sex Matters: Understanding the Effect of Sex on Shaping the Tumor and Response to Cancer Therapy**

**Chair:** Amy Moran, Portland, OR

- **8:00 a.m.** Sex influences on cancer evolution and biomarkers. Paul C. Boutros, Los Angeles, CA
- **8:30 a.m.** Sex hormones and cancer immunotherapy. Amy Moran, Portland, OR
- **9:00 a.m.** Sex-specific differences in metabolism, microbiome, and cancer. Caroline Johnson, New Haven, CT

Great Hall AD, Convention Center

**Tumor Immunology and Immunotherapy for Nonimmunologists: The Immunological Basis of Durable Responses to Cancer Immunotherapy**

**Chair:** Sandra Demaria, New York, NY

- **8:00 a.m.** Therapeutic interventions to increase memory T cell generation. Sandra Demaria, New York, NY
- **8:30 a.m.** T cell memory and its regulation in the context of tumors. E. John Wherry, Philadelphia, PA
- **9:00 a.m.** Engineering T cells for persistence. Marcela V. Maus, Boston, MA

---

**Methods Workshops • 8:00 a.m.–9:30 a.m.**

New Orleans Theater A, Convention Center

**Artificial Intelligence in Cancer Imaging**

**Chair:** Edward H. Herskovits, Gaithersburg, MD

- **8:00 a.m.** Applications of AI in cancer imaging: Overview. Edward H. Herskovits, Gaithersburg, MD
- **8:30 a.m.** A deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA-targeted PET. Kevin Leung, Baltimore, MD
- **9:00 a.m.** Title to be announced. Marius Mayerhoefer, New York, NY
Room 217-219, Convention Center
Methods and Implications for Race- and Ancestry-based Population Descriptors in Cancer Research

Chair: Alice P. Popejoy, Sacramento, CA

8:00 a.m.  Broadening definitions of diversity to improve access to clinical trials in oncology. Lola A. Fashoyin-Aje, Silver Spring, MD

8:30 a.m.  Mapping population descriptors and open-ended dimensions of diversity to move beyond “Other”. Alice P. Popejoy, Sacramento, CA

9:00 a.m.  Additional speaker to be announced.

Professional Advancement Session • 9:00 a.m.–12:00 p.m.  
NOT ELIGIBLE FOR CME CREDIT

Bissonet Room, New Orleans Marriott
Not Your Mother’s Typical Grant Writing Session – I Promise!: Important Tips for Success from Experienced Scientists

Cochairs: Victoria L. Seewaldt, Duarte, CA; Robert A. Winn, Richmond, VA

Professional Advancement Session • 9:00 a.m.–4:00 p.m.  
NOT ELIGIBLE FOR CME CREDIT

Acadia Room, New Orleans Marriott
17th Annual AACR Undergraduate Student Caucus and Poster Competition (USCPC)

Chair: Kathleen W. Scotto, New Brunswick, NJ

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers
**Educational Sessions • 10:00 a.m.–11:30 a.m.**

Room 217-219, Convention Center

**Addressing Cancer Care Quality and Cancer Outcomes in Medicaid Populations**

**Chair:** Jennifer Tsui, Los Angeles, CA

**10:00 a.m.** Medicaid data as a critically important resource in cancer disparities research. Siran M. Koroukian, Cleveland, OH

**10:30 a.m.** Data and measurement challenges in assessing cancer outcomes in a Medicaid population. Cathy Bradley, Aurora, CO

**11:00 a.m.** Opportunities for using Medicaid data to inform qualitative data collection in cancer care delivery research. Jennifer Tsui, Los Angeles, CA

Room 220-222, Convention Center

**Advances in SHP2 Biology and Therapeutics for Targeting RAS-Driven Cancers**

**Chair:** Trever G. Bivona, San Francisco, CA

**10:00 a.m.** Molecular modifiers of SHP2 inhibitor sensitivity. Trever G. Bivona, San Francisco, CA

**10:30 a.m.** SHP2 inhibitor synthetic lethal drug combinations. René Bernards, Amsterdam, Netherlands

**11:00 a.m.** Title to be announced. Benjamin G. Neel, New York, NY

Room 243-245, Convention Center

**Chemistry to the Clinic, Part 2 of 3: Progress in Small Molecule Cancer Immunology Therapy**

**Cochairs:** Chudi Ndubaku, South San Francisco, CA; Jeffrey Mckenna, Cambridge, MA

**10:00 a.m.** HPK1 inhibition: The key to unleashing tumor-specific T cell responses. George Katibah, South San Francisco, CA

**10:30 a.m.** Discovery of a first-in-class molecular glue degrader for immuno-oncology indications. Simone Bonazzi, Cambridge, MA

**11:00 a.m.** Optimizations leading to ORIC-533: A potent orally bioavailable CD73 inhibitor that restores anti-tumor immunity in high AMP environments. Chudi Ndubaku, South San Francisco, CA
SATURDAY, APRIL 9

Considerations of Tissue-Specific Aging in Cancer Research

Chair: Sandra S. McAllister, Boston, MA

10:00 a.m. Age-induced metabolic reprogramming: A bridge between the aging process and tumorogenesis. Ana Gomes, Tampa, FL

10:30 a.m. The yin and yang of aging: Sex based differences in the aging tumor microenvironment impact tumor progression. Ashani T. Weeraratna, Baltimore, MD

11:00 a.m. Considerations of immunologic age in cancer progression and therapeutic responses. Sandra S. McAllister, Boston, MA

Drug Resistance: Challenges and Prospects

Chair: Sanjay V. Malhotra, Lake Oswego, OR

10:00 a.m. Designing drugs to target resistance. Sanjay V. Malhotra, Lake Oswego, OR

10:30 a.m. Mechanisms of combination cancer therapy in overcoming intrinsic and acquired drug resistance. Peter K. Sorger, Boston, MA

11:00 a.m. Many faces of resistance to targeted therapy. Charles L. Sawyers, New York, NY

Examining Tissue Specific Stroma to Increase Therapeutic Opportunities in Metastasis

Chair: Sheila A. Stewart, St. Louis, MO

10:00 a.m. Getting old stinks: Targeting the metastatic stroma to reduce breast cancer progression. Sheila A. Stewart, St. Louis, MO

10:30 a.m. The balancing act of tissue repair and cancer. Ilaria Malanchi, London, United Kingdom

11:00 a.m. Stromal and immune plasticity shape the metastatic microenvironment. Neta Erez, Tel Aviv, Israel

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers
Great Hall BC, Convention Center

**Minimal Residual Disease in Solid Tumors: What Does It Mean and How Should It Guide Treatment Decision-Making?**

**Chair:** Jeanne Tie, Melbourne, Australia

10:00 a.m.  *Potential and challenges of MRD detection with circulating tumor DNA analysis.* Jeanne Tie, Melbourne, Australia

10:30 a.m.  *Biology of micrometastasis and challenges of MRD detection with circulating tumor cells.* Klaus Pantel, Hamburg, Germany

11:00 a.m.  *Defining the clinical utility of MRD testing: Path to guiding treatment decision making.* Daniel F. Hayes, Ann Arbor, MI

New Orleans Theater A, Convention Center

**Natural Killer (NK) Cells: From Cancer Orchestrators to Car-NK Therapy**

**Chair:** Eric Vivier, Marseille, France

10:00 a.m.  *Engineered NK cells: The next frontier in cancer immunotherapy.* Katayoun Rezvani, Houston, TX

10:30 a.m.  *ANKET: Antibody-dependent NK cell engager therapeutics.* Eric Vivier, Marseille, France

11:00 a.m.  *Expanding the cell-therapy arsenal: CAR-T versus CAR-NK in 2022.* Yvonne Y. Chen, Los Angeles, CA

Room 208-210, Convention Center

**Organoids in Cancer Research**

**Chair:** Luis G. Carvajal-Carmona, Davis, CA

10:00 a.m.  *The utility of patient-derived models to understand cancer biology, develop better therapies, and advance cancer health equity.* Luis G. Carvajal-Carmona, Davis, CA

10:30 a.m.  *Utilizing patient-derived organoid models to address cancer health disparities in gastric cancer.* Nicole B. Halmi, Davis, CA

11:00 a.m.  *Patient-derived models of breast cancer for pre-clinical research and functional precision medicine.* Alana L. Welm, Salt Lake City, UT
Great Hall AD, Convention Center

**Single Cell Biology in Scale and Spatial Genomics**

*Chair:* H. Courtney Hodges, Houston, TX

10:00 a.m.  *Emerging concepts and new technologies for high-resolution tumor biology.*  
H. Courtney Hodges, Houston, TX

10:30 a.m.  *Single cell analysis of epigenome in normal and tumor tissues.*  
Bing Ren, La Jolla, CA

11:00 a.m.  *Decoding spatially-resolved tumor microenvironments at single-cell resolution and massive scale.*  
Aaron M. Newman, Stanford, CA

La Nouvelle Orleans A-B, Convention Center

**Systems Biology Approaches to Cancer**

*Chair:* Laura M. Heiser, Portland, OR

10:00 a.m.  *Systems approaches to improve clinical outcomes.*  
Andrea H. Bild, Monrovia, CA

10:30 a.m.  *Systems approaches to targeting cell states in the tumor ecosystem.*  
Laura M. Heiser, Portland, OR

11:00 a.m.  *Systems approaches for identifying cell states and pathways modulating therapy response.*  
Aaron S. Meyer, Los Angeles, CA

---

**Methods Workshops • 10:00 a.m.–11:30 a.m.**

Room 265-268, Convention Center

**Design and Analysis of Real-World Data for Cancer Research**

*Chair:* Yu Shyr, Nashville, TN

10:00 a.m.  *Statistical strategies for analyzing real-world data in cancer research.*  
Yu Shyr, Nashville, TN

10:25 a.m.  *Network models for multi-omics data.*  
Denise M. Scholtens, Chicago, IL

10:50 a.m.  *Methods for utilizing the external controls and a single arm oncology study for assessing the treatment effect.*  
Lee-Jen Wei, Boston, MA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers*
Spatial Analysis on the Tumor Microenvironment

**Chair:** Long Cai, Pasadena, CA

**10:00 a.m.**  
**Spatial genomics: in situ single cell profiling.** Long Cai, Pasadena, CA

**10:30 a.m.**  
**Assessing tumor heterogeneity through spatial molecular profiling.** John D. Carpten, Los Angeles, CA

**11:00 a.m.**  
**Spatial transcriptomic analysis of complex tumor microenvironments.**  
Kristin Beaumont, New York, NY

---

Educational Sessions • 12:30 p.m.–2:00 p.m.

**Great Hall AD, Convention Center**

**Combination Therapeutic Strategies in the Treatment of Lung Cancer**

**Chair:** David Paul Carbone, Columbus, OH

**12:30 p.m.**  
**Combination of medical therapies with surgery in early stage.** David Paul Carbone, Columbus, OH

**1:00 p.m.**  
**Combining radiation therapy with systemic therapies in lung cancer.**  
Terence M. Williams, Duarte, CA

**1:30 p.m.**  
**Finding rational combinations of medical therapies in lung cancer.** Darren R. Tyson, Nashville, TN

---

Room 356-357, Convention Center

**Regulatory Science and Policy Session**

**Highlighting the AACR/HBS/MMRF Summit: Reducing Disparities and Democratizing Cancer Care**

**Moderators:** Kathy Giusti, Norwalk, CT; John D. Carpten, Los Angeles, CA

**Speakers:**
Kathy Giusti, Norwalk, CT  
John D. Carpten, Los Angeles, CA  
Andy Schmeltz, New York, NY  
Patricia Doykos, New York, NY  
Leonardo Seoane, New Orleans, LA  
Richard Barakat, New Hyde Park, NY  
Brian M. Rivers, Atlanta, GA  
Robert A. Winn, Richmond, VA  
Edith P. Mitchell, Philadelphia, PA  
Lola A. Fashoyin-Aje, Silver Spring, MD  
Catherine Chao, New York, NY  
David Wholley, North Bethesda, MD
Room 353-355, Convention Center

Implementation Science: Efforts to Improve Cancer Health Equity

Cochairs: Camille C.R. Ragin, Philadelphia, PA; Folakemi T. Odedina, Jacksonville, FL

12:30 p.m. Why health equity should be a more prominent and central aim of implementation science. Camille C. R. Ragin, Philadelphia, PA

1:00 p.m. Systems thinking approach in implementation science: Understanding the layers of health inequity. Patti E. Gravitt, Rockville, MD

1:30 p.m. Testing implementation hypothesis: Research designs and best practices. Folakemi T. Odedina, Jacksonville, FL

New Orleans Theater B, Convention Center

Metabolism, Inflammation, and Immunotherapy

Chair: Augusto C. Ochoa, New Orleans, LA

12:30 p.m. Introduction. Augusto C. Ochoa, New Orleans, LA

12:35 p.m. Insulin, insulin-resistance, and biologically aggressive cancers: Targets for intervention. Victoria L. Seewaldt, Duarte, CA

1:03 p.m. Targeting stat3 in breast cancer: Impact on metabolism. Qiang Shen, New Orleans, LA

1:31 p.m. Regulation of anti-tumor immunity by endoplasmic reticulum stress. Paulo C. Rodriguez, Tampa, FL

La Nouvelle Orleans A-B, Convention Center

Novel Antibody Drug Conjugates

Chair: Kenneth S. Thress, Waltham, MA

12:30 p.m. Novel ADC payloads with a focus on radioimmunoconjugates. Kenneth S. Thress, Waltham, MA

1:00 p.m. Antibody drug conjugates and the BCL-XL journey. Andrew J. Souers, North Chicago, IL

1:30 p.m. Patient selection for ADCs with cytotoxic and noncytotoxic payloads. Funda Meric-Bernstam, Houston, TX

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers
Room 208-210, Convention Center

**Radiotheranostics for Cancer**

**Chair:** Lilja B. Solnes, Baltimore, MD

12:30 p.m. **Radioligand therapy in neuroendocrine tumors.** Lilja B. Solnes, Baltimore, MD

1:00 p.m. **Radiotheranostics in prostate cancer.** Steve P. Rowe, Baltimore, MD

1:30 p.m. **Emerging theranostic targets.** Rudolf Werner, Würzburg, Germany

Room 343-345, Convention Center

**Regeneration, Resistance, and Recovery in Irradiated Tissues**

**Chair:** Mary Helen Barcellos-Hoff, San Francisco, CA

12:30 p.m. **The radiobiology of TGFβ in tumor control.** Mary Helen Barcellos-Hoff, San Francisco, CA

1:00 p.m. **Influence of the stem cell niche on post-irradiation regeneration of the salivary gland.** Rob P. Coppes, Groningen, Netherlands

1:30 p.m. **Epithelial cell plasticity in intestinal regeneration.** Elaine E. Storm, South San Francisco, CA

New Orleans Theater A, Convention Center

**Roles of RNA in Cancer and Cancer Therapies**

**Chair:** Chuan He, Chicago, IL

12:30 p.m. **RNA methylation in cancer.** Chuan He, Chicago, IL

1:00 p.m. **Targeting altered RNA expression and splicing in cancer.** Luisa Escobar-Hoyos, New Haven, CT

1:30 p.m. **RNA nanomedicine: A new therapy for cancer.** Jinjun Shi, Boston, MA

Room 217-219, Convention Center

**The Importance of Surgeon Engagement for Translational Cancer Research**

**Chair:** John H. Stewart, New Orleans, LA

12:30 p.m. **A historical perspective on the contributions of surgical oncologists to translational cancer research.** John H. Stewart, New Orleans, LA

1:00 p.m. **Through the lens of a surgeon.** Jen Jen Yeh, Chapel Hill, NC

1:30 p.m. **The power of the surgeon-scientist team: A perspective from a basic, translational researcher.** Jonathan R. Brody, Philadelphia, PA
SATURDAY, APRIL 9

Methods Workshops • 12:30 p.m.–2:00 p.m.

Room 220-222, Convention Center

Introduction to Network Biology and Knowledge Graphs in Cancer Research

Chair: Sarki Abdulkadir, Chicago, IL

12:30 p.m.  Mechanism-centric and network-based computational methods in cancer research. Antonina Mirofanova, Newark, NJ

1:00 p.m.  Cytoscape workflow for cancer genomics and proteomics. John Morris, San Francisco, CA

1:30 p.m.  Biological insights from coessentiality network analysis. Sarki Abdulkadir, Chicago, IL

Room 265-268, Convention Center

Molecular Glues for Targeted Protein Degradation and Beyond

Chair: Eric Sebastian Fischer, Boston, MA

12:30 p.m.  Molecular glues as interface stabilizers for degradation and beyond. Eric Sebastian Fischer, Boston, MA

1:00 p.m.  Co-opting the ubiquitin system for therapeutic benefit. Ingrid E. Wertz, Princeton, NJ

1:30 p.m.  Omics approach to drug discovery. Liron Bar-Peled, Charlestown, MA

Room 243-245, Convention Center

Using Real-World Clinico-genomic Data: AACR Project GENIE as a Use Case

Chair: Shawn Sweeney, Philadelphia, PA

12:30 p.m.  Data collection and quality assurance to ensure data usability. Michele L. LeNoue-Newton, Nashville, TN

1:00 p.m.  Harmonizing different data sources for analysis. Haley Hunter-Zinck, Seattle, WA

1:30 p.m.  Using cBioPortal to explore real-world clinico-genomic data. Ritika Kundra, New York, NY

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers
Educational Sessions • 2:30 p.m.–4:00 p.m.

Room 353-355, Convention Center

Big Data Resources in Pediatric Cancer

Chair: Jinghui Zhang, Memphis, TN

2:30 p.m. Big data resources and cloud-based analysis for pediatric cancers and survivors on St. Jude Cloud. Jinghui Zhang, Memphis, TN

3:00 p.m. Democratizing pediatric cancer research data through the pediatric cancer data commons. Samuel L. Volchenboum, Chicago, IL

3:30 p.m. Advancing collaborative accelerated discovery through the Gabriella Miller Kids First Data Resource. Adam C. Resnick, Philadelphia, PA

New Orleans Theater A, Convention Center

Chemistry to the Clinic, Part 3 of 3: Evolution of Computational Tools and Strategies to Advance Oncology Drug Development

Cochairs: Patrick Walters, Cambridge, MA; Hans Purkey, South San Francisco, CA

2:30 p.m. Introduction. Hans Purkey, South San Francisco, CA

2:31 p.m. Computational molecular design in drug discovery programs: What is used? What is useful? What comes next? Clara Christ, Berlin, Germany

3:01 p.m. The impact of artificial intelligence on molecular design. Patrick Walters, Cambridge, MA

3:31 p.m. Computational tools for the rational design and optimization of degraders. Huan Rui, Thousand Oaks, CA

La Nouvelle Orleans A-B, Convention Center

Diet and Lifestyle Risks for Cancer

Chair: Lewis C. Cantley, New York, NY

2:30 p.m. Dietary patterns and prostate cancer risk and progression. Lorelei A. Mucci, Boston, MA

3:00 p.m. Reducing cancers by limiting certain amino acids in diets. Karen H. Vousden, London, United Kingdom

3:30 p.m. Insulin-lowering diets for preventing or treating cancers. Lewis C. Cantley, New York, NY
Great Hall BC, Convention Center
**Immunocytokines: Strategies for Drug Delivery and Tissue Targeting**

**Chair:** Laura Codarri Deak, Zurich, Switzerland

**2:30 p.m.** Anti-PD1/IL7v immunocytokine promotes durable T-cell responses and overcomes anti-PD1 resistance. Nicolas Poirier, Nantes, France

**3:00 p.m.** Potency reduction and half-life extension of cytokines improves therapeutic index for the treatment of cancer: XmAb662 (IL12-Fc) case study. Matthew J. Bernett, Monrovia, CA

**3:30 p.m.** Differentiating tumor-specific PD-1+TCF-1+ stem-like resource CD8 T cells towards a distinct effector T cell population through PD-1 mediated delivery of IL-2v. Laura Codarri Deak, Zurich, Switzerland

Great Hall AD, Convention Center
**Neoadjuvant Immunotherapy: The Next Steps Towards Perfectionism and Personalization**

**Chair:** Christian Blank, Amsterdam, Netherlands

**2:30 p.m.** Good timing: The science of neoadjuvant immunotherapy. Elizabeth Ahern, Victoria, Australia

**3:00 p.m.** Maximizing translational discoveries in neoadjuvant IO clinical trials. Kellie N. Smith, Baltimore, MD

**3:30 p.m.** Melanoma as a posterchild for personalized neoadjuvant immunotherapy. Christian Blank, Amsterdam, Netherlands

Room 343-345, Convention Center
**Outreach and Education in COVID-19 Times: Opportunities and Lessons Learned**

**Chair:** Laura Fejerman, San Francisco, CA

**2:35 p.m.** Adaptation of a hereditary breast cancer community health educator-led outreach and education program during the COVID-19 lockdown. Laura Fejerman, San Francisco, CA

**2:55 p.m.** Using digital advocacy strategies to promote health equity amid COVID-19. Amelie G. Ramirez, San Antonio, TX

**3:25 p.m.** Education, engagement, and outreach during a pandemic. Carolina Aristizabal, Los Angeles, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers*
Room 208-210, Convention Center
**Polygenic Risk Scores: Considerations for Development and Evaluation**

**Chair:** Stephen J. Chanock, Rockville, MD

**2:30 p.m.** Facts and fiction of polygenic risk scores in cancer. Stephen J. Chanock, Rockville, MD

**3:00 p.m.** Methods for constructing a trans-ancestry polygenic risk score and application to prostate cancer. David V. Conti, Los Angeles, CA

**3:30 p.m.** Polygenic risk scores for breast cancer risk prediction. Weang-Kee Ho, Semenyih, Malaysia

Room 243-245, Convention Center
**Unfolding the Unfolded Protein Response (UPR) as a Potential Therapeutic Target in Cancer**

**Chair:** J. Alan Diehl, Columbus, OH

**2:30 p.m.** PERK responsive micro-RNAs coordinate cell fate in response to proteotoxic activation of the UPR. J. Alan Diehl, Columbus, OH

**3:00 p.m.** Intracellular and extracellular roles of protein disulfide isomerases in cancer. Boaz Tirosh, Jerusalem, Israel

**3:30 p.m.** Microenvironment stress in the intratumoral cytotoxic T lymphocytes. Serge Y. Fuchs, Philadelphia, PA

---

**Methods Workshops • 2:30 p.m.–4:00 p.m.**

Room 265-268, Convention Center
**Engineering a New Generation of Nanomedicines**

**Chair:** Gabe Kwong, Atlanta, GA

**2:30 p.m.** Synthetic biomarkers: A twenty-first century path to early cancer detection. Gabe Kwong, Atlanta, GA

**3:00 p.m.** Ultra-pH sensitive nanoparticles for tumor-activatable biologics delivery and immunotherapy. Jinming Gao, Dallas, TX

**3:30 p.m.** Discovery and translation of therapeutics via nanotechnologies. Daniel A. Heller, New York, NY
Room 220-222, Convention Center  
**Mitochondrial Dynamics**

*Chair:* David Kashatus, Charlottesville, VA

**2:30 p.m.**  
A live cell imaging pipeline for quantifying mitochondrial inter-organelle interactions.  
Anne Hamacher-Brady, Baltimore, MD

**3:00 p.m.**  
An automated, code-free method for single cell analysis of mitochondrial structure.  
David Kashatus, Charlottesville, VA

**3:30 p.m.**  
3-dimensional structural and functional imaging of mitochondrial networks in lung tumors.  
David B. Shackelford, Los Angeles, CA

New Orleans Theater B, Convention Center  
**Three-dimensional Genome Organization is Important for Proper Gene Regulation and Normal Cell Functions**

*Chair:* Feng Yue, Chicago, IL

**2:30 p.m.**  
Characterizing regulatory chromatin loops in the cancer.  
Feng Yue, Chicago, IL

**3:00 p.m.**  
Structural variants and their impact on 3D genome regulation in cancer genome.  
Jesse Dixon, La Jolla, CA

**3:30 p.m.**  
Strategies for multi-omics mapping of 3D epigenomes in cancer.  
Chia-Lin Wei, Bar Harbor, ME

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers*
Plenary Session • 4:15 p.m.–6:15 p.m.

Hall B-C, Convention Center
Precancer Discovery Science

Chair: Catriona H.M. Jamieson, La Jolla, CA

4:15 p.m.  Introduction. Catriona H.M. Jamieson, La Jolla, CA

4:20 p.m.  Niche dependent pre-cancer stem cell detection and eradication.
           Catriona H.M. Jamieson, La Jolla, CA

4:42 p.m.  Transforming early detection and interception via a pre-cancer atlas.
           Avrum E. Spira, Boston, MA

5:04 p.m.  From population to personalized prevention: Lessons from Barrett’s esophagus.
           Rebecca Fitzgerald, Cambridge, United Kingdom

5:26 p.m.  Somatic mosaicism for classic oncogenic drivers: Unique insights into cancer.
           Veronica Kinsler, London, United Kingdom

5:48 p.m.  Genomic medicine meets cancer interception. Susan M. Domchek,
           Philadelphia, PA

6:10 p.m.  Wrap-up and opportunities for the future. Catriona H.M. Jamieson,
           La Jolla, CA
**SUNDAY, APRIL 10**

Meet-the-Expert Sessions • 7:00 a.m.–7:45 a.m.

- Room 243-245, Convention Center
  The Current Status of Precision Medicine Trials in Cancer: Towards a Future Precision Medicine Strategy
  Gary Middleton, Birmingham, United Kingdom

- Room 260-262, Convention Center
  The Genomics of HPV Integration in Cancers
  Maura L. Gillison, Houston, TX

- Room 293-294, Convention Center
  Improving Treatment of Primary and Metastatic Brain Tumors: Emerging Strategies
  Rakesh K. Jain, Boston, MA

- Room 208-210, Convention Center
  Integrating Evolutionary Dynamics into Treatment for Metastatic Cancers
  Robert A. Gatenby, Tampa, FL

- Room 220-222, Convention Center
  Lessons Learned Leading a Comprehensive Translational Program in Pancreatic Cancer: Precision Medicine One Patient at a Time
  Jennifer J. Knox, Toronto, ON, Canada

- Room 265-268, Convention Center
  Mechanisms of Malignant Transformation of the Immune System and Precision Immunotherapy
  Ari M. Melnick, New York, NY

- Room 353-355, Convention Center
  Novel Data Science Development
  Xihong Lin, Boston, MA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room 217-219, Convention Center  
**Patient-Derived Organoids: From Drug Development to Precision Oncology**  
Nicola Valeri, Sutton, United Kingdom

Room 278-282, Convention Center  
**The Role of a Commonly Used Medication in the Prevention of Ovarian and Endometrial Cancers: A Spotlight on Statins**  
Britton Trabert, Salt Lake City, UT

Room 295-296, Convention Center  
**Targeting Clonal Heterogeneity in Treatment-refractory Brain Cancers with Rationally Designed Immunotherapies: Advances and Challenges**  
Sheila Kumari Singh, Dundas, ON, Canada

---

**Opening Ceremony • 7:45 a.m.–9:45 a.m.**  
*NOT ELIGIBLE FOR CME CREDIT*

Hall B-C, Convention Center  
Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science.  
Highlights of this year’s Opening Ceremony will feature

• a live performance by the Preservation Hall All-Stars Jazz Band;  
• a special 115th Anniversary video marking the progress of the AACR as the Driving Force to Eradicate Cancer;  
• presentation of the Inaugural AACR James S. Ewing-Thema B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research;  
• presentation of the Inaugural Victoria’s Secret Global Fund for Women’s Cancers 2022 Meritorious Awards, In Partnership with Pelotonia and AACR;  
• presentation of the Inaugural AACR Award for Outstanding Achievement in Blood Cancer Research award;  
• and many other important recognitions and awards. Don’t miss this exciting event!
SUNDAY, APRIL 10

Opening Plenary Session • 9:45 a.m.–12:00 p.m.

Hall B-C, Convention Center
Opening Plenary Session: Decoding Cancer Complexity, Integrating Science, Transforming Patient Outcomes

Chair: Marcia R. Cruz-Correa, San Juan, PR

9:45 a.m.  Introduction. Marcia R. Cruz-Correa, San Juan, PR

9:50 a.m.  The pathogenesis of cancer susceptibility due to inherited DNA repair defects. Michael R. Stratton, Cambridge, United Kingdom

10:10 a.m.  Quantitative approaches to tumor evolution and therapeutic resistance. Franziska Michor, Boston, MA

10:30 a.m.  Genotoxic gut bacterial metabolites and their roles in colorectal cancer initiation. Jason M. Crawford, West Haven, CT

10:50 a.m.  The role of metabolites and diet in anti-tumor immunity. Marcia Haigis, Boston, MA

11:10 a.m.  Multi-cancer early detection: Opportunity and challenges. Nickolas Papadopoulos, Baltimore, MD

11:30 a.m.  Future of cancer research in transforming patient outcomes. Charles L. Sawyers, New York, NY

11:45 a.m.  Wrap-up and final remarks. Marcia R. Cruz-Correa, San Juan, PR

Special Session • 1:00 p.m.–2:00 p.m.

Room 343-345, Convention Center
Decoding Cancer Complexity and Transforming Patient Outcomes Using AACR Project GENIE

Chair: Philippe L. Bedard, Toronto, ON, Canada

1:05 p.m.  Using genetic ancestry to redefine the role of race and ethnicity in patient prognosis and outcomes. Jian Carrot-Zhang, Cambridge, MA

1:20 p.m.  The BPC NSCLC 2.0-public release, a new open-access tool for decoding the complexity of lung cancer. Gregory J. Riely, New York, NY

1:35 p.m.  Title to be announced. Rob Scharpf, Baltimore, MD

1:50 p.m.  Charting the future of GENIE. Philippe L. Bedard, Toronto, ON, Canada

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
NCI/NIH-Sponsored Session • 1:00 p.m.–2:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room 298-299, Convention Center

NCI Consortia Initiative: Response to Cancer Moonshot Recommendation to Establish a Network for Direct Patient Engagement

Moderator: Leah E. Mechanic, Rockville, MD

Presenters:

The Cancer Moonshot Biobank.
Helen M. Moore, Rockville, MD
Janet Freeman-Daily, Washington, DC

My Pediatric and Adult Rare Tumor (MyPART) Network.
Abby Sandler, Bethesda, MD
Josh Sommer, Durham, NC

Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT)
Terri S. Armstrong, Bethesda, MD
Kimberly Wallgren, Zionsville, IN

Count Me In: Osteosarcoma and Leiomyosarcoma Projects
Nikhil Wagle, Cambridge, MA
Maeve Smart, Cambridge, MA

CME Advances in Diagnostics and Therapeutics
1:00 p.m.–2:30 p.m.

Great Hall AD, Convention Center

Advances in Precision Diagnostics and Therapeutics

Chair: Andrea Califano, New York, NY

1:00 p.m. Introduction. Andrea Califano, New York, NY

1:05 p.m. Precision non-oncogene dependence targeting at the single cell level. Andrea Califano, New York, NY

1:30 p.m. Targeting adaptive responses to therapy in cancer. Gordon B. Mills, Portland, OR

1:55 p.m. Illuminating actionable dependencies in cancer pathways. Michael T. McManus, San Francisco, CA
Room 265-268, Convention Center

**The Bone Marrow Immune Microenvironment**

**Chair:** Hind Medyouf, Frankfurt, Germany

1:00 p.m. **Introduction.** Hind Medyouf, Frankfurt, Germany
1:05 p.m. **Niche co-option and immune evasion in acute leukemia.** Hind Medyouf, Frankfurt, Germany
1:30 p.m. **The role of inflammation in the initiation and progression of acute myeloid leukemia.** Iannis Aifantis, New York, NY
1:55 p.m. **Defining the role of the immune microenvironment in disease progression from MGUS to myeloma.** Irene M. Ghobrial, Boston, MA

Room 243-245, Convention Center

**Cancer Metabolic Phenotypes: A Precision Medicine Perspective for Radiation Oncology?**

**Chair:** David G. Kirsch, Durham, NC

1:00 p.m. **Introduction.** David G. Kirsch, Durham, NC
1:05 p.m. **Targeting metabolism to improve sarcoma response to radiation therapy.** David G. Kirsch, Durham, NC
1:30 p.m. **Targeting metabolic vulnerabilities to sensitize non-small cell lung cancer (NSCLC) to radiation.** Faith Zhang, Dallas, TX
1:55 p.m. **Linking glioblastoma purine metabolism and radiation resistance in the laboratory and clinic.** Daniel Richard Wahl, Ann Arbor, MI

** hm Advances in Organ Site Research • 1:00 p.m.–2:30 p.m.**

La Nouvelle Orleans C, Convention Center

**Understanding Microbe-Tumor Relationships in Colorectal Cancer**

**Chair:** Woong-Yang Park, Seoul, Republic of Korea

1:00 p.m. **Introduction.** Woong-Yang Park, Seoul, Republic of Korea
1:05 p.m. **Interaction of microbiome and host immune cell in colorectal cancer.** Woong-Yang Park, Seoul, Korea, Republic of
1:30 p.m. **Biofilms, bacteria, and host gene interactions in colon cancer.** Cynthia L. Sears, Baltimore, MD
1:55 p.m. **Microbiota shapes the tumor microenvironment to promote anticancer immunity.** Romina Goldszmid, Bethesda, MD

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Advances in Prevention Research • 1:00 p.m.–2:30 p.m.
Room 260-262, Convention Center

Combustible and Non-Combustible Tobacco Products
Chair: Jonathan M. Samet, Aurora, CO

1:00 p.m.  Introduction. Jonathan M. Samet, Aurora, CO
1:05 p.m.  Characteristics of combustible and non-combustible products: Recent developments and insights. Irina Stepanov, Minneapolis, MN
1:30 p.m.  Non-combustible and combustible tobacco products: Unsettled issues on risks and benefits. Loic Le Marchand, Honolulu, HI
1:55 p.m.  New and old tobacco products: Setting policies that protect public health. Jonathan M. Samet, Aurora, CO

Advances in the Science of Cancer Health Disparities
1:00 p.m.–2:30 p.m.
Room 208-210, Convention Center

Molecular Epidemiology of Stress and Discrimination and Cancer Outcomes
Chair: Melissa B. Davis, New York, NY

1:00 p.m.  Introduction. Melissa B. Davis, New York, NY
1:05 p.m.  Structure and stress: An examination of discrimination and health outcomes in breast cancer survivors. Vanessa B. Sheppard, Richmond, VA
1:30 p.m.  Digging deeper: The biologic manifestation of area-level neighborhood deprivation in breast cancer outcomes. Lauren E. McCullough, Atlanta, GA
1:55 p.m.  The influence of racial constructs vs genetic ancestry on tumor biology of triple-negative breast cancer. Melissa B. Davis, New York, NY

Major Symposia • 1:00 p.m.–2:30 p.m.
Room 217-219, Convention Center

Adipose Tissue as a Driver of Carcinogenesis
Chair: Cornelia M. Ulrich, Salt Lake City, UT

1:00 p.m.  Introduction. Cornelia M. Ulrich, Salt Lake City, UT
1:05 p.m.  Disrupting the adipose-tumor link in experimental models of obesity-driven colon and breast cancer. Stephen D. Hursting, Chapel Hill, NC
1:30 p.m.  Does fat = fat? Eavesdropping on tumor-adipose tissue crosstalk in colorectal cancer patients. Cornelia M. Ulrich, Salt Lake City, UT
New Orleans Theater B, Convention Center

**Artificial Intelligence in Cancer Research and Care**

**Chair:** Olga Troyanskaya, New York, NY

1:00 p.m.  **Introduction.** Olga Troyanskaya, New York, NY
1:05 p.m.  **Title to be announced.** Olga Troyanskaya, New York, NY
1:30 p.m.  **Title to be announced.** John Quackenbush, Dover, MA
1:55 p.m.  **Title to be announced.** Dana Pe’er, New York, NY

New Orleans Theater A, Convention Center

**Evolutionary, Metabolic, and Microenvironmental Control of Cancer Cell Dormancy**

**Chair:** Julio A. Aguirre-Ghiso, New York, NY

1:00 p.m.  **Introduction.** Julio A. Aguirre-Ghiso, New York, NY
1:05 p.m.  **Tissue resident macrophages and a mesenchymal-like program control early disseminated cancer cell dormancy.** Julio A. Aguirre-Ghiso, New York, NY
1:27 PM  **Revisiting NK cell immunity to prevent metastasis.** Ana Luisa P. Correia, Basel, Switzerland
1:46 PM  **Modelling tumor dormancy.** Erik Sahai, London, United Kingdom
2:08 PM  **Uncovering targetable dependencies of latent brain metastatic cells.** Srinivas Malladi, Dallas, TX

Room 220-222, Convention Center

**Extrachromosomal DNA: Origins and Significance**

**Chair:** Roel Verhaak, Farmington, CT

1:00 p.m.  **Introduction.** Roel Verhaak, Farmington, CT
1:05 p.m.  **Extrachromosomal DNA amplifications: Evolution and intratumoral heterogeneity.** Roel Verhaak, Farmington, CT
1:30 p.m.  **Extrachromosomal DNA (ecDNA): Cancer’s dynamic circular genome.** Paul S. Mischel, Stanford, CA
1:55 p.m.  **Guilt by association: ecDNA trans-activates gene expression through chromatin interactions in cancer.** Chia-Lin Wei, Bar Harbor, ME

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
New Orleans Theater C, Convention Center

**Genome Instability as a Driver of Cancer Evolution**

**Chair:** Mariam Jamal-Hanjani, London, United Kingdom

1:00 p.m. **Introduction.** Mariam Jamal-Hanjani, London, United Kingdom

1:05 p.m. **The DNA damageome and cancer evolution.** Susan Rosenberg, Houston, TX

1:30 p.m. **Accessing evolutionary programs to enable therapeutic resistance.**
Kenneth J. Pienta, Baltimore, MD

1:55 p.m. **Lung cancer evolution and its prognostic impact.** Mariam Jamal-Hanjani, London, United Kingdom

Room 278-282, Convention Center

**Identification of Pediatric Cancer Dependencies**

**Chair:** William C. Hahn, Boston, MA

1:00 p.m. **Introduction.** William C. Hahn, Boston, MA

1:05 p.m. **A first generation pediatric cancer dependency map.** Kimberly Stegmaier, Boston, MA

1:30 p.m. **Genome-informed vulnerabilities for treatment of osteosarcoma.**
E. Alejandro Sweet-Cordero, San Francisco, CA

1:55 p.m. **Using the cancer dependency map.** William C. Hahn, Boston, MA

Room 353-355, Convention Center

**The Microenvironment and Immune System in Cancer Stem Cells**

**Chair:** Tannishtha Reya, La Jolla, CA

1:00 p.m. **Introduction.** Tannishtha Reya, La Jolla, CA

1:05 p.m. **Tumor-initiating stem cells shape the microenvironment into an immunosuppressive barrier and a pro-tumorigenic niche.** Linheng Li, Kansas City, MO

1:30 p.m. **Glioma cancer stem cells: Evolving heterogeneity after recurrence.** Luis F. Parada, New York, NY

1:55 p.m. **Imaging stem cell signals in cancer progression and therapy resistance.**
Tannishtha Reya, La Jolla, CA
**SUNDAY, APRIL 10**

**Special Session • 1:00 p.m.–2:30 p.m.**
La Nouvelle Orleans A-B, Convention Center

**New Drugs on the Horizon: Part 1**

_Cochairs:_ Joachim Rudolph, South San Francisco, CA; Christopher Nasveschuk, Stoneham, MA

1:00 p.m.  **Introduction.** Joachim Rudolph, South San Francisco, CA

1:05 p.m.  **ND01**  
KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies. Andrew Wylie, Cambridge, MA

1:25 p.m.  **ND02**  
MRTX0902: A SOS1 inhibitor for therapeutic intervention of KRAS-driven cancers. Jacob R. Haling, San Diego, CA

1:45 p.m.  **ND03**  
AMX-818: Next generation conditionally active, masked T-cell engager for the treatment of HER2-expressing solid tumors. Bryan Irving, South San Francisco, CA

2:05 p.m.  **ND04**  
BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy. Heidi Greulich, Cambridge, MA

2:05 p.m.  **Closing Remarks.** Christopher Nasveschuk, Stoneham, MA

**Clinical Trials Plenary Session 1• 1:00 p.m.–3:00 p.m.**
Hall B-C, Convention Center

**Clinical Trials of Cellular Immunotherapies**

_Cochairs:_ Roisin O’Cearrbhaill, New York, NY; Marcela V. Maus, Boston, MA

1:00 p.m.  **Introduction.** Roisin O’Cearrbhaill, New York, NY

1:01 p.m.  **CT001**  
Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells. Robbie G. Majzner, Stanford, CA

1:16 p.m.  **Discussant.** Hideho Okada, San Francisco, CA

1:31 p.m.  **CT002**  
BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. John B.A.G. Haanen, Amsterdam, Netherlands

1:46 p.m.  **Discussant.** Vincent K. Lam, Baltimore, MD

2:01 p.m.  **CT003**  
Innate cell engager (ICE™) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. Yago Nieto, Houston, TX

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
2:16 p.m.  Discussant.  Jeffrey S. Miller, Minneapolis, MN
2:31 p.m.  CT004  Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma.  Simone Filosto, Santa Monica, CA
2:16 p.m.  Discussant.  To be announced
2:46 p.m.  Concluding Remarks.  Marcela V. Maus, Boston, MA

POSTER SESSIONS • 1:30 p.m. –5:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Halls D-H, Convention Center
Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App, and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall. All posters (including in-person posters) are available at www.aacr.org/eposters22.

Prevention / Early Detection / Interception
Section 1  Preclinical Prevention, Early Detection, and Interception 1

Population Sciences
Section 2  Descriptive Epidemiology Covering Cancer Incidence, Mortality, Clusters, and Trends

Molecular/Cellular Biology and Genetics
Section 3  Cancer Genomics 1
Section 4  Cancer Genomics 2
Section 5  Cell Signaling
Section 6  Cellular Stress Responses 1: Hypoxia and Oxidative Stress
Section 7  Cellular Stress Responses 2: Senescence and Unfolded Protein Response
Section 8  Kinases and Phosphatases

Tumor Biology
Section 9  3D Models and Microfluidics
Section 10  Biological Modification of Radiosponse
Section 11  Carcinogenesis
Section 12  Drug Targeting and Treatment Response of the Microenvironment
Section 13  Evolution, Immune Regulation, and the Microenvironment of Metastasis
Section 14  Tissue Recombinant, Organ Slice, and Decellularized Models
Section 18  Late-Breaking Research: Tumor Biology 1
SUNDAY, APRIL 10

Chemistry
Section 20 Nanotechnology Drug Delivery

Experimental and Molecular Therapeutics
Section 21 Antibodies and Immune Therapies
Section 22 Biological Therapeutic Agents and Novel Drugs
Section 23 Cell Death and Other Pathways in Oncology
Section 24 Nanoparticles and Other Novel Strategies for Drug Delivery
Section 25 Cancer Drug Resistance and Reversal of Resistance
Section 26 Protein Degraders and Proteasome Inhibitors

COVID-19 and Cancer
Section 27 COVID-19 and Cancer

Bioinformatics / Convergence Science / Systems Biology
Section 28 Artificial Intelligence and Digital Pathology
Section 29 Cancer Systems Biology

Clinical Research Excluding Trials
Section 30 Clinical Research in Special Populations / Supportive Care and Survivorship Research
Section 31 Prognostic Biomarkers 1
Section 32 Prognostic Biomarkers 2
Section 17 Late-Breaking Research: Clinical Research 1

Immunology
Section 36 Adoptive Cell Therapy 1
Section 37 Adoptive Cell Therapy 2
Section 38 Immune Checkpoints
Section 39 Immune Response to Therapies 2 / Immune Monitoring and Clinical Correlates

Meet and Greet • 2:00 p.m.–3:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center
Meet the Editors-in-Chief of Cancer Discovery:
Lewis C. Cantley, PhD and Luis A. Diaz, Jr., MD

Lewis C. Cantley, New York, NY
Luis A. Diaz, New York, NY

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Meet and Greet • 2:00 p.m.–4:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Central, Exhibit Halls D-H, Convention Center

Minorities in Cancer Research (MICR) Meet and Greet

Cochairs: Gerardo Colon-Otero, Jacksonville, FL; John D. Carpten, Los Angeles, CA; Clayton C. Yates, Tuskegee, AL

Panelists:
Sarki Abdulkadir, Chicago, IL
Nadine J. Barrett, Durham, NC
Lourdes Baezconde, Los Angeles, CA
Melissa B. Davis, New York, NY
Luis A. Diaz, New York, NY
Martin Mendoza, Rockville, MD
Lisa A. Newman, New York, NY
Dorothy A. Rhoades, Oklahoma City, OK
Sanya A. Springfield, Rockville, MD

AACR Central, Exhibit Halls D-H, Convention Center

Women in Cancer Research (WICR) Meet and Greet

Cochairs: Amelie G. Ramirez, San Antonio, TX; Marcia R. Cruz-Correa, San Juan, PR; Sheila Kumari Singh, Dundas, ON, Canada

Panelists:
Abenaa M. Brewster, Houston, TX
Andrea Anita Hayes-Jordan, Chapel Hill, NC
Nada Jabado, Montréal, QC, Canada
Beverly D. Lyn-Cook, Little Rock, AR
Shiva Malek, Cambridge, MA
Lilli Petruzzelli, San Francisco, CA
Victoria L. Seewaldt, Duarte, CA
NCI/NIH-Sponsored Session • 2:30 p.m.–3:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room 298-299, Convention Center

NCI Consortia for Developing New Frontiers, Addressing Challenges and Accelerating Early Detection of Pancreatic Cancer

Moderators: Sudhir Srivastava, Rockville, MD; Sharmistha Ghosh-Janjigian, Rockville, MD

2:20 p.m. Introduction. Sharmistha Ghosh-Janjigian, Rockville, MD

2:32 p.m. EDRN: A successful hub and spoke model. Sudhir Srivastava, Rockville, MD

2:40 p.m. PCDC: Overview and funding opportunities. Sharmistha Ghosh-Janjigian, Rockville, MD

2:48 p.m. High-risk individuals and consortia resources. Gloria M. Petersen, Rochester, MN

2:56 p.m. New multimodality approaches for superior clinical decision making. Michael G. Goggins, Baltimore, MD

3:04 p.m. Imaging, artificial intelligence, and resources. Eugene Jon Koay, Houston, TX

3:12 p.m. Single cell analysis for greater insight. Anirban Maitra, Houston, TX

3:20 p.m. Panel Discussion

Meet and Greet • 3:00 p.m.–4:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center

Meet the Editor-in-Chief of Cancer Epidemiology, Biomarkers & Prevention: Elizabeth A. Platz, ScD, MPH

Elizabeth A. Platz, Baltimore, MD

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Major Symposium • 3:00 p.m.–4:30 p.m.
Room 356-357, Convention Center
Regulatory Science and Policy Session
Quality Over Quantity: Advancing Real World Data toward Real World Evidence
Moderator: Donna R. Rivera, Rockville, MD

3:00 p.m.  Introduction. Donna R. Rivera, Rockville, MD
3:10 p.m.  Deborah Schrag, New York, NY
3:20 p.m.  Katherine Panageas, New York, NY
3:30 p.m.  Marcelo C. Pasquini, Milwaukee, WI
3:40 p.m.  Ran Balicer, Ramat-Gan, Israel
3:50 p.m.  Nicolle Gatto, New York, NY
4:00 p.m.  Keith Marsolo, Durham, NC

Special Session • 3:00 p.m.–4:30 p.m.
La Nouvelle Orleans A-B, Convention Center
New Drugs on the Horizon: Part 2
Cochairs: Mary M. Mader, Indianapolis, IN; Ivan Cornella-Taracido, Boston, MA

3:00 p.m.  Introduction. Mary M. Mader, Indianapolis, IN
3:05 p.m.  ND06  ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killing. Christina K. Baumgartner, North Chicago, IL; Marcia N. Paddock, San Francisco, CA
3:25 p.m.  ND07  JNJ-78306358: A first-in-class bispecific T cell redirecting HLA-G antibody. Nataša Obermajer, Beerse, Belgium
4:05 p.m.  ND08  NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor. Paul Workman, London, United Kingdom
4:05 p.m.  ND09  The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers. Katrina L. Jackson, Watertown, MA
4:25 p.m.  Closing Remarks. Ivan Cornella-Taracido, Boston, MA
Clinical Trials Plenary Session 2 • 3:00 p.m.–5:00 p.m.
Great Hall AD, Convention Center

Clinical Trials Targeting the DNA Damage Response and KRAS

Cochairs: Keith Thomas Flaherty, Boston, MA; Kathleen N. Moore, Oklahoma City, OK

3:00 p.m. Introduction. Keith Thomas Flaherty, Boston, MA

3:01 p.m. CT005 Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial. Benoît You, Pierre Benite, France

3:16 p.m. Discussant. Rowan E. Miller, London, United Kingdom

3:31 p.m. CT006 Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects. Timothy A. Yap, Houston, TX

3:46 p.m. Discussant. Anish Thomas, Bethesda, MD

4:01 p.m. CT007 PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations. Timothy A. Yap, Houston, TX

4:16 p.m. Discussant. Patricia M. LoRusso, New Haven, CT

4:31 p.m. CT008 Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100. Grace K. Dy, Buffalo, NY

4:46 p.m. Discussant. Mark Awad, Boston, MA

5:00 p.m. Concluding Remarks. Kathleen N. Moore, Oklahoma City, OK

Clinical Trials Minisymposium 1 • 3:00 p.m.–5:00 p.m.
Great Hall BC, Convention Center

Biomarker Advances in Clinical Trials

Cochairs: Kurt Alex Schalper, New Haven, CT; Benedito A. Carneiro, Providence, RI

3:00 p.m. Introduction. Kurt Alex Schalper, New Haven, CT

3:02 p.m. CT021 PD-1 blockade in solid tumors with defects in polymerase epsilon. Benoît Rousseau, New York, NY

3:17 p.m. CT022 CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Michael Schenker, Craiova, Romania

3:32 p.m. CT023 Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses. Ming Lei, Princeton, NJ

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:47 p.m.  CT024  Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN. Yashaswi Shrestha, Gaithersburg, MD

4:02 p.m.  CT025  BT8009-100 phase I/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression. Meredith McKean, Nashville, TN

4:17 p.m.  CT026  The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial. Meenakshi Anurag, Houston, TX

4:32 p.m.  CT027  Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. Yaqi Zhao, Memphis, TN

4:32 p.m.  Concluding Remarks. Benedito A. Carneiro, Providence, RI

Minisymposium • 3:00 p.m.–4:45 p.m.
Room 353-355, Convention Center
Bioinformatics / Convergence Science / Systems Biology
Emerging Topics in Computational Oncology
Cochairs: Benjamin Dylan Greenbaum, New York, NY; Ben J. Raphael, Princeton, NJ

3:00 p.m.  Introduction. Benjamin Dylan Greenbaum, New York, NY

3:05 p.m.  633  Delineating tumor-neural communication in brain metastasis with spatiotemporal transcriptomic analysis and multi-cellular crosstalk modeling. Hong Zhao, Houston, TX

3:20 p.m.  634  Mutation agnostic diagnosis of clonal hematopoiesis of indeterminate potential using fluctuating methylation clocks. Ryan O. Schenck, Tampa, FL

3:35 p.m.  635  Concordance between dogs and humans: The use of AI in evaluating clinical cancer genomic datasets. Kevin Wu, Palo Alto, CA

3:50 p.m.  636  Prediction of therapeutic response via data-driven maps of tumor cell architecture. Erica N. Silva, San Diego, CA

4:05 p.m.  637  Spatial transcriptomics for FFPE characterizes the molecular and cellular architecture of malignant changes in pancreatic pre-malignant lesions. Luciane T. Kagohara, Baltimore, MD

4:20 p.m.  639  Rapidly evaluating cancer dependencies by label-free imaging of zero-passage primary cells. Mushriq Al-Jazrawe, Cambridge, MA

4:35 p.m.  Closing Remarks. Ben J. Raphael, Princeton, NJ
Minisymposia • 3:00 p.m.–5:00 p.m.

New Orleans Theater A, Convention Center
Clinical Research Excluding Trials
Biomarkers 1

Chair: Justin F. Gainor, Boston, MA

3:00 p.m.  Introduction. Justin F. Gainor, Boston, MA

3:05 p.m.  640  Genome sequencing of circulating multiple myeloma cells for minimally invasive molecular characterization of precursor disease pathology. Ankit K. Dutta, Boston, MA

3:20 p.m.  641  Single-cell RNA sequencing of rare circulating tumor cells in precursor myeloma patients reveals molecular underpinnings of tumor cell circulation. Elizabeth D. Lightbody, Boston, MA

3:35 p.m.  642  Spatial analysis of tumor infiltrating lymphocytes in histological images using deep learning predicts progression-free survival in colorectal cancer. Tae Hyun Hwang, Jacksonville, FL

3:50 p.m.  643  Non-classical sources of tumour specific antigen in checkpoint inhibitor response. Krupa Thakkar, London, United Kingdom

4:05 p.m.  644  Deep learning-based H&E analyzer reveals distinct immune profiles and clinical outcomes among immune phenotypes in uterine corpus endometrial carcinoma. Horyun Choi, Honolulu, HI

4:20 p.m.  645  Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study. Crispin T. Hiley, London, United Kingdom

4:35 p.m.  646  Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC. Jiaren Zhang, New York, NY

4:50 p.m.  Closing Remarks. Justin F. Gainor, Boston, MA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room 260-262, Convention Center

Endocrinology

New Approaches to Targeting Hormone Dependent Cancers

Chair: Steffi Oesterreich, Pittsburgh, PA

3:00 p.m.  Introduction. Steffi Oesterreich, Pittsburgh, PA

3:05 p.m.  647  Association between adrenal-restrictive HSD3B1 inheritance and hormone independent subtypes of endometrial and breast cancer. Jeffrey M. McManus, Cleveland, OH

3:20 p.m.  648  A novel small molecule targeting oncogenic PELP1 demonstrates anti-tumor activity in wild-type and mutant ER-positive breast cancer. Kristin Ann Altwegg, San Antonio, TX

3:35 p.m.  649  Targeting progesterone receptor (PR) with the antiprogestin onapristone in patient-derived xenograft (PDX) models of estrogen receptor positive (ER+), PR positive (PR+) bone metastasis of breast cancer. Martin Lehr, Philadelphia, PA

3:50 p.m.  650  Reparixin, CXCR1/2 inhibitor in combination with CDK4/6 inhibitors attenuates endocrine resistant breast cancer growth and metastasis. Kideok Jin, Albany, NY

4:05 p.m.  651  Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models. Bernard Haendler, Berlin, Germany

4:20 p.m.  652  An androgen receptor-associated transcription factor regulates fatty acid metabolism driving tumor growth in androgen receptor-positive breast cancer. Sarah-Jane Neuberth, Heidelberg, Germany

4:35 p.m.  653  Molecular pathology of metastatic prostatic adenocarcinoma treated with bipolar androgen therapy (BAT) reveals a correlation between MYC mRNA and protein. Carolina Gomes Alexandre, Baltimore, MD

4:50 p.m.  Closing Remarks. Steffi Oesterreich, Pittsburgh, PA
New Orleans Theater C, Convention Center  
**Experimental and Molecular Therapeutics**  
**Elucidating Disease Biology and Drug Resistance Mechanisms**

**Cochairs:** Andriy Marusyk, Tampa, FL; Katerina A. Politi, New Haven, CT

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 p.m.</td>
<td><strong>Introduction.</strong></td>
<td>Andriy Marusyk, Tampa, FL</td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td>654 CD28 shedding is a novel resistance mechanism to anti PD-1 therapy.</td>
<td>Motti Hakim, Misgav, Israel</td>
</tr>
<tr>
<td>3:20 p.m.</td>
<td>655 Macrophage mediated resistance to TKI therapy in ALK fusion positive non-small cell lung cancer.</td>
<td>Melanie Mandell, Aurora, CO</td>
</tr>
<tr>
<td>3:35 p.m.</td>
<td>656 DNA repair-interfering molecule AsiDNA® overcomes resistance to tyrosine kinase inhibitors in lung cancer.</td>
<td>Olivier Calvayrac, Toulouse, France</td>
</tr>
<tr>
<td>3:50 p.m.</td>
<td>657 Impact of therapy induced APOBEC3A mutagenesis on tumor evolution in non small cell lung cancer.</td>
<td>Hideko Isozaki, Boston, MA</td>
</tr>
<tr>
<td>4:05 p.m.</td>
<td>658 AKT pathway as a therapeutic target to constrain lineage plasticity leading to histological transdifferentiation.</td>
<td>Alvaro Quintanal-Villalonga, New York, NY</td>
</tr>
<tr>
<td>4:20 p.m.</td>
<td>659 Mechanisms of resistance to SHP2 inhibition.</td>
<td>Wei Wei, New York, NY</td>
</tr>
<tr>
<td>4:35 p.m.</td>
<td>660 Predicting imatinib responses in exon 18 PDGFRA-mutant GIST.</td>
<td>Homma M. Khosroyani, Portland, OR</td>
</tr>
<tr>
<td>4:50 p.m.</td>
<td><strong>Closing Remarks.</strong></td>
<td>Katerina A. Politi, New Haven, CT</td>
</tr>
</tbody>
</table>

New Orleans Theater B, Convention Center  
**Immunology**  
**Immune Checkpoint and Immune Modulatory Therapy**

**Chair:** Benjamin Izar, New York, NY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 p.m.</td>
<td><strong>Introduction.</strong></td>
<td>Benjamin Izar, New York, NY</td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td>661 Androgen deprivation therapy allows for effective anti-TIGIT immunotherapy in murine model of castration resistant prostate cancer.</td>
<td>Fanny Polesso, Portland, OR</td>
</tr>
<tr>
<td>3:20 p.m.</td>
<td>662 Late CTLA-4 Ig treatment improves antitumor efficacy of immunotherapy.</td>
<td>Stephen Mok, Houston, TX</td>
</tr>
<tr>
<td>3:35 p.m.</td>
<td>663 Systemic targeting of therapeutic RNA to cancer via a novel, cell-penetrating and nucleic acid binding, monoclonal antibody.</td>
<td>Elias Quijano, New Haven, CT</td>
</tr>
</tbody>
</table>

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
3:50 p.m. 664 Immune inhibitory receptors ILT2 and ILT4 exhibit both distinct and overlapping biology in vitro and in vivo. Geoffrey W. Stone, South San Francisco, CA

4:05 p.m. 665 Correlation between a CTLA-4 single nucleotide polymorphism and high response to anti-PD1/PDL1 immunotherapy in advanced non small cell lung cancer. India A. Allen, Sydney, Australia

4:20 p.m. 666 A phase 1 study to detect adverse events after SBRT and immunotherapy by electronic nose in advanced NSCLC. M Benthe Muntinghe-Wagenaar, Groningen, Netherlands

4:35 p.m. 667 Inhibition of protein-protein interaction between STING and TRIM29 is a new approach to enhance anti-tumor immune response. Seung Bum Park, Seoul, Republic of Korea

4:50 p.m. Closing Remarks. Benjamin Izar, New York, NY

Room 220-222, Convention Center
Molecular/Cellular Biology and Genetics
Oncogenic Signaling Drivers

Chair: Andrew Durrell Hollenbach, New Orleans, LA

3:00 p.m. Introduction. Andrew Durrell Hollenbach, New Orleans, LA

3:05 p.m. 668 A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo. Silvia Pomella, Roma, Italy

3:20 p.m. 669 Nuclear FAK drives thyroid cancer growth and survival. Meghan Kellett, Aurora, CO

3:35 p.m. 670 Distinct biochemical properties of KRAS Q61H mutant render cancer cells resistant to SHP2 inhibitors. Teklab Gebregiorgis, Toronto, ON, Canada

3:50 p.m. 671 Cryo-electronmicroscopy of PI3K reveals additional regulatory features. Jonathan R. Hart, La Jolla, CA

4:05 p.m. 672 Development and validation of nanobodies specific to the oncogenic phosphatase protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3). Caroline Noel Smith, Lexington, KY

4:20 p.m. 673 The EMT activator ZEB1 initiates polarized secretion of pro-tumorigenic effector proteins to drive lung adenocarcinoma progression. Guan-Yu Xiao, Houston, TX

4:35 p.m. 674 Tracking the transcriptome of lung cancer-associated fibroblasts within the TRACERx lung study from patient to culture models reveals phenotypic plasticity and instructive cues from cancer cells. Yutaka Naito, Tokyo, Japan

4:50 p.m. Closing Remarks. Andrew Durrell Hollenbach, New Orleans, LA
Room 288-290, Convention Center
Molecular/Cellular Biology and Genetics
Transcription Factors in Cancer

Cochairs: Gang Huang, San Antonio, TX; Robert Welner, Birmingham, AL

3:00 p.m. Invited Speaker. Gang Huang, San Antonio, TX

3:05 p.m. 675 Facilitating G-quadruplex formation in the KRAS promoter with polypurine reverse Hoogsteen oligonucleotides. Tracy A. Brooks, Johnson City, NY

3:20 p.m. 676 ZEB1 acetylation regulates dimerization and protein stability to promote lung adenocarcinoma progression and metastasis. Mabel G. Perez-Oquendo, Houston, TX

3:35 p.m. 677 Bi-directional crosstalk between the HIF and AHR transcription factors in clear cell kidney cancer. Véronique N. Lafleur, Oxford, United Kingdom

3:50 p.m. 678 Identification of an E3 ligase regulating the catalytic subunit of RNA polymerase I. Stephanie Pitts, Baltimore, MD

4:05 p.m. 679 Inhibition of Notch signaling causes progenitor-to-hepatocyte differentiation and regressions in a subset of hepatocellular carcinoma by controlling C/EBPα expression and HNF4α activity. Robert Piskol, South San Francisco, CA

4:20 p.m. 680 Topoisomerase 2 beta facilitates chromatin reorganization during Androgen Receptor induced transcription and contributes to chromoplexy in prostate cancer. Minh-Tam N. Pham, Baltimore, MD

4:35 p.m. 681 Targeted MLL-AF9 degradation is phenocopied by combined DOT1L and Menin inhibition. Sarah Naomi Olsen, Boston, MA

4:50 p.m. Closing Remarks. Robert Welner, Birmingham, AL

Room 217-219, Convention Center
Population Sciences
Molecular Genomics of Cancer Risk and Prognosis

Chair: Laura A. Kresty, Ann Arbor, MI

3:00 p.m. Introduction. Laura A. Kresty, Ann Arbor, MI

3:05 p.m. 682 Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance]). En Cheng, Oakland, CA

3:20 p.m. 683 Identification of common germline variants associated with pediatric rhabdomyosarcoma survival: A report from the Children’s Oncology Group (COG). Bailey A. Martin-Giacalone, Houston, TX

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:35 p.m.  684  Body mass index throughout adulthood and incidence of colorectal cancer subclassified by T cell, macrophage, and myeloid cell infiltrates in cancer tissue.  Tomotaka Ugai, Boston, MA

3:50 p.m.  685  Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.  Jongeun Rhee, Rockville, MD

4:05 p.m.  686  Subsequent invasive breast cancer risk after DCIS treatment in multinational PRECISION consortium cohorts comprising 48,576 patients.  Renee S. Schmitz, Amsterdam, Netherlands

4:20 p.m.  687  The oral microbiome and the risk of head and neck cancer: A nested case-control study in the NIH-AARP.  Zeni Wu, Rockville, MD

4:35 p.m.  688  Multi-stage exome sequencing study of 17,546 aggressive and non-aggressive prostate cancer cases.  Burcu F. Darst, Los Angeles, CA

4:50 p.m.  Closing Remarks.  Laura A. Kresty, Ann Arbor, MI

Room 295-296, Convention Center
Prevention / Early Detection / Interception
New Targets and Strategies for Prevention and Risk Reduction
Chair: Adriana Albini, Milano, Italy

3:00 p.m.  Introduction.  Adriana Albini, Milano, Italy

3:00 p.m.  631  Validation of a panel of methylated DNA and protein markers for multi-cancer detection in plasma.  Hatim T. Allawi, Madison, WI

3:00 p.m.  632  The immune consequences of a ketogenic diet in GBM and its therapeutic implications.  Pravin Kesarwani, Royal Oak, MI

3:00 p.m.  689  A randomized phase III study assessing the efficacy of liquid biopsy in early diagnosis of recurrence and second malignancies in lung cancer survivors.  Sana Raoof, New York, NY

3:00 p.m.  690  An anti-leprosy drug, clofazimine, targets Wnt/β-catenin pathway in cadmium-transformed benign prostatic hyperplasia cells.  Rifika Jain, Rockford, IL

3:00 p.m.  691  Antineoplastic effect of marina crystal minerals (MCM) against the growth of murine mammary adenocarcinoma cells in vivo.  Nariman K. Badr El-Din, Mansoura, Egypt

3:00 p.m.  727  Detection of early-stage lung cancer using a liquid biopsy test based on extracellular vesicle proteins.  Juan P. Hinestrosa, San Diego, CA

4:50 p.m.  Closing Remarks.  Adriana Albini, Milano, Italy
**Tumor Biology**

**Ex Vivo Models for Understanding Genetic Variation, Metastasis, and Treatment Sensitivity**

**Chair:** David W. Cescon, Toronto, ON, Canada

**3:00 p.m.** *Introduction.* David W. Cescon, Toronto, ON, Canada

**3:05 p.m.** 692 Patient-derived co-cultures of TRACERx lung cancer organoids and autologous T-cells reveal heterogeneity in immune evasion between cancer subclones. Krijn K. Dijkstra, London, United Kingdom

**3:20 p.m.** 693 TGFβ-mediated targeting of the extracellular matrix enhances the migration and cytotoxicity of CAR-T cells in 3D models of ovarian cancer. Joash Dominic Joy, London, United Kingdom

**3:35 p.m.** 694 E-slice: A novel 3D culture platform for precision medicine. Kyuson Yun, Houston, TX

**3:50 p.m.** 695 Patient derived organoids model lung adenocarcinoma metastases. Yuan Liu, New York, NY

**4:05 p.m.** 696 Spatially patterned, 3D in vitro models of cancer metastasis to bone for elucidating key drivers of metastasis and drug discovery. Eva C. González Díaz, Palo Alto, CA

**4:20 p.m.** 697 Partnering with patients to create a rare soft tissue sarcoma target discovery platform as a community resource. Mushriq Al-Jazrawe, Cambridge, MA

**4:35 p.m.** 698 Establishing and characterizing patient derived models from racial/ethnic minority gastric cancer patients to advance cancer precision health equity. Nicole B. Halmai, Davis, CA

**4:50 p.m.** *Closing Remarks.* David W. Cescon, Toronto, ON, Canada

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Room 208-210, Convention Center

**Tumor Biology**

**From Mechanisms to New Therapeutic Targets in Childhood Cancer**

**Cochairs:** Sharon E. Plon, Houston, TX; Mariella G. Filbin, Boston, MA

3:00 p.m. **Introduction.** Sharon E. Plon, Houston, TX

3:05 p.m. **699** NF-kB is a master regulator of resistance to therapy in high-risk neuroblastoma. Liron D. Grossmann, Philadelphia, PA

3:20 p.m. **700** Targeting transcriptional co-activators YAP1/TAZ in fusion-positive rhabdomyosarcoma demonstrates a novel strategy in ablating fusion-driven sarcoma transcriptional programing. Adam F. Pecoraro, Durham, NC

3:35 p.m. **701** Loss of PRC2 enforces a mesenchymal neural crest stem cell phenotype in NF1-deficient cancer through activation of core transcription factors. Xiyuan Zhang, Bethesda, MD

3:50 p.m. **702** Interaction between genetic ancestry and EWS-FLI induced transcription in Ewing sarcoma tumorigenesis. Rachel M. Moss, Minneapolis, MN

4:05 p.m. **703** Novel histone lysine demethylase inhibitors disrupt PAX3-FOXO1-driven transcriptional output in fusion-positive rhabdomyosarcoma. Yong Yean Kim, Bethesda, MD

4:20 p.m. **704** Development of a patient-derived xenograft (PDX) modeling program to enable pediatric precision medicine. Filemon S. Dela Cruz, New York, NY

4:35 p.m. **705** Inhibition of H3.3 S31 phosphorylation by the pediatric glioma driver mutation, H3.3 K27M, results in chromosomal instability, loss of p53 regulation, and tumorigenesis. Charles Day, Austin, MN

4:50 p.m. **Closing Remarks.** Mariella G. Filbin, Boston, MA

---

**Meet and Greet • 4:00 p.m.–5:00 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center

Meet the Editor-in-Chief of *Cancer Research*: Chi Van Dang, MD, PhD

Chi Van Dang, Philadelphia, PA


SUNDAY, APRIL 10

NCI/NIH-Sponsored Session • 4:00 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room 298-299, Convention Center

NCI Resource: Informatics Tools and Training Opportunities

Moderator: Kelly Crotty, Rockville, MD

Speakers:

Welcome and session overview. Kelly Crotty, Rockville, MD

ITCR program overview. Juli Klemm, Rockville, MD

The ITCR training network. Candace Savonen, Baltimore, MD

The ITCR training network. Carrie Wright, Baltimore, MD

The ITCR training network. Rohan Jeremiah, Chicago, IL

The BD-STEP program. Michelle A. Berny-Lang, Rockville, MD

Career Development Forum • 4:00 p.m.–5:15 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room 293-294, Convention Center

Inspiring and Empowering Current and Future Generations of Women in Cancer Research

Featuring the 2022 Victoria’s Secret Global Fund for Women’s Cancers Meritorious Award Recipients

Panelists to be announced.

Awards and Lectures • 5:30 p.m.–6:15 p.m.

La Nouvelle Orleans C, Convention Center

Presidential Address

Chair: William N. Hait, New Brunswick, NJ

5:30 p.m. Introduction. William N. Hait, New Brunswick, NJ

5:35 p.m. Basic research reveals clinical opportunities in pancreatic cancer. David A. Tuveson, Cold Spring Harbor, NY

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Professional Advancement Session • 5:30 p.m.–7:00 p.m.  
NOT ELIGIBLE FOR CME CREDIT

Carondelet Room, New Orleans Marriott

How to Design a Successful Career Path in Cancer Research: The Dos and Don'ts for Early-Stage Investigators

**Cochairs:** Kathleen W. Scotto, New Brunswick, NJ; Jose G. Trevino, Richmond, VA

**Panelist:** Robert A. Winn, Richmond, VA

---

Professional Advancement Session • 5:30 p.m.–7:30 p.m.  
NOT ELIGIBLE FOR CME CREDIT

Mardi Gras Salon D-E, New Orleans Marriott

Personalized Career Conversations

**Cochairs:** Antonio T. Baines, Greensboro, NC; Danny R. Welch, Kansas City, KS; Victoria M. Richon, Weston, MA

**Mentors:**
John D. Carpten, Los Angeles, CA
Gerardo Colon-Otero, Jacksonville, FL
Clayton C. Yates, Tuskegee, AL
James P. Allison, Houston, TX
J. Carl Barrett, Waltham, MA
Michael A. Caligiuri, Duarte, CA
John M. Carethers, Ann Arbor, MI
Johann S. de Bono, Sutton, United Kingdom
Caroline Dive, Manchester, United Kingdom
Jeremy R. Graff, Dartmouth, NS, Canada
Scott W. Lowe, New York, NY
Lisa A. Newman, New York, NY
Lillian L. Siu, Toronto, ON, Canada
SUNDAY, APRIL 10

Special Session • 6:30 p.m.–8:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Mosaic Room Foyer, Convention Center

Networking Hubs

Networking Hubs:
Computational Cancer Science and Bioinformatics
Hematological Malignancies
Cancer Prevention and Interception
Pathology

Town Meetings • 6:30 p.m.–8:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

Jefferson Ballroom, Hilton New Orleans Riverside

Cancer Evolution Working Group (CEWG) Town Hall Meeting and Networking Reception

Cochairs: Charles Swanton, London, United Kingdom; Frank Laukien, Billerica, MA

Pediatric Cancer Working Group (PCWG) Town Hall Meeting and Networking Reception

Chair: Katherine A. Janeway, Boston, MA

Tumor Microenvironment Working Group (TME) Town Hall Meeting and Networking Reception

Cochairs: Theresa A. Guise, Houston, TX; Mikala Egeblad, Cold Spring Harbor, NY

Meet and Greet • 8:00 p.m.–9:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

Salon A, Hilton New Orleans Riverside

Associate Member Meet and Greet

Cochairs: Kristin G. Anderson, Seattle, WA; Francesco Caiazza, San Francisco, CA; Maeve Mullooly, Dublin, Ireland

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
MONDAY, APRIL 11*

Meet-the-Expert Sessions • 7:00 a.m.–7:45 a.m.

Room 278-282, Convention Center
**Advances in Science and Treatment of Myeloproliferative Neoplasms**
Ruben A. Mesa, San Antonio, TX

Room 265-268, Convention Center
**Epigenomics in Cancer Therapeutics**
Daniel D. De Carvalho, Toronto, ON, Canada

Room 343-345, Convention Center
**Epithelial Stem Cells: How Memories of Stressful Experiences Fuel Cancer**
Elaine Fuchs, New York, NY

Room 353-355, Convention Center
**Evolutionary Therapy**
Alexander R.A. Anderson, Tampa, FL

Room 288-290, Convention Center
**Exploring Latino Cancer Health Disparities with a Focus on Prevention and Community Intervention**
Amelie G. Ramirez, San Antonio, TX

Room 260-262, Convention Center
**Human Natural Killer Cells: Basic Biology and Novel Clinical Applications for Cancer**
Michael A. Caligiuri, Duarte, CA

Room 243-245, Convention Center
**Immunogenomics of High-Grade CNS Malignancies**
Elaine R. Mardis, Columbus, OH

**Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.**
MONDAY, APRIL 11

Room 295-296, Convention Center
**Predicting Outcomes in Neuroendocrine Tumors**
Michelle K. Kim, New York, NY

Room 208-210, Convention Center
**Proteogenomics as a Driver for Discovery of Novel Mechanisms and Therapeutic Targets in Lymphoma**
Kojo Elenitoba-Johnson, Philadelphia, PA

Room 217-219, Convention Center
**Recent Developments in the Treatment of Soft Tissue Sarcomas and GIST: Biology Driven Drug Development**
Suzanne George, Boston, MA

---

**Plenary Session • 8:00 a.m.–10:00 a.m.**

Hall B-C, Convention Center
**Decoding Cancer Health Disparities: Integration of Complex Data and Diversity to Achieve Equity**

Chair: Mariana C. Stern, Los Angeles, CA

**8:00 a.m.** Introduction. Mariana C. Stern, Los Angeles, CA

**8:05 a.m.** Integration of complex data. Yu Shyr, Nashville, TN

**8:27 a.m.** Somatic mutations, germline risk and ancestry in lung adenocarcinoma. Matthew L. Meyerson, Boston, MA

**8:49 a.m.** Building organ specific biobanks in Nigeria: Donor perspectives, benefits, and success strategies. Olusegun I. Alatise, Ile-Ife, Nigeria

**9:11 a.m.** Rare cancer patient profiling and engagement. Andy Futreal, Houston, TX

**9:33 a.m.** A framework for community-engaged participatory research in cancer genomic sequencing: A collaborative with sovereign tribal nations in the American southwest. Cheryl L. Willman, Albuquerque, NM

**9:55 a.m.** Wrap-up and opportunities for the future. Mariana C. Stern, Los Angeles, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Poster Session • 9:00 a.m. –12:30 p.m.
NOT ELIGIBLE FOR CME CREDIT

Halls D-H, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App, and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall. All posters (including in-person posters) are available at AACR.org/eposters22.

Prevention / Early Detection / Interception
Section 1 Preclinical Prevention, Early Detection, and Interception 2

Population Sciences
Section 2 Diet, Alcohol, Tobacco Use, and Other Lifestyle Risk Factors

Molecular/Cellular Biology and Genetics
Section 3 Cancer Genomics 3
Section 4 Gene Expression and Cell Differentiation
Section 5 Genomic Instability 1
Section 6 Oncogenes and Tumor Suppressor Genes 1
Section 7 Oncogenes and Tumor Suppressor Genes 2
Section 8 Post-Transcriptional and Translational Control
Section 16 Late-Breaking Research: Molecular/Cellular Biology and Genetics 1

Tumor Biology
Section 9 Cancer Stem Cells
Section 10 Genetically Engineered Mouse Models 1
Section 11 Genetically Engineered Mouse Models 2
Section 12 Metastatic Cell Plasticity: EMT and Stem Cell
Section 13 Transcriptional and Metabolic Regulation of Metastasis
Section 14 Tumor Adhesion
Section 17 Late-Breaking Research: Tumor Biology 2

Regulatory Science and Policy
Section 15 Science and Health Policy / Regulatory Science and Policy

Experimental and Molecular Therapeutics
Section 20 Biological Therapeutic Agents
Section 21 Combinations
Section 22 Drug Conjugates / Bispecific Antibodies
Section 23 Lung Cancer Treatment Resistance
Section 24 Mechanisms of Drug Action 3
Section 25 Preclinical and Clinical Pharmacology

Multidisciplinary
Section 26 AACR Project GENIE Use Cases 1
Section 27 AACR Project GENIE Use Cases 2
MONDAY, APRIL 11

**Bioinformatics / Convergence Science / Systems Biology**
- Section 28  Database Resources and Web Applications
- Section 29  New Algorithms and Tools for Data Analysis

**Clinical Research Excluding Trials**
- Section 30  Biomarkers Predictive of Therapeutic Benefit 1
- Section 31  Biomarkers Predictive of Therapeutic Benefit 2
- Section 32  Immune Mechanisms Invoked by Other Therapies

**Clinical Trials**
- Section 33  Phase II Clinical Trials 1
- Section 34  Phase II Trials in Progress

**Immunology**
- Section 35  Immune Mechanisms Invoked by Other Therapies
- Section 36  Inflammation, Tumor Initiation and Progression
- Section 37  Molecular Signaling and Metabolic and Epigenetic Regulation in Adaptive Tumor Immunity
- Section 38  Tumor Antigens, Antigen Presentation, and Tumor Immunity

**Chemistry**
- Section 40  High-throughput Screening, Drug Design, and Natural Products in Cancer

---

**Meet and Greet • 9:30 a.m.–10:30 a.m.**

**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 2101, Exhibit Halls D-H

**Meet the Editors-in-Chief of Cancer Immunology Research:**
**Robert D. Schreiber, PhD and Philip D. Greenberg, MD**

Robert D. Schreiber, St. Louis, MO
Philip D. Greenberg, Seattle, WA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
NCI/NIH-Sponsored Session • 10:15 a.m.–11:15 a.m.
NOT ELIGIBLE FOR CME CREDIT
Room 298-299, Convention Center
NCI-NIH: Intramural and Extramural Training and Career Development Awards and Opportunities

Moderator: Nastaran Zahir, Rockville, MD

Speakers:

Overview of NCI intramural training programs. Erika Ginsburg, Rockville, MD

NCI fellowship funding opportunities for predocs and postdocs. Yansong Bian, Rockville, MD

NCI career development award funding opportunities: Tips for early-career-stage investigators. Corinne Boulanger-Espeut, Rockville, MD

Advances in Diagnostics and Therapeutics
10:15 a.m.–11:45 a.m.
New Orleans Theater B, Convention Center
Clinical to Genetic Monitoring for Hereditary Cancers

Chair: Judy E. Garber, Boston, MA

10:15 a.m. Introduction. Judy E. Garber, Boston, MA

10:20 a.m. Integrating parallel tumor-normal sequencing for the identification and management of hereditary cancers. Zsofia K. Stadler, New York, NY

10:45 a.m. Early detection of PDAC in the cancer of the pancreas screening (CAPSS) program in mutation carriers. Michael G. Goggins, Baltimore, MD

11:10 a.m. Identification of and monitoring in inherited multicancer syndromes. Judy E. Garber, Boston, MA
MONDAY, APRIL 11

Interpreting and Building Trust in Artificial Intelligence Models

Chair: Trey Ideker, La Jolla, CA

10:15 a.m.  Introduction.  Trey Ideker, La Jolla, CA
10:20 a.m.  Building the mind of cancer.  Trey Ideker, La Jolla, CA
10:45 a.m.  Convergence of biology and machine learning for cancer genome discovery.  Eliezer M. Van Allen, Boston, MA
11:10 a.m.  Explainable AI: Where we are and how to move forward for cancer pharmacogenomics.  Su-In Lee, Seattle, WA

Room 217-219, Convention Center
Targeting Transcription Factors

Chair: Angela N. Koehler, Cambridge, MA

10:15 a.m.  Introduction.  Angela N. Koehler, Cambridge, MA
10:20 a.m.  Attenuating oncogenic transcription with small molecules.  Angela N. Koehler, Cambridge, MA
10:45 a.m.  Proof of therapeutic utility of targeting a developmental transcription factor with small molecules: Application from a rare disease to cancer.  Mathias Francois, Camperdown, Australia
11:10 a.m.  Characterization of a first-in-class molecular glue degrader to modulate T cell activity in cancer.  Eva d’Hennezel, Cambridge, MA

Advances in Organ Site Research
10:15 a.m.–11:45 a.m.

Room 353-355, Convention Center
Gastric Cancer: From Biology to Therapy

Chair: Timothy C. Wang, New York, NY

10:15 a.m.  Introduction.  Timothy C. Wang, New York, NY
10:20 a.m.  Turning back TIME (Tissue Immune Microenvironment) before gastric cancer.  Juanita L. Merchant, Tucson, AZ
10:45 a.m.  Ecosystem disturbance due to inflammation toward gastric cancer.  Toshikazu Ushijima, Tokyo, Japan
11:10 a.m.  Emergence of chromosomal instability in gastric adenocarcinoma.  Adam J. Bass, Boston, MA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
The Next Generation of Targets for Prostate Cancer

Chair: Cory Abate-Shen, New York, NY

10:15 a.m.  Introduction. Cory Abate-Shen, New York, NY

10:25 a.m.  Targeting the PTGES3-AR axis in advanced prostate cancer. Luke A. Gilbert, San Francisco, CA

10:45 a.m.  T cell intrinsic androgen receptor activity limits immunotherapy responses in prostate cancer patients. Amy Moran, Portland, OR

11:05 a.m.  Targeting lineage plasticity in prostate cancer. Wouter Karthaus, Lausanne, Switzerland

11:25 a.m.  Prostate cancer: Multi-omics comparison between European, African American, and Native African men with prostate cancer. Isra Awadalla Elhussin, Tuskegee, AL

Career Development Forum • 10:15 a.m.–11:45 a.m.

NOT ELIGIBLE FOR CME CREDIT

Room 208-210, Convention Center

Minorities in Cancer Research (MICR) Forum: So, You Want to Dismantle Systemic Racism at Your Cancer Center? Models, Methods, and Outcomes

Cochairs: Clayton C. Yates, Tuskegee, AL; Nadine J. Barrett, Durham, NC

Panelists:
Robert A. Winn, Richmond, VA
Ruben A. Mesa, San Antonio, TX
Steven R. Patierno, Durham, NC
**MONDAY, APRIL 11**

**Major Symposia • 10:15 a.m.–11:45 a.m.**

Great Hall BC, Convention Center

**Dharma Master Jiantai Symposium in Targeted Therapy: Novel Genetic Screening Strategies to Identify Therapeutic Targets in Cancer**

**Chair:** John Doench, Cambridge, MA

**10:15 a.m.**  
Introduction. John Doench, Cambridge, MA

**10:16 a.m.**  
A human paralog genetic interaction map with implications for cancer therapy and tumor evolution. Alice Berger, Seattle, WA

**10:41 a.m.**  
Applications of base editor technology in small molecule: Target validation.  
John Doench, Cambridge, MA

**11:06 a.m.**  
Controllable genome editing with split CRISPR base editors. Junwei Shi, Philadelphia, PA

La Nouvelle Orleans C, Convention Center

**Epigenetics, Chromatin Architecture, and Gene Regulation: Mechanisms and Therapeutic Opportunities in Cancer**

**Chair:** Cigall Kadoch, Boston, MA

**10:15 a.m.**  
Introduction. Cigall Kadoch, Boston, MA

**10:20 a.m.**  
Structure and function of ATP-dependent chromatin remodeling complexes in human cancer. Cigall Kadoch, Boston, MA

**10:45 a.m.**  
Nuclear condensates in gene regulation and disease. Richard A. Young, Cambridge, MA

**11:10 a.m.**  
Epigenetic regulation in immuno-oncology. Yang Shi, Oxford, United Kingdom

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Room 260-262, Convention Center

**Nerves, Cancer, and Immunity**

**Chair:** Humsa Venkatesh, Boston, MA

10:15 a.m. **Introduction.** Humsa Venkatesh, Boston, MA

10:20 a.m. **Neuronal activity driven growth of primary and secondary brain cancers.** Humsa Venkatesh, Boston, MA

10:42 a.m. **Neural regulation of tumors and their microenvironment: Novel, actionable, hallmark of cancer.** Moran Amit, Houston, TX

11:04 a.m. **Neuron-immune cell axis control of brain tumor growth.** David H. Gutmann, St. Louis, MO

11:26 a.m. **Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy.** William L. Hwang, Boston, MA

Room 356-357, Convention Center

**Regulatory Science and Policy Session**

**Pediatric Oncology Drug Discovery and Development**

Pediatric Oncology Drug Discovery and Development-related session, in conjunction with the AACR Pediatric Cancer Working Group

**Chair:** Katherine A. Janeway, Boston, MA

Participants to be announced.

Room 343-345, Convention Center

**Predictive Biomarkers for Precision Radiation Oncology**

**Chair:** Silvia C. Formenti, New York, NY

10:15 a.m. **Introduction.** Silvia C. Formenti, New York, NY

10:20 a.m. **Integrated molecular subtyping to personalize radiation therapy for oligometastatic disease.** Sean Pitroda, Chicago, IL

10:45 a.m. **Using imaging and genomics to identify markers of radiation sensitivity.** Julie K. Schwarz, Saint Louis, MO

11:10 a.m. **Combining intrinsic and extrinsic tumor cell predictors of radiotherapy response in pelvic tumors.** Anna Wilkins, London, United Kingdom
MONDAY, APRIL 11

New Orleans Theater C, Convention Center

Presidential Select Symposium: Aging, Stress, and Cancer

Chair: David A. Tuveson, Cold Spring Harbor, NY

10:15 a.m.  Introduction.  David A. Tuveson, Cold Spring Harbor, NY
10:16 a.m.  Social stresses that promote cancer.  Electra D. Paskett, Columbus, OH
10:34 a.m.  The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.  Ayesha Shafi, Bethesda, MD
10:49 a.m.  Title to be announced.  E. John Wherry, Philadelphia, PA
11:07 a.m.  Cancer and the ravages of TiME: How the aging tumor/immune microenvironment drives tumor progression.  Ashani T. Weeraratna, Baltimore, MD
11:25 a.m.  Panel Discussion

Room 220-222, Convention Center

Role of the Metastatic Microenvironment

Chair: Josh Neman, Los Angeles, CA

10:15 a.m.  Introduction.  Josh Neman, Tarzana, CA
10:20 a.m.  Immune-mediated regulation of metastatic outgrowth in the lung.  Alana L. Welm, Salt Lake City, UT
10:45 a.m.  Brain metastasis: From perspective of cancer neuroscience.  Josh Neman, Los Angeles, CA
11:10 a.m.  Microenvironment regulation of metastasis.  Kandice Tanner, Bethesda, MD

Room 265-268, Convention Center

Screening, Detecting, Intervening Earlier in Clinical Care of Underserved Populations

Chair: Chanita Hughes-Halbert, Los Angeles, CA

10:15 a.m.  Introduction.  Chanita Hughes-Halbert, Los Angeles, CA
10:20 a.m.  Translational issues in lung cancer disparities: A vision for cancer equity.  Chanita Hughes-Halbert, Los Angeles, CA
10:45 a.m.  Targeted, community-based screening for prostate cancer.  Bettina Drake, Saint Louis, MO
11:10 a.m.  Colorectal cancer screening in underserved populations: COVID, silver linings, and challenges ahead.  Maria Elena Martinez, La Jolla, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room 278-282, Convention Center
**The Shape-Shifting Cancer Genome**

**Chair:** David S. Pellman, Boston, MA

**10:15 a.m.**  **Introduction.** David Pellman, Boston, MA

**10:45 a.m.**  **Complete (T2T) human genomes and advancing studies of human centromeric regions and acrocentric short arms.** Karen H. Miga, Santa Cruz, CA

**10:20 a.m.**  **A mechanism for breakage of chromosomes in the cytoplasm.** David Pellman, Boston, MA

**11:10 a.m.**  **Homologous recombination deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.** Maria Jasin, New York, NY

---

**Special Session • 10:15 a.m.–11:45 a.m.**

La Nouvelle Orleans A-B, Convention Center

**New Drugs on the Horizon: Part 3**

**Cochairs:** Philip Jones, Houston, TX; Rima Al-awar, Toronto, ON, Canada

**10:15 a.m.**  **Introduction.** Philip Jones, Houston, TX

**10:20 a.m.**  **ND11 Discovered GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers.** Hans Purkey, South San Francisco, CA

**10:40 a.m.**  **ND12 Discovery and First Structural Disclosure of EZM0414: A potent and selective small molecule inhibitor of the histone methyltransferase SETD2.** Jeffery L. Kutok, Cambridge, MA

**11:00 a.m.**  **ND13 The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma.** James A. Henderson, Watertown, MA

**11:20 a.m.**  **ND14 Pharmacological profile and anti-tumor properties of FHD-286: A novel BAF inhibitor for the treatment of transcription factor-driven cancers.** Murphy Hentemann, Cambridge, MA

**11:40 a.m.**  **Closing Remarks.** Rima S. Al-awar, Toronto, ON, Canada
MONDAY, APRIL 11

Clinical Trials Plenary Session 3 • 10:15 a.m.–12:15 p.m.

Hall B-C, Convention Center

Neoadjuvant and Perioperative Immunotherapy Clinical Trials

Cochairs: Julie R. Brahmer, Baltimore, MD; Padmanee Sharma, Houston, TX

10:15 a.m. Introduction. Padmanee Sharma, Houston, TX

10:16 a.m. CT009 Phase II trial of perioperative pembrolizumab plus capecitabine and oxaliplatin followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma. Gulam A. Manji, New York, NY

10:31 a.m. Discussant. Elizabeth Smyth, Cambridge, United Kingdom

10:46 a.m. CT010 A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer (KGOG 3046/ TRU-D). Junsik Park, Seoul, Korea, Republic of

11:01 a.m. Discussant. Amir A. Jazaeri, Houston, TX

11:16 a.m. CT011 NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC). Tina Cascone, Houston, TX

11:31 a.m. Discussant. Edward B. Garon, Santa Monica, CA

11:46 a.m. CT012 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial. Nicolas Girard, Paris, France

12:01 p.m. Discussant. David Paul Carbone, Columbus, OH

12:16 p.m. Concluding Remarks. Julie R. Brahmer, Baltimore, MD

Meet and Greet • 10:30 a.m.–11:30 a.m.

AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center

Meet the Editors-in-Chief of Blood Cancer Discovery:
Riccardo Dalla-Favera, MD and Kenneth C. Anderson, MD

Riccardo Dalla-Favera, New York, NY
Kenneth C. Anderson, Boston, MA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Meet and Greet • 11:30 a.m.–12:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center
Meet the Editor-in-Chief of Molecular Cancer Research: Massimo Loda, MD
Massimo Loda, New York, NY

Special Session • 12:00 p.m. –1:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room 293-294, Convention Center
Annual Business Meeting of Members
AACR Chief Executive Officer: Margaret Foti, Philadelphia, PA
AACR President: David A. Tuveson, Cold Spring Harbor, NY
AACR President-Elect: Lisa M. Coussens, Portland, OR
AACR Past President: Antoni Ribas, Los Angeles, CA
AACR Treasurer: William N. Hait, New Brunswick, NJ

NCI/NIH-SPONSORED SESSION • 12:30 p.m.–1:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room 298-299, Convention Center
NCI Opportunities in Funding: Cancer Prevention and Control Clinical Trials Planning Grant Program
Moderator: Brandy Heckman-Stoddard, Rockville, MD

12:30 p.m. Overview of Cancer Prevention and Control Clinical Trials Planning Grants Program. Brandy Heckman-Stoddard, Rockville, MD
12:35 p.m. Planning grants for cancer prevention, screening, and symptom management. Brandy Heckman-Stoddard, Rockville, MD
12:50 p.m. Planning grants for behavioral interventions in cancer prevention and control. Susan Czajkowski, Rockville, MD
1:05 p.m. Use of the planning grant mechanism for trials conducted through the NCI Community Oncology Research Program (NCORP) - U34. Worta McCaskill-Stevens, Rockville, MD
1:20 p.m. Panel Discussion
MONDAY, APRIL 11

**Advances in Diagnostics and Therapeutics**
12:30 p.m.–2:00 p.m.
Room 343-345, Convention Center

**Deep Learning for Cancer Imaging**

*Chair:* Theo A. Knijnenburg, Seattle, WA

**12:30 p.m.** 
**Introduction.** Theo A. Knijnenburg, Seattle, WA

**12:35 p.m.** 
**Using live imaging and machine learning in stem cells to understand and predict cell states.** Theo A. Knijnenburg, Seattle, WA

**1:00 p.m.** 
**Deep learning applications in multiplex tissue imaging for precision oncology.** Jeremy Goecks, Portland, OR

**1:25 p.m.** 
**AI and whole slide imaging biomarkers.** Joel H. Saltz, Stony Brook, NY

Great Hall AD, Convention Center

**New Horizons in Neoadjuvant and Adjuvant Immunotherapy for Solid Tumors**

*Chair:* Patrick M. Forde, Baltimore, MD

**12:30 p.m.** 
**Introduction.** Patrick M. Forde, Baltimore, MD

**12:35 p.m.** 
**Checkpoint inhibition for early-stage triple-negative breast cancer: Does sequencing and timing of administration matter?** Sara M. Tolaney, Boston, MA

**1:00 p.m.** 
**Gastroesophageal cancer: Moving toward cure with combination therapy.** Elizabeth Smyth, Cambridge, United Kingdom

**1:25 p.m.** 
**Immunotherapy for resectable lung cancer: Clinical use and molecular predictors of benefit.** Patrick M. Forde, Baltimore, MD

Room 217-219, Convention Center

**Peptide Interaction Inhibitors in Cancer Therapeutics**

*Chair:* Tomasz Cierpicki, Ann Arbor, MI

**12:30 p.m.** 
**Introduction.** Tomasz Cierpicki, Ann Arbor, MI

**12:35 p.m.** 
**Inhibiting and stabilizing protein-protein interactions to block cancer signals.** Michelle R. Arkin, South San Francisco, CA

**1:00 p.m.** 
**Targeting transcription factor drivers in cancer.** John H. Bushweller, Charlottesville, VA

**1:25 p.m.** 
**Predicting druggability of protein-protein interactions to discover new cancer therapeutics.** Tomasz Cierpicki, Ann Arbor, MI

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Advances in Organ Site Research • 12:30 p.m.–2:00 p.m.

Room 208-210, Convention Center

Advances in Glioblastoma Cancer Research and Cancer Care

Chair: Howard A. Fine, New York, NY

12:35 p.m. Title to be announced. Howard A. Fine, Bethesda, MD

12:57 p.m. IDO: Going beyond enzyme activity to eradicate glioblastoma. Derek A. Wainwright, Chicago, IL

1:16 p.m. Title to be announced. Elizabeth A. Maher, Dallas, TX

1:38 p.m. Deciphering brain tumor biology by single-cell genomics. Mario L. Suva, Charlestown, MA

Room 260-262, Convention Center

Advances in Ovarian Cancer Detection and Treatment

Chair: Beth Y. Karlan, Los Angeles, CA

12:35 p.m. Integrating genetics/genomics into routine ovarian cancer care. Beth Y. Karlan, Los Angeles, CA

12:57 PM Early detection of ovarian and other cancers using cell-free DNA fragmentomes. Victor E. Velculescu, Baltimore, MD

1:19 PM Dissecting mechanisms of NK cell dysfunction and re-engagement in high grade serous ovarian cancer. Sarah J. Hill, Boston, MA

1:38 PM Novel strategies for overcoming adaptive responses and drug resistance in ovarian cancer. Gottfried E. Konecny, Los Angeles, CA

Room 265-268, Convention Center

Triple Negative Breast Cancer: Molecular Insights and Treatment Advances

Chair: Edison T. Liu, Bar Harbor, ME

12:30 p.m. Introduction. Edison T. Liu, Bar Harbor, ME

12:35 p.m. Genomic landscape of triple negative breast cancer: From description to mechanism. Edison T. Liu, Bar Harbor, ME

12:57 PM Challenges of triple negative breast cancer: From the individual to the community. Lisa A. Carey, Chapel Hill, NC

1:19 PM STING mediated inflammatory signaling in BRCA-mutant breast cancer. Eileen E. Parkes, Oxford, United Kingdom

1:41 PM It takes two: Cooperating oncogenic mutations in the HER2/HER3 pathway. Ariella B. Hanker, Dallas, TX
**Monday, April 11**

**Advances in Population Sciences • 12:30 p.m.–2:00 p.m.**

Room 353-355, Convention Center

Impact of Off-Label Therapies in Cancer Care and Outcomes across Populations

Chair: Michael T. Halpern, Bethesda, MD

12:30 p.m.  **Introduction.** Michael T. Halpern, Bethesda, MD

12:35 p.m.  **Patient and hospital factors affecting off-label therapy use for individuals with advanced cancer: Findings from the NCI Patterns of Care Study.** Michael T. Halpern, Bethesda, MD

1:00 p.m.  **Leveraging large databases to study repurposing and off-label use of common drugs in cancer: Opportunities and challenges.** Ami Vyas, Kingston, RI

1:25 p.m.  **The use of off-label drugs for supportive and palliative care in patients with advanced cancer: Challenges and opportunities.** Eduardo Bruera, Houston, TX

**Advances in the Science of Cancer Health Disparities 12:30 p.m.–2:00 p.m.**

New Orleans Theater C, Convention Center

Obesity and Health Disparities in Cancer

Chair: Kristy A. Brown, New York, NY

12:30 p.m.  **Introduction.** Kristy A. Brown, New York, NY

12:35 p.m.  **Obesity and adipose tissue: More than just fat.** Mikael Ryden, Solna, Sweden

1:00 p.m.  **Adipose-derived extracellular vesicles: New players in the obesity-breast cancer link.** Kristy A. Brown, New York, NY

1:25 p.m.  **Obesity-associated inflammation and cancer: Adding fuel to the fire.** Daniela F. Quail, Montreal, QC, Canada

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Major Symposia • 12:30 p.m.–2:00 p.m.
La Nouvelle Orleans A-B, Convention Center
AACR-Bayard D. Clarkson Symposium on Cancer Stem Cell Metabolism, Proteostasis, and Metastasis

Chair: Andreas Trumpp, Heidelberg, Germany

12:30 p.m.  Introduction.  Andreas Trumpp, Heidelberg, Germany
12:35 p.m.  The role of leukemic stem cells in therapy resistance.  Andreas Trumpp, Heidelberg, Germany
1:00 p.m.   Epigenetic influence of our (fatty) diet on metastatic-initiating cells: Role of intra-tumor Schwann cells.  Salvador Aznar-Benitah, Barcelona, Spain
1:25 p.m.   Cancer specific amino acid metabolism.  Oliver Maddocks, Glasgow, United Kingdom

Room 356-357, Convention Center
Regulatory Science and Policy Session
Accelerated, Conditional, Provisional, or Temporary? A Comparison of International Expedited Approval Programs

Moderator: Gautam Mehta, Silver Spring, MD

12:30 p.m.  Introduction and overview of Project Orbis and international regulatory collaboration.  Lauren Tesh Hotaki, Silver Spring, MD
12:35 p.m.  Overview of the Accelerated Approval program in the US.  Gautam Mehta, Silver Spring, MD
12:45 p.m.  Overview of Provisional Approval in Australia.  Michael Shum, Canberra, Australia
12:55 p.m.  Overview of Conditional Marketing Authorization in the EU.  Francesco Pignatti, London, United Kingdom
1:05 p.m.   Overview of Temporary Authorization in Switzerland.  Ulrich-Peter Rohr, Hamburg, Germany
1:15 p.m.   Panelist.  Angelo de Claro, Silver Spring, MD
Major Symposia (cont’d)

New Orleans Theater B, Convention Center

**CAR T cells for Solid Tumors: Bullish or Bearish?**

**Chair:** Crystal L. Mackall, Stanford, CA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 p.m.</td>
<td>Introduction.</td>
<td>Crystal L. Mackall, Stanford, CA</td>
</tr>
<tr>
<td>12:35 p.m.</td>
<td>Mechanisms behind CAR T cells.</td>
<td>Marcela V. Maus, Boston, MA</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Multi-modal genetic engineering approaches to overcoming barriers in CAR T cell therapy for solid cancers.</td>
<td>Martin Pule, London, United Kingdom</td>
</tr>
<tr>
<td>1:25 p.m.</td>
<td>CAR T cells for solid tumors: Charting a path forward.</td>
<td>Crystal L. Mackall, Stanford, CA</td>
</tr>
</tbody>
</table>

New Orleans Theater A, Convention Center

**Epigenetic Alterations as Cancer Therapeutic Targets**

**Chair:** Bradley E. Bernstein, Boston, MA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 p.m.</td>
<td>Introduction.</td>
<td>Bradley E. Bernstein, Boston, MA</td>
</tr>
<tr>
<td>12:35 p.m.</td>
<td>Title to be announced.</td>
<td>Shelley L. Berger, Philadelphia, PA</td>
</tr>
<tr>
<td>12:55 p.m.</td>
<td>Suppression of tumor intrinsic immunogenicity by Setdb1.</td>
<td>Bradley E. Bernstein, Boston, MA</td>
</tr>
<tr>
<td>1:15 p.m.</td>
<td>Identification of SIRT1 as a novel therapeutic target in T-ALL.</td>
<td>Daniel Herranz, New Brunswick, NJ</td>
</tr>
<tr>
<td>1:32 p.m.</td>
<td>Epigenetic regulation of endogenous retroelements as an emerging vulnerability and therapeutic opportunity in cancer.</td>
<td>Daniel D. De Carvalho, Toronto, ON, Canada</td>
</tr>
</tbody>
</table>

Hall B-C, Convention Center

**KRAS Anniversary Session: Novel Mechanisms for Targeting KRAS**

**Chair:** Patricia M. LoRusso, New Haven, CT

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 p.m.</td>
<td>Introduction.</td>
<td>Patricia M. LoRusso, Hamden, CT</td>
</tr>
<tr>
<td>12:34 p.m.</td>
<td>Targeting KRAS: Light at the end of the tunnel.</td>
<td>Mariano Barbacid, Madrid, Spain</td>
</tr>
<tr>
<td>12:54 p.m.</td>
<td>How Ras proteins cause cancer.</td>
<td>Frank McCormick, San Francisco, CA</td>
</tr>
<tr>
<td>1:11 p.m.</td>
<td>Discovering and deploying chemical strategies to drug KRAS: The formerly undruggable oncogene.</td>
<td>Kevan Michael Shokat, San Francisco, CA</td>
</tr>
<tr>
<td>1:28 p.m.</td>
<td>The clinical successes and challenges of drugging KRAS.</td>
<td>Patricia M. LoRusso, New Haven, CT</td>
</tr>
</tbody>
</table>

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
La Nouvelle Orleans C, Convention Center

**Novel Cancer Dependencies and Synthetic Lethality Strategies Beyond the PARP/BRCA Paradigm**

**Chair:** Daniel Durocher, Toronto, ON, Canada

**12:30 p.m.**  
**Introduction.** Daniel Durocher, Toronto, ON, Canada

**12:35 p.m.**  
**Mapping effective drug combinations in molecularly stratified cancer cells.** Mathew Garnett, Cambridge, United Kingdom

**1:00 p.m.**  
**Discovery of PKMYT1 as a synthetic-lethal target in CCNE1-amplified cancers.** Daniel Durocher, Toronto, ON, Canada

**1:25 p.m.**  
**Development of novel therapeutic strategies to target the DNA damage response in the clinic.** Timothy A. Yap, Houston, TX

Room 220-222, Convention Center

**Targeted Protein Degradation: Exploring New Targets and E3 Ligases**

**Chair:** Craig M. Crews, New Haven, CT

**12:30 p.m.**  
**Introduction.** Craig M. Crews, New Haven, CT

**12:35 p.m.**  
**Scalable discovery and multi-omic characterization of molecular glue degraders.** Cristina Mayor-Ruiz, Barcelona, Spain

**1:00 p.m.**  
**Chemoproteomic approaches for mapping degradable target space.** Fleur Ferguson, LaJolla, CA

**1:25 p.m.**  
**Reimagining druggability using chemoproteomic platforms.** Daniel K. Nomura, Berkeley, CA

Great Hall BC, Convention Center

**Understanding Microbe-Tumor Interactions in Health and Disease: From Basic Mechanisms to Applied Microbial-Based Cancer Therapy**

**Chair:** Beth McCormick, Boston, MA

**12:30 p.m.**  
**Introduction.** Beth McCormick, Boston, MA

**12:35 p.m.**  
**Microbiome regulation of the intestinal multidrug efflux transporter P-Glycoprotein in health and disease.** Beth McCormick, Boston, MA

**1:00 p.m.**  
**Gut microbiome in immuno-oncology: From a biomarker to adjuvant therapeutic.** Bertrand Routy, Montreal, QC, Canada

**1:25 p.m.**  
**Targeting microbes to promote health and end cancer.** Jennifer A. Wargo, Houston, TX
MONDAY, APRIL 11

Special Session • 12:30 p.m.–2:00 p.m.

**NOT ELIGIBLE FOR CME CREDIT**

Room 243-245, Convention Center

**Optimizing Cell-based Therapies for Clinical Impact: Stand Up to Cancer Open Scientific Session**

**Moderator:** Raymond N. DuBois, Charleston, SC

12:30 p.m.  
*Mutant KRas-redirected T cell therapy approach.* Beatriz M. Carreno, Philadelphia, PA

12:52 p.m.  
*CD5 CAR-NK approaches.* Katayoun Rezvani, Houston, TX

1:16 p.m.  
*Utilizing organoids in optimizing T-cell based therapeutics.* William Freed-Pastor, Cambridge, MA

1:38 p.m.  
*Pediatric Cancer CAR T clinical trial update.* John M. Maris, Philadelphia, PA

Meet and Greet • 1:30 p.m.–2:30 p.m.

**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center

**Meet the Editor-in-Chief of *Clinical Cancer Research:* Keith T. Flaherty, MD**

Keith T. Flaherty, Boston, MA

Forum • 1:30 p.m.–3:00 p.m.

Room 295-296, Convention Center

**Trust in Science**

**Chair:** William S. Dalton, Tampa, FL

**Speakers:**
Patricia Spears, Raleigh, NC
Jesse Nodora, La Jolla, CA

**Panelists:**
Stacey J. Adam, North Bethesda, MD
John D. Carpten, Los Angeles, CA
Cimona V. Hinton, Atlanta, GA
James W. Lillard, Smyrna, GA
Tracy G. Lively, Rockville, MD
Eric H. Rubin, North Wales, PA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Poster Sessions • 1:30 p.m. –5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Halls D-H, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App, and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall. All posters (including in-person posters) are available at www.aacr.org/eposters22.

Prevention / Early Detection / Interception
Section 1 Preclinical Prevention, Early Detection, and Interception 3

Population Sciences
Section 2 Genetic and Environmental Cancer Risk Factors

Molecular/Cellular Biology and Genetics
Section 3 Chromatin, Enhancers, Promoters, and Regulation of Transcription Factor Function
Section 4 Diagnostic and Therapeutic Applications of MicroRNAs
Section 5 Genomic Instability 2
Section 6 Growth Factor and Receptors
Section 7 Short and Long Noncoding RNA Regulating Cancer Biology
Section 8 Tumor-Microenvironment Interactions

Tumor Biology
Section 10 Causes and Consequences of Tumor Heterogeneity
Section 11 Cell Line and Animal Models
Section 12 Humanized Mouse Models, Imaging, and Immuno-Oncology
Section 13 Leveraging Single Cell Sequencing Technologies and New Models to Study Pediatric Malignancies
Section 14 Methods to Measure Tumor Evolution and Heterogeneity
Section 15 Tumor Immune Profiling and Spatial Analysis

Chemistry
Section 20 Applied Nanotechnology and Drug Delivery Approaches toward Potential Cancer Therapeutics
Section 16 Late-Breaking Research: Experimental and Molecular Therapeutics 1 / Chemistry

Experimental and Molecular Therapeutics
Section 21 Antibody-Drug Conjugates
Section 22 Breast Cancer Drug Resistance and Novel Targets
Section 23 Drug Targets
Section 24 Mechanisms of Drug Action 1
Section 25 Mechanisms of Drug Action 2
Section 26 New Technologies for Drug Discovery
Section 16 Late-Breaking Research: Experimental and Molecular Therapeutics 1 / Chemistry
MONDAY, APRIL 11

**Survivorship**  
Section 27  Advocates Poster Session 1 (Scientist↔Survivor Program)

**Bioinformatics / Convergence Science / Systems Biology**  
Section 28  Computational Frameworks and Resources  
Section 29  Machine Learning Across Cancer Research

**Clinical Research Excluding Trials**  
Section 30  Circulating Tumor Cells and Prognostic Biomarkers  
Section 31  Immune Response to Therapies / Immune Monitoring and Clinical Correlates  
Section 32  Inflammation / Modifiers of the Tumor Microenvironment  
Section 33  Pediatric Oncology: Clinical Investigation  
Section 34  Spatial Proteomics and Transcriptomics

**Clinical Trials**  
Section 35  Phase I Clinical Trials 1  
Section 36  Phase II Clinical Trials 2

**Immunology**  
Section 37  Immune Response to Therapies 1  
Section 38  Immunomodulatory Agents and Interventions 1  
Section 39  Inflammation, Immunity, and Cancer  
Section 40  Innate Immunity to Cancer  
Section 18  Late-Breaking Research: Immunology 1

---

**Major Symposium • 2:30 p.m.–4:30 p.m.**

Room 356-357, Convention Center

**Regulatory Science and Policy Session**

**Successful Development of Cancer Therapies for Ultra-Rare Indications**

**Moderator:** Jeff L. Summers, Silver Spring White Oak, MD

**Speakers:**

Donald C. Lo, Bethesda, MD  
Deepa Narayanan, Bethesda, MD  
Josh Sommer, Durham, NC  
Jeffrey A. Toretsky, Washington, DC  
Michael Stebbins, Alexandria, VA  
Marc R. Theoret, Silver Spring, MD

---

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Clinical Trials Minisymposium 2 • 2:30 p.m.–4:30 p.m.

Great Hall BC, Convention Center

Patient Selection Strategies for Molecularly Targeted Agents in Clinical Trials

Cochairs: Susan Halabi, Durham, NC; Edith P. Mitchell, Philadelphia, PA

2:30 p.m.  Introduction. Susan Halabi, Durham, NC

2:35 p.m.  CT028 Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study. John N. Allan, New York, NY

2:50 p.m.  CT029 Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC). Funda Meric-Bernstam, Houston, TX

3:05 p.m.  CT030 Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial. Timothy A. Yap, Houston, TX

3:20 p.m.  CT031 Title: TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity. Johann S. de Bono, London, United Kingdom

3:35 p.m.  CT032 Activity and safety of alectinib for ALK-altered solid tumors from MyPathway. Charles Swanton, London, United Kingdom

3:50 p.m.  CT033 KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors. Daniel S. Tan, Singapore, Singapore

4:05 p.m.  CT034 Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study). Shun Lu, Shanghai, China

4:20 p.m.  Closing Remarks. Edith P. Mitchell, Philadelphia, PA
**MONDAY, APRIL 11**

**Minisymposium • 2:30 p.m.–4:15 p.m.**

Room 217-219, Convention Center  
**Multidisciplinary**  
**Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases**

**Chair:** Rob Scharpf, Baltimore, MD

2:30 p.m.  
**Introduction.** Rob Scharpf, Baltimore, MD

2:35 p.m.  
2181  
*Genomic correlates of Metastasis in KRAS mutant lung adenocarcinoma.* Daniel Boiarsky, Boston, MA

2:50 p.m.  
2182  
*Ancestry inference and population-specific disparities in a real-world clinical sequencing cohort.* Kanika Arora, New York, NY

3:05 p.m.  
2183  
*Interrogating the molecular profile of colorectal cancer: detection of clinically actionable alterations in Hispanics.* Ingrid M. Montes-Rodriguez, San Juan, PR

3:20 p.m.  
2184  
*Landscape of genomic alterations of ultra-rare sarcomas (URS) from 1,079 patients in the AACR GENIE real world database: Clinical implications.* Justin Tyler Moyers, Orange, CA

3:35 p.m.  
2185  
*MicroSEC: Sequence error filter for formalin-fixed and paraffin-embedded samples.* Masachika Ikegami, Tokyo, Japan

3:50 p.m.  
2186  
*Distinct aggressive biology drives the evolution of metastatic cancer.* Ditte Sigaard Christensen, Aarhus N, Denmark

4:05 p.m.  
**Closing Remarks.** Rob Scharpf, Baltimore, MD

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Minisymposia • 2:30 p.m.–4:30 p.m.

La Nouvelle Orleans C, Convention Center

Bioinformatics / Convergence Science / Systems Biology
Single-cell and Spatial Profiling of Tumor Cells and
the Immune Microenvironment

Chair: Sohrab Shah, New York, NY

2:30 p.m.  Introduction. Sohrab Shah, New York, NY

2:35 p.m.  2125   Towards a spatial view of immune cell function in cancer. Maryam
Pourmaleki, New York, NY

2:50 p.m.  2126   Single-cell sequencing of early-stage lung adenocarcinomas reveals
prominent intratumoral heterogeneity and epithelial plasticity programs.
Guangchun Han, Houston, TX

3:05 p.m.  2127   Master regulator analysis of the tumor microenvironment and the
distinctive tumor sub-populations in pancreatic ductal adenocarcinoma.
Jinjie Ling, New York, NY

3:20 p.m.  2128   Single-cell replication dynamics in genomically unstable cancers.
Adam C. Weiner, New York, NY

3:35 p.m.  2129   Spatial charting of single cell transcriptomes in tissues. Runmin Wei,
Houston, TX

3:50 p.m.  2130   Uncovering the spatial landscape of tumor-immune interactions
using latent spaces from spatial transcriptomics. Atul Deshpande, Baltimore,
MD

4:05 p.m.  2131   Curating cartography: Enabling the harmonisation, visualisation, and
reuse of diverse multiplexed imaging data through the Human Tumor Atlas
Network Data Coordinating Center. Adam J. Taylor, Seattle, WA

4:20 p.m.  Closing Remarks. Sohrab Shah, New York, NY
MONDAY, APRIL 11

New Orleans Theater B, Convention Center

Chemistry

Drug Design and Lead Optimization Strategies Toward Novel or Difficult-to-Drug Cancer Targets

Cochairs: James B. Jaquith, Toronto, ON, Canada; Iain D. Watson, Toronto, ON, Canada

2:30 p.m. **Introduction.** James B. Jaquith, Toronto, ON, Canada

2:35 p.m. **2133** In pursuit of MCL-1 inhibitors with improved therapeutic window for the treatment of hematological malignancies: Discovery of JNJ-4355. Frederik J. Rombouts, Beerse, Belgium

2:50 p.m. **2134** Discovery and structure activity relationships of BAY 2666605: PDE3A-SLFN12 complex inducer for cancer therapy. Stefan Gradl, Berlin, Germany

3:05 p.m. **2135** Targeting N-Myc in neuroblastoma cells with selective Aurora kinase A degraders. Jian Tang, Minneapolis, MN

3:20 p.m. **2136** Prediction of small molecule-protein binding events for BRD4 and EGFR inhibitors using HR-LiP, a novel structural proteomics approach. Nigel Beaton, Schlieren, Switzerland

3:35 p.m. **2137** Glioblastoma mitochondrial respiration as a target for a new class of metabolic compounds capable of crossing the blood brain barrier. Krzysztof Reiss, New Orleans, LA

3:50 p.m. **2138** Creating next-generation biologics using a novel chemistry platform technology. Bertolt Kreft, Basel, Switzerland

4:05 p.m. **Closing Remarks.** Iain D. G. Watson, Toronto, ON, Canada

La Nouvelle Orleans A-B, Convention Center

Clinical Research Excluding Trials

Biomarkers 2

Chair: Pasi A. Jänne, Boston, MA

2:30 p.m. **Introduction.** Pasi A. Jänne, Boston, MA

2:35 p.m. **2139** Evaluation of tissue- and plasma-derived tumor mutational burden and genomic alterations of interest from the CheckMate 848 clinical trial. Jonathan Baden, Princeton, NJ

2:50 p.m. **2140** Association between gene expression signatures and outcomes of pembrolizumab (pembro) and paclitaxel (pac) in advanced gastric cancer (GC): Exploratory analysis from KEYNOTE-061. Kohei Shitara, Chiba, Japan

3:05 p.m. **2141** Development of a highly-sensitive targeted cell-free DNA epigenomic assay for early-stage multi-cancer screening. AmirAli Talasaz, Redwood City, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:20 p.m.  2142 Prognostic and predictive applications from mesenchymal gene expression subtype analysis for early-stage, HPV(-) head and neck squamous cell carcinoma. D. Neil Hayes, MD, MS, MPH, Memphis, TN

3:35 p.m.  2143 Clinicopathologic, genomic and immunophenotypic landscape of ATM mutations in non-small cell lung cancer. Biagio Ricciuti, Boston, MA

3:50 p.m.  2144 Holistic sampling of clonal dynamics using cfDNA in lung TRACERx. Alexander Mark Frankell, London, United Kingdom

4:05 p.m.  2145 Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial. Jaclyn Neely, Princeton, NJ

4:20 p.m.  Closing Remarks. Pasi A. Jänne, Boston, MA

Room 220-222, Convention Center
Experimental and Molecular Therapeutics
Biomarkers, Models, and Mechanisms
Chair: Matthew L. Meyerson, Boston, MA

2:30 p.m.  Introduction. Matthew L. Meyerson, Boston, MA

2:35 p.m.  2146 A quantitative in vivo pharmacogenomics platform uncovers biomarkers of therapy response. Michael Rosen, Mountain View, CA

2:50 p.m.  2147 Synthetic lethality of VRK1 in VRK2-methylated cancers. Jonathan So, Boston, MA

3:05 p.m.  2148 Pre-clinical models recapitulating the spectrum of response of BRCA associated pancreatic cancer. Talia Golan, Tel Hashomer, Israel

3:20 p.m.  2149 Biomarker-driven selection of polyADP ribose polymerase inhibitors (PARPi)-based combination therapies in patients with metastatic triple negative breast cancer (mTNBC). Zahi I. Mitri, Portland, OR

3:35 p.m.  2150 LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade. Chendi Li, Charlestown, MA

3:50 p.m.  2151 Identification and proteogenomic characterization of novel lung adenocarcinoma subtypes with therapeutic relevance. Yifat Geffen, Cambridge, MA

4:05 p.m.  2152 TNIK, a novel activator of FAK and YAP signaling, is a therapeutic target in lung squamous cell carcinoma. Pedro Torres-Ayuso, Frederick, MD

4:20 p.m.  Closing Remarks. Matthew L. Meyerson, Boston, MA
Minisymposia (cont’d)

MONDAY, APRIL 11

Great Hall AD, Convention Center
Experimental and Molecular Therapeutics
Emerging New Anticancer Agents

**Cochairs:** Rima S. Al-awar, Toronto, ON, Canada; Gordon B. Mills, Portland, OR

2:30 p.m. **Introduction.** Rima S. Al-awar, Toronto, ON, Canada

2:35 p.m. **2153** ATR inhibition augments the efficacy of the lurbinectedin in small cell lung cancer. Christopher William Schultz, Bethesda, MD

2:50 p.m. **2154** PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models. Jennifer R. Molina, Cambridge, MA

3:05 p.m. **2155** PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer. Luc Furic, Melbourne, Australia

3:20 p.m. **2156** IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway. Benjamin S. Amidon, Boston, MA

3:35 p.m. **2158** Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers. Mathew E. Sowa, Watertown, MA

3:50 p.m. **2159** PRMT5 inhibitor PRT543 displays potent antitumor activity in U2AF1^35af and RBM10^10of spliceosome-mutant non-small cell lung cancer in vitro and in vivo. Jack Carter, Wilmington, DE

4:05 p.m. **2157** SCR-6277, a potent and high selective arginine methyltransferase 5 (PRMT5) inhibitor with high tumor/plasma distribution ratio demonstrated robust anti-tumor activities and decreased hematological toxicities. Feng Zhou, Shanghai, China

4:20 p.m. **Closing Remarks.** Gordon B. Mills, Portland, OR

New Orleans Theater A, Convention Center
Immunology
Cancer Biology and Tumor Immunity

**Cochairs:** Samuel F. Bakhoum, New York, NY; John V. Heymach, Houston, TX

2:30 p.m. **Introduction.** Samuel F. Bakhoum, New York, NY

2:35 p.m. **2160** MCT4 blockade reverses lactate-mediated immunosuppression in LKB1-deficient NSCLC. Yu Qian, Houston, TX

2:50 p.m. **2161** Fasting fueled ketogenesis inhibits ovarian cancer and promotes anti-tumor T cell response. Mary Priyanka Udumula, Detroit, MI

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:05 p.m. 2162 Inhibition of GPR65 counteracts low pH induced immunosuppressive polarization of macrophages: *in vitro* and *in vivo* characterization of potent, selective and orally bioavailable small molecule GPR65 antagonists. Barbara Cipriani, Oxford, United Kingdom

3:20 p.m. 2163 Gender and estrogens as key factors in the response to immunotherapy in non small cell lung cancer. Sofia La Vecchia, Torino, Italy

3:35 p.m. 2164 Chromosomal instability as a mediator of anti-tumor immunity in pancreatic cancer. Daniel Bronder, New York, NY

3:50 p.m. 2165 CD58:CD2 - a multi-dimensional axis in cancer immunotherapy resistance. Patricia Ho, New York, NY

4:05 p.m. 2166 Ibuprofen induces ferroptosis to potentiate antitumor immunity. Ronan Talty, New Haven, CT

4:20 p.m. Closing Remarks. John V. Heymach, Houston, TX

Room 208-210, Convention Center
Molecular/Cellular Biology and Genetics
Cancer Genomics and Biology
Cochairs: Eliezer M. Van Allen, Boston, MA; Remond J. A. Fijneman, Amsterdam, Netherlands

2:30 p.m. Introduction. Eliezer M. Van Allen, Boston, MA

2:35 p.m. 2167 Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. Edwin Cuppen, Amsterdam, Netherlands

2:50 p.m. 2168 Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment. Frederick S. Varn, Farmington, CT

3:05 p.m. 2169 New telomeres and chromosomal arm fusions in cancer genomes revealed by long-read genome sequencing. Kar-Tong Tan, Boston, MA

3:20 p.m. 2170 Automated analysis of significant noncoding mutations in somatic whole cancer genomes. Felix Dietlein, Boston, MA

3:35 p.m. 2171 The spatial landscape of clonal somatic mutations in benign and malignant tissue. Andrew Erickson, Oxford, United Kingdom

3:50 p.m. 2172 Tumor break load is a biologically relevant characteristic of genomic instability with prognostic value for patients with localized colorectal cancer. Soufyan Lakbir, Amsterdam, Netherlands

4:05 p.m. 2173 Ancestry bias in CRISPR guide design impedes discovery of genetic dependencies. Sean Alexander Misek, Boston, MA

4:20 p.m. Closing Remarks. Remond J.A. Fijneman, Amsterdam, Netherlands
MONDAY, APRIL 11

Room 243-245, Convention Center
Molecular/Cellular Biology and Genetics
Cancer Metabolism

Cochairs: Karen H. Vousden, London, United Kingdom; Oliver Maddocks, Glasgow, United Kingdom

2:30 p.m.  Introduction. Karen H. Vousden, London, United Kingdom

2:35 p.m.  2174  Sirpiglenastat (DRP-104), a novel broad acting glutamine antagonist, has therapeutic potential in targeting KEAP1-mutant lung cancer. Thales Papagiannakopoulos, New York, NY

2:50 p.m.  2175  Tumor-derived IL-6 impairs hepatic adaptive response to undernutrition in pancreatic cancer cachexia. Paige C. Arneson-Wissink, Portland, OR

3:05 p.m.  2176  NADPH production and redox homeostasis regulate acinar to ductal metaplasia. Megan D. Radyk, Ann Arbor, MI

3:20 p.m.  2177  Myeloid-derived arginase depletes microenvironmental arginine in PDAC tumors and leads to activation of arginine de novo biosynthesis in cancer cells. Juan Apiz-Saab, Chicago, IL

3:35 p.m.  2178  Diet-modulated SCAP-SREBP signaling is essential for acinar cell differentiation, pancreatic morphogenesis, and pancreatic adiposity. Anna C. Lilly, Philadelphia, PA

3:50 p.m.  2179  Increased BCAT1 expression creates a pseudo-hypoxic environment that promotes cell proliferation in a subtype of glioblastoma. Maria Fala, Cambridge, United Kingdom

4:05 p.m.  2180  Deciphering the Warburg effect: Redox is the key to tumor differentiation. Jiang Haowen, Palo Alto, CA

4:20 p.m.  Closing Remarks. Oliver Maddocks, Glasgow, United Kingdom

Room 260-262, Convention Center
Tumor Biology
Molecular Principles of Metastasis

Cochairs: Cimona V. Hinton, Atlanta, GA; Nikki A. Delk, Richardson, TX

2:30 p.m.  Introduction. Cimona V. Hinton, Atlanta, GA

2:35 p.m.  2187  A multiplexed staining method to quantify EMT derived tumor heterogeneity presents a means of predicting patient prognosis based on EMT state. Meredith S. Brown, Hanover, NH

2:50 p.m.  2188  The N6-methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer. Brandon Tan, Duarte, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
2189  The role of generational obesity on the ovarian metastatic niche. Tyvette Hilliard, South Bend, IN

2190  Brain-seeking extracellular vesicles derived from metastatic breast cancer cells modulate brain endothelial cell metabolism. Sara Busatto, Boston, MA

2191  Alteration of anti-tumoral immunity in the pre-metastatic bone microenvironment via autonomic nerve system dysfunction. Eun Jung Lee, Seoul, Korea, Republic of

2192  HSF1 downregulation of CCL5 reduces CD8+ T cell trafficking in breast cancer. Curteisha LeeAnn Jacobs, Bloomington, IN

2193  Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy. Jieyi Zhang, Philadelphia, PA

2194  Rapid interrogation of colon cancer driver genes in vivo using split Cre and CRISPR-Cas9. Daniel Zhang, Cambridge, MA

2195  A tissue atlas of oncogenic RAS mutation. Ozgun Erdogan, Durham, NC

2196  Oncogenic context drives the landscape of tumor suppression in lung cancer. Ian Winters, Mountain View, CA

2197  Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance. Deborah Caswell, London, United Kingdom

2198  The impact of carcinogens, obesity, and chronic inflammatory processes on mutational signatures and cancer risk in mouse tumor models. Yun Rose Li, Duarte, CA

2199  Molecular dissection of a novel, highly proliferative lineage in a model of Helicobacter pylori-driven gastric metaplasia and dysplasia. Valerie Phoebe O’Brien, Seattle, WA

2200  Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling. Samir Zaidi, New York, NY

Closing Remarks. Nikki A. Delk, Richardson, TX

Room 278-282, Convention Center
Tumor Biology
Next-Gen Genetically Engineered Mouse Models

Cochairs: David A. Largaespada, Minneapolis, MN; Katerina A. Politi, New Haven, CT

2:30 p.m.  Introduction. David A. Largaespada, Minneapolis, MN

2:35 p.m.  2194  Rapid interrogation of colon cancer driver genes in vivo using split Cre and CRISPR-Cas9. Daniel Zhang, Cambridge, MA

2:50 p.m.  2195  A tissue atlas of oncogenic RAS mutation. Ozgun Erdogan, Durham, NC

3:05 p.m.  2196  Oncogenic context drives the landscape of tumor suppression in lung cancer. Ian Winters, Mountain View, CA

3:20 p.m.  2197  Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance. Deborah Caswell, London, United Kingdom

3:35 p.m.  2198  The impact of carcinogens, obesity, and chronic inflammatory processes on mutational signatures and cancer risk in mouse tumor models. Yun Rose Li, Duarte, CA

3:50 p.m.  2199  Molecular dissection of a novel, highly proliferative lineage in a model of Helicobacter pylori-driven gastric metaplasia and dysplasia. Valerie Phoebe O’Brien, Seattle, WA

4:05 p.m.  2200  Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling. Samir Zaidi, New York, NY

4:20 p.m.  Closing Remarks. Katerina A. Politi, New Haven, CT
MONDAY, APRIL 11

**Special Session • 2:30 p.m.–4:30 p.m.**

Room 265-268, Convention Center

**AACR-JCA Joint Session on Organoids: Tumor Cells, Microenvironments, and Beyond**

**Cochairs:** Calvin J. Kuo, Stanford, CA; Masanobu Oshima, Kanazawa, Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30</td>
<td><strong>Introduction.</strong> Calvin J. Kuo, Stanford, CA</td>
<td></td>
</tr>
<tr>
<td>2:35</td>
<td><strong>Introduction.</strong> Masanobu Oshima, Kanazawa, Japan</td>
<td></td>
</tr>
<tr>
<td>2:40</td>
<td><strong>Recapitulating pancreatic cancer ecosystems using multicellular cancer organoid cultures.</strong> Keisuke Sekine, Yokohama, Japan</td>
<td></td>
</tr>
<tr>
<td>3:05</td>
<td><strong>Organoids to model human diseases.</strong> Hans Clevers, Basel, Switzerland</td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td><strong>Modeling polyclonal metastasis of colon cancer by organoids.</strong> Masanobu Oshima, Kanazawa, Japan</td>
<td></td>
</tr>
<tr>
<td>3:55</td>
<td><strong>Building function and complexity into cancer organoid models.</strong> Calvin J. Kuo, Stanford, CA</td>
<td></td>
</tr>
<tr>
<td>4:40</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Awards and Lectures • 3:00 p.m.–3:45 p.m.**

Room 343-345, Convention Center

**NCI Director’s Address**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00</td>
<td><strong>Introduction.</strong> David A. Tuveson, Cold Spring Harbor, NY</td>
<td></td>
</tr>
<tr>
<td>3:05</td>
<td><strong>NCI Director’s Address.</strong> Norman E. Sharpless, Bethesda, MD</td>
<td></td>
</tr>
<tr>
<td>3:20</td>
<td><strong>Fireside Chat with Drs. Sharpless and Tuveson</strong></td>
<td></td>
</tr>
</tbody>
</table>

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Career Development Forum • 3:30 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room 288-290, Convention Center


Cochairs: Victoria L. Seewaldt, Duarte, CA; Sheila Kumari Singh, Dundas, ON, Canada; Abenaa M. Brewster, Houston, TX; Shiva Malek, Cambridge, MA

Panelists:
Veronica Jones, Duarte, CA
Florence McAllister, Houston, TX

NCI/NIH-Sponsored Session • 4:00 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room 298-299, Convention Center

NCI-NIH: Cancer and Aging Research and Resource Development Opportunities

Moderator: Ana I. Robles, Rockville, MD

Speakers:
Chamelli Jhappan, Rockville, MD
Lisa M. Galicchio, Rockville, MD
Ronald Kohanski, Bethesda, MD
Basil Eldadah, Bethesda, MD
Konstantin Salnikow, Rockville, MD
Gosia Klauzinska, Rockville, MD
MONDAY, APRIL 11

Forums • 5:00 p.m.–6:30 p.m.

New Orleans Theater B, Convention Center

Dharma Master Jiantai Forum on Advances in Lung Cancer

Chair: Roy S. Herbst, New Haven, CT

5:00 p.m.  Introduction. Roy S. Herbst, New Haven, CT

5:22 p.m.  Progress in harnessing the immune system to fight lung cancer. Julie R. Brahmer, Baltimore, MD

5:10 p.m.  Targeted therapies and resistance. Chris H. Boshoff, New York, NY

5:34 p.m.  Hope. Promise. What's next: A patient's perspective. Andrea E. Ferris, Bethesda, MD

5:46 p.m.  Panel Discussion

Great Hall BC, Convention Center

How Have Genome-Wide Association Studies Impacted Cancer Research?

Chair: Paul David Peter Pharoah, Cambridge, United Kingdom

5:00 p.m.  Introduction. Paul David Peter Pharoah, Cambridge, United Kingdom

5:25 p.m.  GWAS and the emperor’s new clothes. Joseph Terwilliger, New York, NY

5:10 p.m.  GWA studies and cancer: The best is yet to come. Paul J. Brennan, Lyon, France

5:40 p.m.  Panel Discussion

Room 265-268, Convention Center

Impact of Telehealth on Cancer Care Delivery

Chair: Ana Maria Lopez, Philadelphia, PA

5:00 p.m.  Introduction. Ana Maria Lopez, Philadelphia, PA

5:10 p.m.  Impact on telehealth on clinical trial delivery. Tobias Janowitz, Cold Spring Harbor, NY

5:25 p.m.  Examining variation in telehealth use by patient factors, pandemic phase, and clinic site at Norris Cotton Cancer Center in northern New England. Matthew Mackwood, Hanover, NH

5:40 p.m.  Panel Discussion

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
La Nouvelle Orleans A-B, Convention Center
Pancreas Cancer: Why Are We Moving So Slowly?

Chair: Anirban Maitra, Houston, TX

5:00 p.m. Introduction. Anirban Maitra, Houston, TX

5:10 p.m. Pancreas cancer: Critical challenges and opportunities in the clinical arena. Eileen M. O’Reilly, New York, NY

5:25 p.m. Basic and translational research in pancreatic cancer: Pushing boulders up the hill. Michael A. Hollingsworth, Omaha, NE

5:40 p.m. Panel Discussion

Great Hall AD, Convention Center
Untangling Mechanisms of Sensitivity and Resistance to Immune Checkpoint Blockade

Chair: Suzanne L. Topalian, Baltimore, MD

5:00 p.m. Introduction. Suzanne L. Topalian, Baltimore, MD

5:08 p.m. Immunological mechanisms of response and resistance to checkpoint inhibitors. Ira Mellman, South San Francisco, CA

5:20 p.m. From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy. Padmanee Sharma, Houston, TX

5:32 p.m. Decoding the role of the tumor microenvironment in immune evasion and therapeutic resistance through multi-dimensional analysis and data integration. Kurt Alex Schalper, New Haven, CT

5:44 p.m. Panel Discussion

La Nouvelle Orleans C, Convention Center
Vaccine Effectiveness in Cancer Patients with Immunotherapy

Chair: Catherine J. Wu, Boston, MA

5:00 p.m. Introduction. Catherine J. Wu, Boston, MA

5:10 p.m. Immune responses to SARS-CoV-2 mRNA vaccines in healthy subjects and patients with cancer. E. John Wherry, Philadelphia, PA

5:25 p.m. Vaccine efficacy (or lack thereof) in patients with hematological cancers. Paolo Ghia, Milano, Italy

5:45 p.m. Panel Discussion
MONDAY, APRIL 11

Special Sessions • 5:00 p.m.–6:30 p.m.

Room 243-245, Convention Center

AACR-ASCO Joint Session: Pathophysiology and New Treatments for Cancer-Associated Thrombosis

Cochairs: David A. Tuveson, Cold Spring Harbor, NY; Everett E. Vokes, Chicago, IL

5:00 p.m.  Welcome Remarks. David A. Tuveson, Cold Spring Harbor, NY
5:02 p.m.  Introduction. Everett E. Vokes, Chicago, IL
5:24 p.m.  Epidemiology and biology of cancer-associated thrombosis and its therapy. Jeffrey Zwicker, Boston, MA
5:44 p.m.  Update on thromboprophylaxis for ambulatory patients with cancer undergoing chemotherapy. Marc Carrier, Ottawa, ON, Canada
5:04 p.m.  Tailoring anticoagulation for cancer associated thrombosis: Maximizing benefit and minimizing harm. Deborah Siegal, Ottawa, ON, Canada
6:04 p.m.  Panelist. Ruben A. Mesa, San Antonio, TX
6:05 p.m.  Panel Discussion

Room 293-294, Convention Center

Fostering Entrepreneurship Part 1: Shopping Your Intellectual Property and Establishing Partnerships

NOT ELIGIBLE FOR CME CREDIT

Moderators: Christiana Goh Bardon, Boston, MA; Susan M. Galbraith, Cambridge, United Kingdom

Panelists:
Julian Adams, Boston, MA
Jeffrey A. Engelman, Cambridge, MA
William N. Hait, Princeton, NJ
Elaine R. Mardis, Columbus, OH
Dirk Nagorsen, Thousand Oaks, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
**Professional Advancement Session • 5:30 p.m.–7:00 p.m.**

*NOT ELIGIBLE FOR CME CREDIT*

Mardis Gras Salon, F-H, New Orleans Marriott

**Productive Peer Review: Improving Science while Avoiding Pitfalls**

**Moderators:** Chi Van Dang, Philadelphia, PA; Christine M. Lovly, Nashville, TN

5:40 p.m.  
Interactive Discussion

---

**Town Meeting • 5:30 p.m. - 7:00 p.m.**

*NOT ELIGIBLE FOR CME CREDIT*

Mardi Gras Salon D-E, Marriott New Orleans

**Minorities in Cancer Research (MICR) Town Hall Meeting**

**Chair:** Gerardo Colon-Otero, Jacksonville, FL

**Speakers:**

John D. Carpten, Los Angeles, CA  
Lisa A. Newman, New York, NY  
Sarki Abdulkadir, Chicago, IL  
Clayton C. Yates, Tuskegee, AL  
Luis A. Diaz, New York, NY  
Sanya A. Springfield, Rockville, MD  
Melissa B. Davis, New York, NY  
Dorothy A. Rhoades, Oklahoma City, OK  
Camille C.R. Ragin, Philadelphia, PA  
Martin Mendoza, Bethesda, MD  
Folakemi T. Odedina. Jacksonville, FL  
Lourdes Baezconde, Los Angeles, CA  
Nadine J. Barrett, Durham, NC
MONDAY, APRIL 11

Town Meetings • 6:30 p.m.–8:30 p.m.
NOT ELIGIBLE FOR CME CREDIT

Grand Ballroom C, Hilton New Orleans Riverside
Cancer Immunology Working Group (CIMM)
Town Hall Meeting and Networking Reception

Cochairs: Sandra Demaria, New York, NY; Kunle Odunsi, Chicago, IL

Jefferson Ballroom, Hilton New Orleans Riverside
Cancer Prevention Working Group (CPWG)
Town Hall Meeting and Networking Reception

Chair: Adriana Albini, Milano, Italy

Grand Ballroom D, Hilton New Orleans Riverside
Chemistry in Cancer Research (CICR) Working Group
Town Hall and Networking Reception

Cochairs: Joachim Rudolph, South San Francisco, CA; Mary M. Mader, Cambridge, MA

Moderators:
Mary M. Mader, Cambridge, MA
Ingo Hartung, Darmstadt, Germany

Panelists:
Clara Christ, Berlin, Germany
Alex Zhavoronkov, Hong Kong, China

Special Session • 6:30 p.m.–8:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

New Orleans Theater C, Convention Center

Special Documentary Screening—
“José Baselga: Cancer’s Fiercest Opponent”

6:30 p.m. Reception
6:45 p.m. Remarks. Margaret Foti and Susan M. Galbraith
6:55 p.m. Special screening of the documentary

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Professional Advancement Session • 7:00 p.m.–9:00 p.m.

Acadia Room, New Orleans Marriott

Navigating the Path to a Successful Career in Cancer Research

Cochairs: Oliver Bogler, Bethesda, MD; Beverly D. Lyn-Cook, Little Rock, AR; Brian M. Rivers, Atlanta, GA

Mentors:
A. William Blackstock, Winston Salem, NC
Wayne D. Bowen, Providence, RI
Oliver Bogler, Bethesda, MD
John M. Carethers, Ann Arbor, MI
Mariam Eljanne, Bethesda, MD
Chanita Hughes-Halbert, Los Angeles, CA
Christine M. Lovly, Nashville, TN
Beverly D. Lyn-Cook, Little Rock, AR
Kim L. O’Neill, Provo, UT
Lili Petruzzelli, South San Francisco, CA
Sheila Kumari Singh, Dundas, ON, Canada
Mariana C. Stern, Los Angeles, CA
Jose G. Trevino, Gainesville, FL
Danny R. Welch, Kansas City, KS
Clayton C. Yates, Tuskegee, AL
TUESDAY, APRIL 12*

Meet-the-Expert Sessions • 7:00 a.m.–7:45 a.m.

Room 243-245, Convention Center
#ResearchMatters: Tales from a Translational Physician Scientist Tackling Thoracic Tumors
Christine M. Lovly, Nashville, TN

Room 278-282, Convention Center
Base Excision Repair and Cancer
Joann Sweasy, Tucson, AZ

Room 288-290, Convention Center
Decoding Kidney Cancer
James Brugarolas, Dallas, TX

Room 356-357, Convention Center
Glycans Tell Us About Function and Status: Applying this Information to the Detection and Treatment of Cancer
Brian B. Haab, Grand Rapids, MI

Room 260-262, Convention Center
History of Infections and Targets of Successful Immune Defense Inform Designs of Preventive Cancer Vaccines
Olivera J. Finn, Pittsburgh, PA

Room 208-210, Convention Center
Next Generation Pathology: From Histopathology to Artificial Intelligence
Massimo Loda, New York, NY

Room 220-222, Convention Center
The Melanoma Revolution and Lessons Learned from Basic Biology of Skin
David E. Fisher, Boston, MA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room 265-268, Convention Center
**Obesity, Diabetes, and Breast Cancer**
Lucio Miele, New Orleans, LA

Room 217-219, Convention Center
**Understanding and Targeting Aberrant RNA Splicing in Cancer**
Omar Abdel-Wahab, New York, NY

Room 343-345, Convention Center
**Update on Agonist CD40 Antibodies for Cancer Immunotherapy**
Robert H. Vonderheide, Philadelphia, PA

Room 295-296, Convention Center
**Using Genetically Engineered Mouse Models and Patient-Derived Orthotopic Xenografts to Develop New Therapies for Pediatric Brain Tumors**
Martine F. Roussel, Memphis, TN

---

**Plenary Session • 8:00 a.m.–10:00 a.m.**

Hall B-C, Convention Center
**Precision Medicine for Immuno-Oncology and the Promise for the Future**

**Chair:** Carl H. June, Philadelphia, PA

8:00 a.m.  **Introduction.** Carl H. June, Philadelphia, PA

8:10 a.m.  **T cell reactivity in human cancer.** Ton N. Schumacher, Haarlem, The, Netherlands

8:35 a.m.  **Stromal-immune interactions in health, inflammation, and immunotherapy.** Shannon J. Turley, South San Francisco, CA

9:00 a.m.  **Germline and microbiome variants impact immunotherapy efficacy through modulation of myeloid cells.** Thomas F. Gajewski, Chicago, IL

9:25 a.m.  **Tumor intrinsic features of immunotherapeutic response to PD-1 blockade.** Luis A. Diaz, New York, NY

9:50 a.m.  **Wrap-up and opportunities for the future.** Carl H. June, Philadelphia, PA
TUESDAY, APRIL 12

Poster Sessions • 9:00 a.m.–12:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

Halls D-H, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App, and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall. All posters (including in-person posters) are available at AACR.org/eposters22.

Prevention / Early Detection / Interception
Section 1  Premalignant Lesions, Intervention, and Health Disparities
Section 2  Risk Assessment, Biomarkers, Early Detection, and Screening

Population Sciences
Section 3  Biomarkers of Endogenous or Exogenous Exposures, Early Detection, and Biologic Effects

Molecular/Cellular Biology and Genetics
Section 4  Cancer Genomics 4
Section 5  Cell Cycle Control and Cell Cycle Regulators as Therapeutic Targets
Section 6  Metabolic Therapies, Detection, and Technologies
Section 7  Oncogenic Transcription Factors
Section 8  Tumor-associated Metabolic Changes
Section 18  Late-Breaking Research: Molecular/Cellular Biology and Genetics 2

Tumor Biology
Section 9  Cellular and Molecular Processes of Metastasis 1
Section 10  Cellular and Molecular Processes of Metastasis 2 / Tumor Dormancy
Section 11  In Vivo Imaging 1
Section 12  In Vivo Imaging 2
Section 13  Omics Approaches: Disease Classification, Biomarkers of Response, and Outcome Prediction in Pediatric Oncology
Section 14  Organ-specific Tumor Microenvironment 1
Section 15  Organ-specific Tumor Microenvironment 2

Survivorship
Section 20  Advocates Poster Session 2

Experimental and Molecular Therapeutics
Section 21  Cell Cycle, Replication Inhibitors, and Immunotherapy Agents
Section 22  DNA Damage Response and Repair
Section 23  Gastrointestinal Cancer Treatment Resistance
Section 24  Novel Targets and Pathways
Section 25  Signaling Pathway Inhibitors

Endocrinology
Section 27  Molecular, Preclinical, and Clinical Endocrinology

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Bioinformatics / Convergence Science / Systems Biology
Section 28 Application of Bioinformatics to Cancer Biology 1
Section 29 Mathematical Models

Clinical Research Excluding Trials
Section 30 Adoptive Cell Therapy
Section 31 Biomarkers Predictive of Therapeutic Benefit 3
Section 32 Diagnostic Biomarkers
Section 17 Late-Breaking Research: Clinical Research 2

Clinical Trials
Section 33 Phase I Clinical Trials 2
Section 34 Phase I Trials in Progress 1

Immunology
Section 35 Adoptive Cell Therapy 3
Section 36 Adoptive Cell Therapy 4
Section 37 Therapeutic Antibodies 1
Section 38 Therapeutic Antibodies 2

Chemistry
Section 40 Structural and Chemical Biology

Meet and Greet • 9:30 a.m.–10:30 a.m.
NOT ELIGIBLE FOR CME CREDIT
AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center
Meet the Editor-in-Chief of Molecular Cancer Therapeutics:
Beverly A. Teicher, PhD

Beverly A. Teicher, Bethesda, MD
NCI/NIH-Sponsored Session • 10:15 a.m.–11:15 a.m.

NOT ELIGIBLE FOR CME CREDIT

Room 298-299, Convention Center

NCI Opportunities in Funding: Addressing How Obesity Drives Cancer Risk

Moderator: Linda Nebeling, Rockville, MD

10:15 a.m. Introduction and overview of the OCWG. Linda Nebeling, Rockville, MD

10:25 a.m. Mechanisms driving obesity and cancer FOAs. Edward Richard Sauter, Rockville, MD

10:35 a.m. NCI interest in metabolic dysregulation in obesity and cancer. Sharon Ross, Rockville, MD

10:45 a.m. NCI interest in mechanisms of the obesogenic microbiome in cancer. Phillip J. Daschner, Rockville, MD

10:55 a.m. Discussion

Advances in Diagnostics and Therapeutics

10:15 a.m.–11:45 a.m.

Great Hall AD, Convention Center

Next-Generation Costimulatory Receptor Agonists for Cancer Immunotherapy and Combination Therapy

Chair: Christian Klein, Schlieren, Switzerland

10:15 a.m. Introduction. Christian Klein, Schlieren, Switzerland

10:20 a.m. Conditional activation of costimulatory receptors via the DuoBody technology: GEN1046 (PD-L1x4-1Bb) and GEN1042 (CD40x4-1BB). Maria N. Jure-Kunkel, Plainsboro, NJ

10:45 a.m. Tumor-targeted 4-1BB agonists and their combination with T cell bispecific antibodies. Christian Klein, Schlieren, Switzerland

11:10 a.m. Human costimulatory bispecifics antibodies in cancer immunotherapy. Dimitris Skokos, New York, NY

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
La Nouvelle Orleans A-B, Convention Center

**Technologies to Understand Malignant Clonal Behavior at Single Cell Resolution**

**Chair:** Anna C. Obenauf, Vienna, Austria

10:15 a.m. **Introduction.** Anna C. Obenauf, Vienna, Austria

10:20 a.m. **Exploiting novel tools and approaches to understand lung cancer evolution and selection.** Nicholas McGranahan, London, United Kingdom

10:45 a.m. **The power of ONE: Immunology in the age of single cell genomics.** Ido Amit, Rehovot, Israel

11:10 a.m. **Functional lineage tracing approaches to understand tumor evolution in metastasis and therapy resistance.** Anna C. Obenauf, Vienna, Austria

Room 217-219, Convention Center

**Theranostics: The Interception of Detection and Treatment**

**Chair:** Julie Sutcliffe, Sacramento, CA

10:15 a.m. **Introduction.** Julie Sutcliffe, Sacramento, CA

10:20 a.m. **Theranostics: What does it mean? A basic scientist’s perspective.** Julie Sutcliffe, Sacramento, CA

10:40 a.m. **Theranostics: What have we learned and what have we yet to learn? A clinical perspective.** Lisa Bodei, New York, NY

11:00 a.m. **Radiotheranostics and RLTs: An industry perspective.** Thomas Reiner, Basel, Switzerland

---

**CME**

**Advances in Organ Site Research • 10:15 a.m.–11:45 a.m.**

Room 353-355, Convention Center

**Advances in Neuroblastoma Research**

**Chair:** John M. Maris, Philadelphia, PA

10:15 a.m. **Introduction.** John M. Maris, Philadelphia, PA

10:20 a.m. **What we can learn from single neuroblastoma cell transcriptomes.** Sam Behjati, Cambridgeshire, United Kingdom

10:45 a.m. **Title to be announced.** Carol J. Thiele, Bethesda, MD

11:10 a.m. **Immunotherapeutic targeting of lineage restricted intracellular oncoproteins.** John M. Maris, Philadelphia, PA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
TUESDAY, APRIL 12

Room 208-210, Convention Center
Models for Rare Cancers
Chair: Olivier Elemento, New York, NY

10:20 a.m. Towards organoids-driven precision medicine. Olivier Elemento, New York, NY
10:42 a.m. Integration of patient-derived data and models for discovery. Andrew L. Kung, New York, NY
11:04 a.m. Patient-derived sarcoma tumor organoids for drug discovery and precision medicine applications. Alice Soragni, Los Angeles, CA
11:26 a.m. The myogenesis program drives clonal selection and drug resistance in pediatric rhabdomyosarcoma. Anand G. Patel, Memphis, TN

Advances in Prevention Research • 10:15 a.m.–11:45 a.m.

Room 343-345, Convention Center
The Role of Bacterial Infection in Cancer
Chair: Masanori Hatakeyama, Tokyo, Japan

10:15 a.m. Introduction. Masanori Hatakeyama, Tokyo, Japan
10:20 a.m. Induction of BRCAness and genome instability by Helicobacter pylori CagA. Masanori Hatakeyama, Tokyo, Japan
10:45 a.m. Bacterial initiators of stomach and colon cancer. Thomas Meyer, Berlin, Germany
11:10 a.m. Taking a deep dive into the molecular mechanism of bacteria-induced carcinogenesis. Christian Jobin, Gainesville, FL

Major Symposia • 10:15 a.m.–11:45 a.m.

New Orleans Theater C, Convention Center
Challenging Drug Targets
Chair: Philip Jones, Houston, TX

10:15 a.m. Introduction. Philip Jones, Houston, TX
10:20 a.m. Translating frontier oncology targets to outsmart cancer. Matthew Holderfield, Redwood City, CA
10:45 a.m. Therapeutic strategies for reactivation of missense and nonsense mutant p53 in cancer. Klas G. Wiman, Stockholm, Sweden
11:10 a.m. Structure-guided allostery for intractable targets and to overcome resistance in cancer. Frederic Zecri, Basel, Switzerland

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
New Orleans Theater A, Convention Center
Dharma Master Jiantai Symposium in Biomarkers:
Biomarkers of Cancer Evolution: From Bench to Clinical Application
Chair: Priscilla K. Brastianos, Brookline, MA

10:15 a.m. Introduction. Priscilla K. Brastianos, Boston, MA

10:20 a.m. Evolution of central nervous system metastases and therapeutic implications. Priscilla K. Brastianos, Boston, MA

10:45 a.m. Liquid biopsies in lung cancer. Caroline Dive, Manchester, United Kingdom

11:10 a.m. Studying melanoma evolution one cell at the time. Jean-Christophe Marine, Leuven, Belgium

La Nouvelle Orleans C, Convention Center
Immunoprevention and Clinical Trials
Chair: Douglas R. Lowy, Bethesda, MD

10:15 a.m. Introduction. Douglas R. Lowy, Bethesda, MD

10:20 a.m. HPV vaccination: Preventing more disease with fewer doses. Douglas R. Lowy, Bethesda, MD

10:45 a.m. Interception of pancreatic cancer development with oncogene-targeted immunotherapy. Elizabeth M. Jaffee, Baltimore, MD

11:10 a.m. Vaccine development for cancer immune interception in Lynch syndrome. Eduardo Vilar-Sanchez, Houston, TX

New Orleans Theater B, Convention Center
Metabolic and Nutritional Regulation of Cancer and Immunity
Chair: Susan M. Kaech, La Jolla, CA

10:15 a.m. Introduction. Susan M. Kaech, La Jolla, CA

10:20 a.m. The influence of environmental factors on tumor growth. Matthew G. Vander Heiden, Cambridge, MA

10:42 a.m. Double-edged “soil”: Stromal microenvironment in breast cancer development. Mustapha Abubakar, Rockville, MD

11:01 a.m. Dietary lipids and anti-tumor immunity. Lydia Lynch, Boston, MA

11:23 a.m. Co-opting immune cells to support cancer progression through metabolic reprogramming. Susan M. Kaech, La Jolla, CA
Minorities in Cancer Research Scientific Symposium: Opportunities to Leverage Legislation and Policies in Addressing Cancer Disparities

**Cochairs:** Lisa A. Newman, New York, NY; Luis A. Diaz, New York, NY

**Speakers:**

Edith P. Mitchell, Philadelphia, PA

John D. Carpten, Los Angeles, CA

Great Hall BC, Convention Center

**Multiomics Approaches for Novel Oncopathogen Discovery and Related Mechanisms**

**Chair:** Bin Tean Teh, Singapore, Singapore

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 a.m.</td>
<td>Introduction. Bin Tean Teh, Singapore, Singapore</td>
</tr>
<tr>
<td>10:20 a.m.</td>
<td>Title to be announced. Vincent Ferretti, Toronto, ON, Canada</td>
</tr>
<tr>
<td>10:45 a.m.</td>
<td>Long-read sequencing reveals complex patterns of wraparound transcription in polyomaviruses. James A. DeCaprio, Boston, MA</td>
</tr>
<tr>
<td>11:10 a.m.</td>
<td>Identification and characterization of human angiosarcoma subtypes through multi-omic multi-dimensional profiling. Jason Yongsheng Chan, Singapore, Singapore</td>
</tr>
</tbody>
</table>

Myeloid Cell Control of Therapeutic Antitumor Immunity

**Chair:** Miriam Merad, New York, NY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 a.m.</td>
<td>Introduction. Miriam Merad, New York, NY</td>
</tr>
<tr>
<td>10:42 a.m.</td>
<td>A convergence of myeloid cells and T cells controls cancer immunity. Ira Mellman, South San Francisco, CA</td>
</tr>
<tr>
<td>11:04 a.m.</td>
<td>Mapping myeloid cells control of tumor immunity. Miriam Merad, New York, NY</td>
</tr>
<tr>
<td>11:26 a.m.</td>
<td>Next-generation macrophage and T cell activation reporters to define functional immune states in solid tumors. Arja Ray, San Francisco, CA</td>
</tr>
</tbody>
</table>

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room 265-268, Convention Center
**Profiling Molecular Proximity in Cancer Research**

**Chair:** Kate Lawrenson, Los Angeles, CA

10:15 a.m. **Introduction.** Kate Lawrenson, Los Angeles, CA

10:20 a.m. **Title to be announced.** Kate Lawrenson, Los Angeles, CA

10:45 a.m. **Dissecting protein kinase and transcription factor signaling using quantitative interaction proteomics.** Markku Varjosalo, Helsinki, Finland

Additional speaker to be announced.

Room 356-357, Convention Center
**Regulatory Science and Policy Session**

**Supporting Smoking Cessation Among Patients with Cancer Who Use Tobacco Products**

**Chair:** Roy S. Herbst, New Haven, CT

10:25 a.m. Roy S. Herbst, New Haven, CT

10:35 a.m. Stephanie R. Land, Rockville, MD

10:45 a.m. Michael Fiore, Madison, WI
Clinical Trials Plenary Session 4 • 10:15 a.m.–12:15 p.m.

Hall B-C, Convention Center

Combination Immunotherapy Clinical Trials

Chair: Timothy A. Yap, Houston, TX

10:15 a.m. Introduction. Timothy A. Yap, Houston, TX

10:16 a.m. CT013 S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy. Ari M. Vanderwalde, Germantown, TN

10:31 a.m. Discussant. Mario Sznol, New Haven, CT

10:46 a.m. CT014 Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study. Iván Márquez-Rodas, Madrid, Spain

11:01 a.m. Discussant. Stefania Scala, Naples, Italy

11:16 a.m. CT015 Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the 1st line treatment of locally advanced or metastatic gastric/GEJ cancer. Zev Wainberg, Los Angeles, CA

11:31 a.m. Discussant. Ian Chau, London, United Kingdom

11:46 a.m. CT016 MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study. Ben Tran, Melbourne, Australia

12:01 p.m. Discussant. Jason John Luke, Pittsburgh, PA

12:15 p.m. Concluding Remarks. Ignacio Melero, Pamplona, Spain

Meet and Greet • 11:30 a.m.–12:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center

Meet the Editors-in-Chief of Cancer Prevention Research:
Raymond N. DuBois, MD, PhD and Michael N. Pollak, MD

Raymond N. DuBois, Charleston, SC
Michael N. Pollak, Montreal, QC, Canada

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
AWARDS AND LECTURES • 12:00 p.m.–12:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room 220-222, Convention Center
**AACR Getrude B. Elion Cancer Research Award Lecture**

12:00 p.m.  Introduction

12:05 p.m.  Functional and computational approaches to uncover selection advantages of cancer aneuploidy. Alison Marie Taylor, New York, NY

NCI/NIH-Sponsored Session • 12:30 p.m.–1:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room 298-299, Convention Center
**NCI-Cancer Diagnosis Program Initiatives, Funding Opportunities and Resources for Investigators**

Chair: Aniruddha Ganguly, Rockville, MD

Speakers:

**Cancer Diagnosis Program Initiatives, funding opportunities, and resources.** Aniruddha Ganguly, Rockville, MD

**Support for NCI’s new Precision Medicine Trials.** Lyndsay N. Harris, Rockville, MD

**Molecular Characterization Laboratory supporting molecular technologies for drug-target discovery, and development of well-characterized and validated clinical assays.** Mickey Williams, Frederick, MD

**Molecular Characterization Laboratory supporting molecular technologies for drug-target discovery, and development of well-characterized and validated clinical assays.** Chris A. Karlovich, Frederick, MD
TUESDAY, APRIL 12

**Advances in Diagnostics and Therapeutics**

*12:30 p.m.–2:00 p.m.*

**Hall B-C, Convention Center**

**Adoptive Cellular Therapy: Treatment for the Masses**

**Chair:** Cassian Yee, Houston, TX

**12:30 p.m.** Introduction. Cassian Yee, Houston, TX

**12:35 p.m.** T cell therapy: The New Math. Cassian Yee, Houston, TX

**1:00 p.m.** Emerging principles to overcome tumor antigen escape. Michel Sadelain, New York, NY

**1:25 p.m.** Engineering multi-functional CAR-T cells for cancer therapy. Yvonne Y. Chen, Los Angeles, CA

**Great Hall AD, Convention Center**

**New Developments in Immunotherapy:**

**Targeting and Localizing Cytokine Activity**

**Chair:** Darrell J. Irvine, Cambridge, MA

**12:30 p.m.** Introduction. Darrell J. Irvine, Cambridge, MA

**12:35 p.m.** Cis-targeting to PD-1 of an IL-2 variant devoid of CD25 binding: Differentiating stem-like, exhausted precursor cells into better effectors for cancer immunotherapy. Pablo Umana, Schlieren, Switzerland

**1:00 p.m.** Transforming powerful proinflammatory mechanisms into novel therapies for cancer patients. Cynthia Seidel-Dugan, Cambridge, MA

**1:25 p.m.** Localizing cytokine activity to tumors using alum-binding therapeutics. Darrell J. Irvine, Cambridge, MA

**Advances in Organ Site Research • 12:30 p.m.–2:00 p.m.**

**Room 353-355, Convention Center**

**Advances in Bladder Cancer**

**Chair:** Dan Theodorescu, Los Angeles, CA

**12:30 p.m.** Introduction. Dan Theodorescu, Los Angeles, CA

**12:35 p.m.** Pparg controls luminal subtype specification and immune infiltration. Cathy L. Mendelsohn, New York, NE

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
1:00 p.m.  Tumor-centric and liquid biomarkers for guiding treatment decisions. Lars Dyrrskjøt, Aarhus N, Denmark

1:25 p.m.  Discovery and clinical relevance of a novel bladder cancer population. Dan Theodorescu, Los Angeles, CA

Room 243-245, Convention Center

Breast Cancer Genomics in Latin America

Chair: Laura Fejerman, Davis, CA

12:30 p.m.  Introduction. Laura Fejerman, Davis, CA

12:35 p.m.  The Latin America Genomics of Breast Cancer (LAGENO-BC) Consortium: A multinational effort to address the underrepresentation of Latin American diversity in breast cancer genetics. Laura Fejerman, Davis, CA

1:00 p.m.  Analysis of transcriptomic pathways in breast cancer tumors from the Latin America Cancer Research Network-Molecular Profile of Breast Cancer Study (LACRN-MPBCS): A focus on prognosis. Andrea S. Llera, Buenos Aires, Argentina

1:25 p.m.  Genetic heterogeneity in breast cancer risk, molecular pathology, and prognosis: Lessons from the Puerto Rico breast cancer genetics and genomics study. Julie Dutil, Ponce, PR

Room 265-268, Convention Center

Pediatric Cancer Pathogenesis and Therapeutic Advances

Chair: Suzanne J. Baker, Memphis, TN

12:30 p.m.  Introduction. Suzanne J. Baker, Memphis, TN

12:35 p.m.  Cell state in origins and pathogenesis of pediatric high-grade glioma. Suzanne J. Baker, Memphis, TN

1:00 p.m.  Leveraging biological insights to enhance anti-GD2 immunotherapies. Robbie G. Majzner, Palo Alto, CA

1:25 p.m.  Targeting fusion-driven pediatric cancers. Kimberly Stegmaier, Boston, MA
TUESDAY, APRIL 12

Advances in Population Sciences • 12:30 p.m.–2:00 p.m.
Great Hall BC, Convention Center
Where You Live Matters: From Biological to Social Determinants of Cancer Outcomes
Chair: Robert A. Winn, Richmond, VA

12:30 p.m.  Introduction. Robert A. Winn, Richmond, VA
12:35 p.m.  Place and space matter. Robert A. Winn, Richmond, VA
12:57 PM  Geospatial implications for cancer control: How we measure and why it matters. Tracy Ongena, Salt lake City, UT
1:19 PM  The vaginal microbiome may operate differently by race to precipitate the risk of pre-cervical cancer. Katherine Y. Tossas, Richmond, VA
1:38 PM  Structural racism and prostate cancer among African American men: The RESPOND Study. Scarlett L. Gomez, San Francisco, CA

Major Symposia • 12:30 p.m.–2:00 p.m.
Room 343-345, Convention Center
Digital and Computational Histopathology: Taking Cancer Diagnostics to the Cutting Edge
Chair: Anil Vasdev Parwani, Columbus, OH

12:30 p.m.  Introduction. Anil Vasdev Parwani, Columbus, OH
12:35 p.m.  Advancing cancer diagnosis: Impact of digital pathology and computational pathology tools. Anil Vasdev Parwani, Columbus, OH
1:00 p.m.  The application of artificial intelligence in pathology and issues related to deployment, clinical validation, and regulation. Liron Pantanowitz, Ann Arbor, MI
1:25 p.m.  Tissue imaging, diagnostic reports, and molecular data: Multi-modal cancer representation. Hamid Tizhoosh, Rochester, MN

La Nouvelle Orleans C, Convention Center
Extracellular Matrix Remodeling in Cancer
Chair: Valerie M. Weaver, San Francisco, CA

12:30 p.m.  Introduction. Valerie M. Weaver, San Francisco, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
12:35 p.m.  Targeting the reciprocal interplay between inflammation, fibrosis, and pro-tumor immunity. Valerie M. Weaver, San Francisco, CA

12:57 p.m.  Elevated cellular stiffness sensitizes metastatic cells to destruction by mechanosurveillance: The mechanical mode of immune surveillance. Ekrem Emrah Er, Chicago, IL

1:16 p.m.  Mesenchymal lineage heterogeneity as a determinant of matrix composition and tumor progression. Mara H. Sherman, Portland, OR

1:38 p.m.  How can we exploit ECM changes to target tumors? Richard O. Hynes, Cambridge, MA

Room 356-357, Convention Center
Regulatory Science and Policy Session
FDA Oncology Center of Excellence Patient Engagement Initiatives: An Interactive Roundtable Discussion

Moderator: Rea Blakey, Silver Spring, MD
Speakers:
Vishal Bhatnagar, Silver Spring, MD
Yelak Biru, Bentonville, AR
Rea Blakey, Silver Spring, MD
Marcia R. Cruz-Correa, San Juan, PR
Shonte’ C. Drakeford, Washington, DC
Donna R. Rivera, Rockville, MD
Julie Schneider, Silver Spring, MD
Karen Winkfield, Nashville, TN
Additional speakers to be announced.

La Nouvelle Orleans A-B, Convention Center
Germline Mutations as Drug Targets
Chair: Timothy A. Yap, Houston, TX

12:30 p.m.  Introduction. Timothy A. Yap, Houston, TX

12:35 p.m.  Exploiting hypoxia, angiogenesis, and metabolism for the development of novel therapeutics in hereditary kidney cancers. W. Kimryn Rathmell, Nashville, TN

1:00 p.m.  Identifying novel targets for therapy and prevention in Cowden syndrome. Joanne Ngeow, Singapore, Singapore

1:25 p.m.  Therapeutic implications of germline testing in patients with advanced cancers. David M. Thomas, Darlinghurst, Australia
TUESDAY, APRIL 12

New Orleans Theater B, Convention Center

**Liquid Biopsy: From Discovery to Clinical Application**

**Chair:** Klaus Pantel, Hamburg, Germany

12:30 p.m.  **Introduction.** Klaus Pantel, Hamburg, Germany

12:35 p.m.  **Opportunities and challenges of liquid biopsy research.** Klaus Pantel, Hamburg, Germany

1:00 p.m.  **Biology and clinical relevance of circulating tumor cells for precision medicine.** Catherine Alix-Panabieres, Montpellier, France

1:25 p.m.  **Clinical relevance of cell-free DNA fragmentomes for cancer detection and monitoring.** Victor E. Velculescu, Baltimore, MD

New Orleans Theater A, Convention Center

**Radiation Sequencing and Immunotherapy**

**Chair:** Samir N. Khleif, Washington, DC

12:30 p.m.  **Introduction.** Samir N. Khleif, Washington, DC

12:35 p.m.  **T cell priming, a crucial strategy for reversing of immunotherapy.** Samir N. Khleif, Washington, DC

1:00 p.m.  **Adapting clinical radiation therapy to immune checkpoint blockade.** Silvia C. Formenti, New York, NY

1:25 p.m.  **Radiation-enhanced antigen presentation and immune priming.** Chandan Guha, Bronx, NY

**Meet and Greet • 1:30 p.m.–2:30 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 2101, Exhibit Halls D-H, Convention Center

**Meet the Editors-in-Chief of *Cancer Research Communications*:**

Elaine R. Mardis, PhD and Lillian L. Siu, MD

Elaine R. Mardis, Columbus, OH

Lillian L. Siu, Toronto, ON, Canada

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Poster Sessions • 1:30 p.m.–5:00 p.m.

Not Eligible for CME Credit

Halls D-H, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App, and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall. All posters (including in-person posters) are available at AACR.org/eposters22.

**Molecular/Cellular Biology and Genetics**
Section 2  Cancer Genomics 5  
Section 3  Chromatin Modifiers: From Mechanism to Therapeutic Opportunity  
Section 4  GTPase and Ubiquitin Signaling  
Section 5  Non-apoptotic Cell Death / Autophagy  
Section 6  Nutrients, Diet, and Metabolic Requirements of Cancer

**Tumor Biology**
Section 8  Microbiome  
Section 9  Organoid-Based Models  
Section 10  Patient-Derived Xenografts  
Section 11  Secreted Soluble Factors and Exosomes in the Microenvironment  
Section 12  Stem Cells and Regulatory Pathways in Cancer  
Section 13  Stromal Tumor Interactions  
Section 14  Tumor Angiogenesis

**Population Sciences / Prevention, Early Detection, and Interception**
Section 20  Survivorship and Prognosis Biomarkers  
Section 17  Late-Breaking Research: Population Sciences / Prevention, Early Detection, and Interception

**Experimental and Molecular Therapeutics**
Section 22  Drug Resistance and Reversal of Resistance  
Section 23  Epigenetic Targets  
Section 24  Gene and Vector-Based Therapy  
Section 25  Preclinical Radiotherapeutics  
Section 26  Tyrosine Kinase and Phosphatase Inhibitors
TUESDAY, APRIL 12

Bioinformatics / Convergence Science / Systems Biology
Section 27  Application of Bioinformatics to Cancer Biology 2
Section 16  Late-Breaking Research: Bioinformatics, Convergence Science, and Systems Biology

Clinical Research Excluding Trials
Section 30  Cell-Free DNA 1
Section 31  Cell-Free DNA 2
Section 32  Combination Immunotherapies / Therapeutic Antibodies
Section 33  Translational and Clinical Science
Section 34  Translational Research: Molecular and Clinical

Clinical Trials
Section 35  Phase III Clinical Trials
Section 36  Phase III Trials in Progress

Immunology
Section 37  Immunomodulatory Agents and Interventions 2
Section 38  Microbiome and Cancer
Section 39  Modifiers of the Tumor Microenvironment
Section 40  Vaccines: Oncolytic and Prophylactic

NCI/NIH-Sponsored Session • 2:30 p.m.–3:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room 298-299, Convention Center
NCI Resource: The Frederick National Laboratory for Cancer Research and the NCI Program for Natural Product Discovery
Cochairs: Vladimir M. Popov, Frederick, MD; Barry R. O’Keefe, Bethesda, MD
2:30 p.m.  The Frederick National Laboratory for Cancer Research. Vladimir M. Popov, Frederick, MD
2:55 p.m.  The NCI Program for Natural Product Discovery. Barry R. O’Keefe, Bethesda, MD
3:20 p.m.  Discussion

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Major Symposium • 2:30 p.m.–4:00 p.m.
Room 356-357, Convention Center
Regulatory Science and Policy Session
Defining Clinical Benefit: Accelerated Approval in Precision Oncology
Moderator: Gautam Mehta, Silver Spring, MD
2:30 p.m.  Introduction. Gautam Mehta, Silver Spring, MD
2:40 p.m.  Designing clinical trials to demonstrate clinical benefit in precision oncology. Vivek Subbiah, Houston, TX
2:50 p.m.  Patient considerations in defining clinical benefit. Sara J. Whitlock, Dayton, OH
3:00 p.m.  Review of FDA Accelerated Approvals of selpercatinib and pralsetinib. Diana Bradford, Silver Spring, MD
3:10 p.m.  Confirmatory trial considerations after Accelerated Approval in precision oncology. Lori J. Wirth, Boston, MA

Special Session • 2:30 p.m.–4:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room 293-294, Convention Center
Fostering Entrepreneurship Part 2: Venture Capital and Philanthropy for Oncology Drug Development
Moderators: Christiana Goh Bardon, Boston, MA; Robert I. Tepper, Boston, MA
Panelists:
Arie S. Belldegrun, Los Angeles, CA
Christina Coughlin, Los Angeles, CA
David R. Parkinson, San Francisco, CA
Antoni Ribas, Los Angeles, CA
Clinical Trials Minisymposium 3 • 2:30 p.m.–4:30 p.m.

La Nouvelle Orleans A-B, Convention Center

Immunotherapy Combination Strategies in Clinical Trials

Cochairs: Thomas Frank Gajewski, Chicago, IL; Maria J. De Miguel Luken, Madrid, Spain

2:30 p.m. Introduction. Thomas Frank Gajewski, Chicago, IL

2:30 p.m. CT035 Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer. Olivier Rixe, Santa Fe, NM

2:30 p.m. CT036 CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). Roger Li, Tampa, FL

2:30 p.m. CT037 Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced nonsmall cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial. Daniel S. Tan, Singapore, Singapore

2:30 p.m. CT038 Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial. Ying Cheng, Changchun, China

2:30 p.m. CT039 Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma. Salah-Eddine Bentebibel, Houston, TX

2:30 p.m. CT040 SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial. Stephane Champiat, Villejuif, France

2:30 p.m. CT041 Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1). Michael Millward, Perth, Australia

2:30 p.m. Concluding Remarks. Maria J. De Miguel Luken, Madrid, Spain

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Late-Breaking Minisymposium • 2:30 p.m.–4:30 p.m.

Room 217-219, Convention Center

Late-Breaking Research

Chair: Michael A. Caligiuri, Duarte, CA

2:30 p.m.  Introduction. Michael A. Caligiuri, Duarte, CA

2:35 p.m.  LB173  ACR president’s initiative - 2020 by 2020: Democratizing precision cancer medicine and advancing health equity in the black belt. Latrisha L. Horne, Atlanta, GA

2:50 p.m.  LB174  Inducing complete and long-lasting tumor eradication at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation. Isabella Attinger-Toller, Zürich, Switzerland

3:05 p.m.  LB175  MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44 and sensitizes to temozolomide. Tae Jin Lee, Houston, TX

3:20 p.m.  LB176  Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network identifies microenvironment features as drivers of metastasis. Susana Garcia Recio, Chapel Hill, NC

3:35 p.m.  LB177  Widespread hypertranscription in aggressive human cancer. Matthew Zatzman, Toronto, ON, Canada

3:50 p.m.  LB178  HK010, a novel anti-PD-L1×CD137 bispecific antibody, shows potent anti-tumor activity and has a favorable safety profile. Zhen Bian, Atlanta, GA

4:05 p.m.  LB179  Patient-derived, vaccine-elicited, anti-MUC1 antibodies directly target tumor cells for elimination via multiple immune mechanisms. Michelle L. McKeague, Pittsburgh, PA
Minisymposia • 2:30 p.m.–4:30 p.m.

New Orleans Theater B, Convention Center
Clinical Research Excluding Trials
Resistance Mechanisms and New Advances in Immunotherapeutics

Chair: Avery D. Posey, Philadelphia, PA

2:30 p.m. **Introduction.** Avery D. Posey, Philadelphia, PA

2:35 p.m. 3576 Identification of T-cell receptors targeting RAS hotspot mutations using TIL IVS in human cancers for use in cell-based immunotherapy. Noam Levin, Bethesda, MD

2:50 p.m. 3575 Differential dynamics of response at single cell resolution between axi-cel and tisa-cel CAR-T therapy in refractory B-cell lymphomas. Nicholas J. Haradhvala, Cambridge, MA

3:05 p.m. 3577 First-in-human phase I study of intraperitoneally administered interferon-activated autologous monocytes in platinum-resistant ovarian cancer. Christopher B. Cole, Bethesda, MD

3:20 p.m. 3578 Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back. Amy R. Rappaport, Emeryville, CA

3:35 p.m. 3579 T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade. Yuki Muroyama, Philadelphia, PA

3:50 p.m. 3580 Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer. Arvind Ravi, Cambridge, MA

4:05 p.m. 3581 Multi-omic analysis identifies mechanisms of resistance to CD19 CAR T-cell therapy in children with acute lymphoblastic leukemia. Katherine E. Masih, Bethesda, MD

4:20 p.m. **Closing Remarks.** Avery D. Posey, Philadelphia, PA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
New Orleans Theater C, Convention Center

**COVID-19 and Cancer**

**Chair:** Sanjay Goel, Bronx, NY

2:30 p.m. **Introduction.** Sanjay Goel, Bronx, NY

2:35 p.m. **3582** Single-cell RNA-sequencing for immune profiling of SARS-CoV2 vaccine response in healthy individuals and patients with precursor plasma cell malignancies. Romanos Sklavenitis-Pistofidis, Boston, MA

2:50 p.m. **3583** Identifying and testing cancer-derived synthetic-lethal anti-SARS-CoV-2 targets. Lipika R. Pal, Bethesda, MD

3:05 p.m. **3584** COVID-19 vaccination primary and secondary hesitancy among veterans with cancer in the Arkansas-Louisiana-Texas Region. Philip A. Haddad, Shreveport, LA

3:20 p.m. **3585** Disparities in cancer treatment delays or discontinuation among cancer patients diagnosed with SARS-CoV-2 infection: An analysis of the U.S. ASCO COVID-19 and cancer registry. Jessica Yasmine Islam, Tampa, FL

3:35 p.m. **3586** Immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CART cell therapy. Thierry Iraguha, Baltimore, MD

3:50 p.m. **3587** Racial disparity in COVID-19 severity after adjusting for chronic illnesses and sociodemographic factors. Xiao-Cheng Wu, New Orleans, LA

4:05 p.m. **CT258** Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency. Claudia Tandler, Tübingen, Germany

4:20 p.m. **CT259** Comprehensive humoral and cellular immune assessments to SARS-CoV-2 (wild type, delta and omicron) following two- and three-dose vaccination schedule in a large adult cancer population: SerOzNET study: placeholder abstract. Elizabeth Ahern, Clayton, Australia

4:35 p.m. **Closing Remarks.** Sanjay Goel, Bronx, NY
TUESDAY, APRIL 12

La Nouvelle Orleans C, Convention Center
Experimental and Molecular Therapeutics
Promising New Therapies

Chair: Victoria M. Richon, Weston, MA

2:30 p.m. Introduction. Victoria M. Richon, Weston, MA

2:35 p.m. 3588 Discovery of potent and selective CSNK1A1 inhibitors for solid tumor therapy. Steven M. Corsello, Cambridge, MA

2:50 p.m. 3590 ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells. David I. Bellovin, Menlo Park, CA

3:05 p.m. 3591 First in class drug ZB131 shows efficacy in cholangiocarcinoma models. Samantha M. Perez, Charlottesville, VA

3:20 p.m. 3592 Targeting SWI/SNF ATPases in enhancer-addicted human cancers. Abhijit Parolia, Ann Arbor, MI

3:35 p.m. 3593 OQL051, a gut-restricted CDK4/6 inhibitor has prophylactic potency for chemotherapy-induced diarrhea. Robert Claude Tyler, Seattle, WA

3:50 p.m. 3594 Exportin 1 inhibition as a therapeutic strategy for small cell lung cancer. Alvaro Quintanal-Villalonga, New York, NY

4:05 p.m. Closing Remarks. Victoria M. Richon, Weston, MA

Room 353-355, Convention Center
Experimental and Molecular Therapeutics
Targeting the RAS Oncogene

Cochairs: Manuel Hidalgo, New York, NY; Kathleen N. Moore, Oklahoma City, OK

2:30 p.m. Introduction. Manuel Hidalgo, New York, NY

2:35 p.m. 3597 Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor. Mallika Singh, Redwood City, CA

2:50 p.m. 3595 RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers. Robert J. Nichols, Redwood City, CA

3:05 p.m. 3596 RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models. John E. Knox, Redwood City, CA

3:20 p.m. 3598 A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13C and drives tumor regressions in preclinical models. Christopher J. Schulze, Redwood City, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:35 p.m.  3599  Helical stapled peptides derived from DIRAS3 block KRAS dimerization and downstream MEK/ERK signaling in pancreatic and ovarian carcinomas. Joshua P. Gray, Houston, TX

3:50 p.m.  3600  DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models. Martin McMahon, Salt Lake City, UT

4:05 p.m.  3601  Discovery of novel dual-acting KRASG12C inhibitors that target both the active and inactive forms of the protein. Kevin R. Webster, South San Francisco, CA

4:20 p.m.  Closing Remarks. Kathleen N. Moore, Oklahoma City, OK

Great Hall AD, Convention Center
Immunology
Adoptive Cell Therapy

Co-chairs: Cassian Yee, Houston, TX; Kristin G. Anderson, Seattle, WA

2:30 p.m.  Introduction. Cassian Yee, Houston, TX

2:35 p.m.  3602  Mechanisms of CAR T cell dysfunction and identification of transcription factors that drive the exhaustion phenotype. M. Angela Aznar, Philadelphia, PA

2:50 p.m.  3603  Reverse fate mapping of CD19-targeted CAR T cells in patients with large B-cell lymphoma. Zinaida Good, Stanford, CA

3:05 p.m.  3604  PSC-derived T cells as a novel source of tumor antigen-specific T cell receptors. Chloe S. Wang, Los Angeles, CA

3:20 p.m.  3605  Human chimeric orthogonal IL9 receptor signaling promotes stemness and polyfunctionality for adoptive T cell therapy of cancer. Anusha Kalbasi, Los Angeles, CA

3:35 p.m.  3606  Lenalidomide switch control of CAR T-cell phenotype and function via degradable membrane-bound IL-7. Michael C. Kann, Boston, MA

3:50 p.m.  3607  A novel adjunctive LAT-activating CAR T (ALA-CART) cell platform demonstrates enhanced antigen sensitivity and eradication of antigen-low leukemia. Catherine Pham-Danis, Aurora, CO

4:05 p.m.  3608  Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer. Kristin G. Anderson, Seattle, WA

4:20 p.m.  Closing Remarks. Kristin G. Anderson, Seattle, WA
New Orleans Theater A, Convention Center
**Immunology**

**Novel Cellular Mechanisms for Immune Evasion in Cancer**

**Chair:** Tonya J. Webb, Baltimore, MD

2:30 p.m.  **Introduction.**  Tonya J. Webb, Baltimore, MD

2:35 p.m.  **3611**  Determining the regulation and role of mreg DC in tumor immunity.  Raphael Mattiuz, New York, NY

2:50 p.m.  **3612**  Elucidating and targeting master regulators of tumor infiltrating regulatory T cells.  Casey R. Ager, New York, NY

3:05 p.m.  **3613**  CD28 signaling controls maintenance and differentiation of PD1+CD8 T cells during chronic antigen stimulation.  Etienne Humblin, New York, NY

3:20 p.m.  **3614**  Macrophages are metabolically heterogeneous in the tumor microenvironment.  Jo Van Ginderachter, Brussels, Belgium

3:35 p.m.  **3615**  TREM2+ macrophages mediate immunosuppression in tumors.  Martina Molgora, St. Louis, MO

3:50 p.m.  **3609**  Defining extrinsic and intrinsic mechanisms of immune evasion in TRACERx using imaging mass cytometry.  Katey Enfield, London, United Kingdom

4:05 p.m.  **3610**  In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.  Juan Dubrot, Cambridge, MA

4:20 p.m.  **Closing Remarks.**  Tonya J. Webb, Baltimore, MD

Room 220-222, Convention Center

**Molecular/Cellular Biology and Genetics**

**Cancer Epigenetics: From Nucleotides to 3D Genome Structure**

**Cochairs:** Paula M. Vertino, Atlanta, GA; Johnathan R. Whetstine, Ambler, PA

2:30 p.m.  **Introduction.**  Johnathan R. Whetstine, Ambler, PA

2:35 p.m.  **3616**  Clonal evolution of epigenetic states during early steps of oncogene-driven tumor initiation.  Nibedita Patel, Baltimore, MD

2:50 p.m.  **3617**  METTL16 drives leukemogenesis and maintains leukemia stem cell self-renewal via reprogramming BCAA metabolism.  Li Han, Monrovia, CA

3:05 p.m.  **3618**  Loss of SETD2 sensitizes kidney cancer cells to DNA methylation inhibitors by inducing viral mimicry and RNA mis-splicing.  Hong-Tao Li, Los Angeles, CA

3:20 p.m.  **3619**  Vitamin D receptor function in African American prostate cancer is disrupted by reduced BAZ1A/SMARCA5.  Shahid Hussain, Columbus, OH

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
3:35 p.m. 3620 Investigating the role of altered replication timing during tumor evolution in lung and breast cancer. Michelle Dietzen, London, United Kingdom

3:50 p.m. 3621 3D spatial sampling and integrated omics reveal sources and patterning of intratumoral heterogeneity in glioblastoma. Radhika Mathur, San Francisco, CA

4:05 p.m. 3622 DNA damage drives DNA methylation and 3D chromatin organization alterations in glioblastoma. Aram S. Modrek, New York, NY

4:20 p.m. Closing Remarks. Paula Vertino, Rochester, NY

Room 260-262, Convention Center
Molecular/Cellular Biology and Genetics
Cancer Genomics and Therapeutic Vulnerabilities

Chair: Michael F. Berger, New York, NY

2:30 p.m. Introduction. Michael F. Berger, New York, NY

2:35 p.m. 3623 Targetable cofactor landscape of transcription factors in human cancers. Venu Thatikonda, Vienna, Austria

2:50 p.m. 3624 Non-canonical proteins are cancer cell vulnerabilities in diverse malignancies. John R. Prensner, Cambridge, MA

3:05 p.m. 3625 Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing. Cameron Herberts, Vancouver, British Columbia, Canada

3:20 p.m. 3626 Genomic evolutionary patterns in matched pre-invasive and invasive lung disease in TRACERx. Clare Puttick, London, United Kingdom

3:35 p.m. 3627 The genomic landscape of breast cancers from CHEK2 c.1100delC mutation carriers. Antoinette Hollestelle, Rotterdam, Netherlands

3:50 p.m. 3628 Comprehensive identification of lineage associated cancer genes in 122 histologies. Chaitanya Bandlamudi, New York, NY

4:05 p.m. 3629 Chromosome arm aneuploidies as genetic vulnerabilities of triple-negative breast cancer. Rohan Dandage, Montréal, QC, Canada

4:20 p.m. Closing Remarks. Michael F. Berger, New York, NY
Room 295-296, Convention Center

**Population Sciences**

**Cancer Health Disparities**

**Cochairs:** Jennifer J. Hu, Miami, FL; L Joseph Su, Little Rock, AR

2:30 p.m.  **Introduction.** Jennifer J. Hu, Miami, FL

2:35 p.m.  **3630** Impact of socioeconomic status on the risk of contralateral breast cancer among Asian/Pacific Islander subgroups. Hsiao-Ching Huang, Chicago, IL

2:50 p.m.  **3631** Transcriptome-wide association study identifies novel genes associated with breast cancer susceptibility in Latinas. Pooja Middha Kapoor, San Francisco, CA

3:05 p.m.  **3632** Differential DNA methylation in the benign and cancerous prostate tissue of African American and European American men. Meytal B. Chernoff, Chicago, IL

3:20 p.m.  **3633** Disparities in relapse among a large multi-ethnic population of children diagnosed with acute lymphoblastic leukemia (ALL): A report from the Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. Pagna Sok, Houston, TX

3:35 p.m.  **3634** Integrative analysis of the contribution of genomic and clinical factors to worse clinical outcomes in non-Hispanic Black patients with colorectal cancer. Francisco Sanchez-Vega, New York, NY

3:50 p.m.  **3635** A randomized trial to examine the effectiveness of an LGBT cultural sensitivity training for oncologists: The COLORS trial. Matthew B. Schabath, Tampa, FL

4:05 p.m.  **3636** Ethnic disparities in methotrexate neurotoxicity during pediatric acute lymphoblastic leukemia therapy: A report from the Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. Austin L. Brown, Houston, TX

4:20 p.m.  **Closing Remarks.** L. Joseph Su, Little Rock, AR

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Room 288-290, Convention Center

Tumor Biology

Age and the Tumor Microenvironment

Cochairs: Sheila A. Stewart, St. Louis, MO; Jing Yang, La Jolla, CA

2:30 p.m. **Introduction.** Sheila A. Stewart, St. Louis, MO

2:35 p.m. **3637** Age-dependent loss of HAPLN1 erodes vascular integrity via upregulation of endothelial ICAM1 in melanoma. Gloria E. Marino, Baltimore, MD

2:50 p.m. **3638** Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer. Daniel J. Zabransky, Baltimore, MD

3:05 p.m. **3639** Senescent stromal cells drive breast cancer tumorigenesis. Jiayu (Jennifer) Ye, St. Louis, MO

3:20 p.m. **3640** Adipocyte age dependent metabolic programming dictates melanoma metastatic burden and tropism. Shilpa Gurung, Manchester, United Kingdom

3:35 p.m. **3641** Age-related changes in microenvironmental collagen affect ovarian cancer metastasis. Elizabeth Harper, South Bend, IN

3:50 p.m. **3642** The aged lung promotes reactivation from metastatic melanoma dormancy. Mitchell Fane, Baltimore, MD

4:05 p.m. **3643** The role of HBP1 in controlling breast cancer dormancy reawakening. Irwin H. Gelman, Buffalo, NY

4:20 p.m. **Closing Remarks.** Jing Yang, La Jolla, CA
Room 278-282, Convention Center

Tumor Biology

Stromal-Epithelial Interactions and PDAC Progression

Cochairs: Edna Cukierman, Philadelphia, PA; Kenneth P. Olive, New York, NY

2:30 p.m.  Introduction. Edna Cukierman, Philadelphia, PA

2:35 p.m.  3644 Schwann cells reshape tumor cells and cancer associated fibroblasts in pancreatic ductal adenocarcinoma microenvironment. Meilin Xue, Shanghai, China

2:50 p.m.  3645 The splanchnic mesenchyme is the main tissue origin of fibroblasts in the pancreas during homeostasis and tumorigenesis. Lu Han, Charleston, SC

3:05 p.m.  3646 Distinct functions of pancreatic stellate cells in PDAC stromal evolution. M. Kathrina Casapao Onate, Portland, OR

3:20 p.m.  3647 Oncogenic Kras drives cancer-associated fibroblast heterogeneity and substate changes in pancreatic cancer. Jennifer S. Thalappillil, Cold Spring Harbor, NY

3:35 p.m.  3648 Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1. Marie C. Hasselluhn, New York, NY

3:50 p.m.  3649 Stromal netrinG1-ligand (NGL1) constitutes a new modulator of pancreatic cancer immunosuppression. Débora B. Vendramini-Costa, Philadelphia, PA

4:05 p.m.  3650 Trace’n’Seq: Assessing neuronal infiltration and its impact in pancreatic ductal carcinoma. Vera Thiel, Heidelberg, Germany

4:20 p.m.  Closing Remarks. Kenneth P. Olive, New York, NY

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
NCI/NIH-Sponsored Session • 4:00 p.m.–5:00 p.m.
NOT ELIGIBLE FOR CME CREDITS

Room 298-299, Convention Center
NCI’s Cloud Resources: Analyzing Cancer Data in the Cloud

Moderator: Anthony Kerlavage, Rockville, MD

4:00 p.m.  Introduction. Anthony Kerlavage, Rockville, MD
4:02 p.m.  NCI’s cloud resource overview. Tanja M. Davidsen, Bethesda, MD
4:12 p.m.  ISB Cancer Gateway in the Cloud. David Pot, Fairfax, VA
4:24 p.m.  SEVEN BRIDGES’ Cancer Genomics Cloud. Brandi N. Davis-Dusenbery, Cambridge, MA
4:36 p.m.  Broad’s Firecloud. Alex Baumann, Cambridge, MA
4:48 p.m.  Discussion

CME Forums • 5:00 p.m.–6:30 p.m.

Room 265-268, Convention Center
Addressing Disparities in Cervical Cancer: A Tale of Two Strategies

Chair: Electra D. Paskett, Columbus, OH

5:00 p.m.  Introduction. Electra D. Paskett, Columbus, OH
5:10 p.m.  Persistent cervical cancer disparity among vulnerable women in high resource settings. Erin N. Kobetz, Miami, FL
5:25 p.m.  Challenges and strategies for improving cervical cancer screening and prevention in LMICs. Ellen Baker, Houston, TX
5:40 p.m.  Panel Discussion
La Nouvelle Orleans A-B, Convention Center

**Breaking Down Silos: If We Did It During the COVID Pandemic, Why Not for Cancer?**

**Chair:** Antoni Ribas, Los Angeles, CA

**Panelists:**
- James H. Doroshow, Bethesda, MD
- Lola A. Fashoyin-Aje, Silver Spring, MD
- Susan M. Galbraith, Cambridge, United Kingdom
- Rebecca Pentz, Atlanta, GA
- Solange Peters, Lausanne, Switzerland

New Orleans Theater B, Convention Center

**Insights into Choosing the Right Immune Oncology Drug Combinations for Patients**

**Chair:** Elizabeth M. Jaffee, Baltimore, MD

5:00 p.m. **Introduction.** Elizabeth M. Jaffee, Baltimore, MD

5:10 p.m. **Choosing combinations: Preclinical vs clinical decision drivers.** Charles G. Drake, Raritan, NJ

5:25 p.m. **Biomarkers to identify rational combinations.** Lisa H. Butterfield, San Francisco, CA

5:40 p.m. **Panel Discussion**

Great Hall BC, Convention Center

**Oligometastatic Disease**

**Chair:** Ralph R. Weichselbaum, Chicago, IL

5:00 p.m. **Introduction.** Ralph R. Weichselbaum, Chicago, IL

5:10 p.m. **Oligometastases clinical trials: Where are we in 2022?** Steven J. Chmura, Chicago, IL

5:25 p.m. **Understanding oligometastatic prostate cancer through biomarker-driven research: Paired basic-clinical interrogation.** Phuoc T. Tran, Baltimore, MD

5:40 p.m. **Beyond oligometastasis: Leveraging a biology-driven approach in clinical trial design, patient selection, and data interpretation for patients with metastatic cancer.** C Jillian Tsai, New York, NY

5:55 p.m. **Panel Discussion**

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Room 243-245, Convention Center

**Putting Precision Oncology into Clinical Practice for Pediatric Cancer Patients**

**Chair:** Katherine A. Janeway, Boston, MA

5:00 p.m. **Introduction.** Katherine A. Janeway, Boston, MA

5:15 p.m. **MAPPYACTS: European prospective trial for patients with recurrent malignancies - Main results and next steps.** Pablo Berlanga, Villejuif, France

5:35 p.m. **Five years of Pediatric MATCH: What have we learned (and what's next?).** Donald W. Parsons, Houston, TX

5:55 p.m. **Panel Discussion**

New Orleans Theater A, Convention Center

**What Is the Causal Link between Race and Early Onset of Colon Cancer?**

**Chair:** John M. Carethers, Ann Arbor, MI

5:00 p.m. **Introduction.** Kevin L. Gardner, New York, NY

5:10 p.m. **Changing epidemiology of CRC: Genetics, geography, and other sociodemographic risk factors.** Elena Stoffel, Ann Arbor, MI

5:25 p.m. **Biological findings and potential triggers of disparities in early onset colorectal cancer.** John M. Carethers, Ann Arbor, MI

5:40 p.m. **The prevention of early and late onset colon cancer in African Americans: Lessons from Africa.** Stephen J. O’Keefe, Pittsburgh, PA

5:55 p.m. **Panel Discussion**
TUESDAY, APRIL 12

Special Session • 5:00 p.m.–6:30 p.m.

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.

Room 293-294, Convention Center
Fostering Entrepreneurship Part 3: Navigating the Regulatory Approval Process

Moderators: Briggs W. Morrison, Waltham, MA; Jeff Summers, Silver Spring, MD

Panelists:
Julian Adams, Cambridge, MA
Christina Coughlin, Los Angeles, CA
Elaine R. Mardis, Columbus, OH
Dirk Nagorsen, Thousand Oaks, CA

Professional Advancement Session • 5:30 p.m.–7:00 p.m.

Carondelet Room, New Orleans Marriott
Building an Effective Mentorship Team: Essential Strategies at Every Stage in Your Career

Chair: Beverly D. Lyn-Cook, Little Rock, AR
Speakers to be announced.

Town Meetings • 6:30 p.m. - 8:30 p.m.

Grand Ballroom C, Hilton New Orleans Riverside
Population Sciences Working Group (PSWG) Town Hall Meeting and Networking Reception

Cochairs: Andrew T. Chan, Boston, MA; Lorelei A. Mucci, Boston, MA

Grand Ballroom D, Hilton New Orleans Riverside
Radiation Science and Medicine Working Group (RSM) Town Hall Meeting and Networking Reception

Cochairs: Silvia C. Formenti, New York, NY; Mary Helen Barcellos-Hoff, San Francisco, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
**WEDNESDAY, APRIL 13**

**Meet-the-Expert Sessions • 7:00 a.m.–7:45 a.m.**

Room 260-262, Convention Center

**A Multilevel Outreach Framework to Increase Representation of African Americans and Latinx Populations in Genomic Research**

Brian M. Rivers, Atlanta, GA

Room 217-219, Convention Center

**Cancer Metabolism: Diet and Therapeutics**

Jason W. Locasale, Durham, NC

Room 208-210, Convention Center

**Circulating Tumor DNA: Concepts, Challenges, and Future Opportunities**

Sarah-Jane Dawson, Melbourne, Australia

Room 293-294, Convention Center

**Endometrial Cancer: Obesity and Disparities**

Melinda S. Yates, Houston, TX

Room 295-296, Convention Center

**Luminal B Breast Cancer Genomics in Hispanic/Latinas: A Window to Tumor Size and Immune Infiltration**

Jovanny Zabaleta, New Orleans, LA

Room 353-355, Convention Center

**NGS Profiling**

Andy Futreal, Houston, TX

Room 220-222, Convention Center

**Seeing Is Believing: Effective Data Visualization**

J. Jack Lee, Houston, TX

Room 278-282, Convention Center

**The KEAP1-NRF2 System in Cancer Biology and Medicine**

Masayuki Yamamoto, Sendai, Japan

**Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.**
**Plenary Session • 8:00 a.m.–10:00 a.m.**

Hall B-C, Convention Center  
**Tumor Evolution and Therapeutic Resistance**

**Cochairs:** Anna D. Barker, Los Angeles, CA; Anna D. Barker, Los Angeles, CA

8:05 a.m.  **Somatic mutations in normal tissues.** Peter J. Campbell, Cambridge, United Kingdom

8:27 a.m.  **Decoding breast cancer with single cell genomics.** Nicholas E. Navin, Houston, TX

8:49 a.m.  **Novel insights into pancreatic cancer genetics and evolution.** Christine A. Iacobuzio-Donahue, New York, NY

9:11 a.m.  **Deregulated hematopoietic stem cell behavior in myeloid malignancies.** Emmanuelle Passegué, New York, NY

9:33 a.m.  **Tracing the origins of the metastatic subclone in lung cancer.** Charles Swanton, London, United Kingdom

9:55 a.m.  **Wrap-up and opportunities for the future.** Anna D. Barker, Los Angeles, CA

**Poster Sessions • 9:00 a.m. –12:30 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**

Halls D-H, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App, and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall. All posters (including in-person posters) are available at AACR.org/eposters22.

**Prevention / Early Detection / Interception**

Section 1  Obesity, Behavioral Science, and Quality of Life

**Population Sciences**

Section 3  Cancer Health Disparities

**Molecular/Cellular Biology and Genetics**

Section 5  Apoptosis
Section 6  Chromatin Modifiers: Mutations and Novel Therapeutics
Section 7  DNA Modification: Mechanism to Biomarkers to Treatment
Section 8  Epigenomics to Molecular Markers
Section 9  Mitochondrial Metabolism in Cancer

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
**Tumor Biology**
Section 11  Clonal Evolution
Section 12  Gene Expression and the Microenvironment
Section 13  Innervation, ECM, and Cell Surface Receptors
Section 14  Models and Technical Approaches to Analyze and Examine the Tumor Microenvironment
Section 15  Therapeutic Targets and Drug Resistance in Pediatric Cancers

**Chemistry**
Section 21  Proteomics, Signaling Networks, and Biomarker Discovery

**Experimental and Molecular Therapeutics**
Section 22  Emerging New Anticancer Agents
Section 23  Hematological and Pediatric Malignancy and Sarcoma Treatment Resistance
Section 24  Identification of Molecular Targets
Section 25  Molecular Classification of Tumors
Section 26  Molecular Pharmacology
Section 27  New Chemotherapy Agents
Section 16  Late-Breaking Research: Experimental and Molecular Therapeutics 2

**Bioinformatics / Convergence Science / Systems Biology**
Section 28  Integrative Single-Cell Analysis

**Clinical Research Excluding Trials**
Section 31  Precision Oncology / Surgical Oncology
Section 32  Real-world Data (RWD) and Real-world Evidence (RWE) / Outcomes Research
Section 33  Translational Research: Imaging
Section 34  Vaccines / Immunomodulatory Agents and Interventions

**Clinical Trials**
Section 35  Phase I Trials in Progress 2

**Immunology**
Section 36  Combination Immunotherapies 1
Section 37  Combination Immunotherapies 2
Section 38  Immunomodulatory Agents and Interventions 3
Section 39  Therapeutic Antibodies 3
Section 18  Late-Breaking Research: Immunology 2
Wednesday, April 13

**Advances in Diagnostics and Therapeutics**
10:15 a.m.–11:45 a.m.

Room 265-268, Convention Center

*How Should Clonal Hematopoiesis Impact Cancer Treatment Decisions?*

**Chair:** Ross L. Levine, New York, NY

10:15 a.m.  **Introduction.** Ross L. Levine, New York, NY

10:20 a.m.  **Clonal hematopoiesis as a hidden driver of various complications and disease processes in oncology care.** Koichi Takahashi, Bellaire, TX

10:45 a.m.  **Therapy-related myeloid neoplasms: What does clonal hematopoiesis teach us about its biology and prevention?** Kelly Bolton, St. Louis, MO

11:10 a.m.  **Precision interception in clonal hematopoiesis: A paradigm for mechanism-based cancer prevention.** Ross L. Levine, New York, NY

New Orleans Theater A, Convention Center

**Machine Learning to Translate the Cancer Genome and Epigenome into Biological and Clinical Insights**

**Chair:** Lajos Pusztai, New Haven, CT

10:15 a.m.  **Introduction.** Lajos Pusztai, New Haven, CT

10:20 a.m.  **Multi-omics in the diagnosis and prognosis prediction of solid tumors.** Balázs Győrffy, Budapest, Hungary

10:45 a.m.  **Deep learning on interactomes for mechanistic predictions in cancer drug discovery.** Marinka Zitnik, Boston, MA

11:10 a.m.  **Limitations of machine learning: Cancer biology as a combinatorial challenge.** Lajos Pusztai, New Haven, CT

**Advances in Organ Site Research • 10:15 a.m.–11:45 a.m.**

Room 260-262, Convention Center

*Progress in Understanding Nonalcoholic Fatty Liver Disease-Induced Liver Cancer and Associated Disparities*

**Chair:** Veronica Wendy Setiawan, Los Angeles, CA

10:15 a.m.  **Introduction.** Veronica Wendy Setiawan, Los Angeles, CA

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
10:20 a.m.  Epidemiologic trends and racial/ethnic disparities in NAFLD-related HCC. Veronica Wendy Setiawan, Los Angeles, CA

10:45 a.m.  NAFLD-related HCC: Pathogenesis, progress and pitfalls in screening. David Huang, Los Angeles, CA, Singapore

11:10 a.m.  Treatment response and outcomes of NASH-related HCC: Does etiology make a difference? Lewis R. Roberts, Rochester, MN

**Advances in Population Sciences • 10:15 a.m.–11:45 a.m.**

New Orleans Theater C, Convention Center

**Functional Role of Long Tail Coding and Non-coding Mutations in Cancer**

Chair: Mark Gerstein, New Haven, CT

10:15 a.m.  **Introduction.** Mark Gerstein, New Haven, CT

10:20 a.m.  **Title to be announced.** Mark Gerstein, New Haven, CT

10:45 a.m.  **Title to be announced.** Mark A. Rubin, Bern, Switzerland

11:10 a.m.  **Title to be announced.** Haiyuan Yu, Ithaca, NY

**Advances in Prevention Research • 10:15 a.m.–11:45 a.m.**

La Nouvelle Orleans A-B, Convention Center

**Can Precancer Early Detection Become a Reality?**

Chair: Nickolas Papadopoulos, Baltimore, MD

10:15 a.m.  **Introduction.** Nickolas Papadopoulos, Baltimore, MD

10:20 a.m.  **What is “precancer,” should we detect it, and if so, under what circumstances?** Philip E. Castle, Rockville, MD

10:45 a.m.  **Detecting precancerous lesions via MCED testing.** Ernest T. Hawk, Houston, TX

11:10 a.m.  **Liquid biopsies for the detection of precancerous lesions. Will a universal test work?** Nickolas Papadopoulos, Baltimore, MD
WEDNESDAY, APRIL 13

Advances in the Science of Cancer Health Disparities
10:15 a.m.–11:45 a.m.

Room 278-282, Convention Center
Applying an Equity Lens to Implementation Research:
A Pathway to Reduce Cancer Health Disparities

Chair: Ophira Ginsburg, Bethesda, MD

10:15 a.m. Introduction. Ophira Ginsburg, Bethesda, MD

10:20 a.m. Global oncology and implementation science: An overview. Ophira Ginsburg, Lyon, France

10:45 a.m. Implementation research to address disparities along the cancer continuum in the U.S. and Tanzania. Anne Rositch, Baltimore, MD

11:10 a.m. The equity gap in implementation research for cancer control: Perspectives from Latin America. Raúl Murillo, Bogotá, Colombia

Major Symposia • 10:15 a.m.–11:45 a.m.

La Nouvelle Orleans C, Convention Center
Aging and the Tumor Microenvironment’s Impact
on Minimal Residual Disease and Cancer Recurrence

Chair: Ashani T. Weeraratna, Baltimore, MD

10:15 a.m. Introduction. Ashani T. Weeraratna, Baltimore, MD

10:20 a.m. Changes in adaptive landscapes and somatic evolution as we age. James V. DeGregori, Aurora, CO

10:42 a.m. Metabolic programs dictating melanoma metastatic tropism. Amaya Viros, Manchester, United Kingdom

11:04 a.m. Modulating cellular senescence to reinstate natural killer cell immunity for pancreatic cancer immunotherapy. Marcus Ruscetti, Worcester, MA

11:23 a.m. And by a sleep to say we end: Tumor dormancy, aging, and recurrent disease. Ashani T. Weeraratna, Baltimore, MD

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room 208-210, Convention Center

**Bone Metastasis**

**Chair:** Yibin Kang, Princeton, NJ

**10:15 a.m.**  
**Introduction.** Yibin Kang, Princeton, NJ

**10:20 a.m.**  
**Bad to the bone: Systemic consequences of bone metastases.** Theresa A. Guise, Houston, TX

**10:45 a.m.**  
**The evolving cancer-niche interaction during bone metastasis.** Xiang Zhang, Houston, TX

**11:10 a.m.**  
**Tumor-stromal crosstalk in bone metastasis.** Yibin Kang, Princeton, NJ

Room 217-219, Convention Center

**Cancer Drugs Repurposing for Rare Genetic Disorders: A Unique Opportunity for Patients**

**Chair:** Guillaume Canaud, Paris, France

**10:15 a.m.**  
**Introduction.** Guillaume Canaud, Paris, France

**10:20 a.m.**  
**PIK3CA-related disorders: A breakthrough in drug repurposing.** Guillaume Canaud, Paris, France

**10:45 a.m.**  
**Langerhans cell histiocytosis at the era of targeted therapies.** Carl Allen, Houston, TX

**11:10 a.m.**  
**Unravelling sporadic vascular malformations due to mosaic RAS/MAPK variants: New therapeutic perspectives.** Satyamaanasa Polubothu, London, United Kingdom

Great Hall BC, Convention Center

**Cancer Vaccines: New Developments and Clinical Response**

**Chair:** Nina Bhardwaj, New York, NY

**10:15 a.m.**  
**Introduction.** Nina Bhardwaj, New York, NY

**10:20 a.m.**  
**A contextual approach to cancer neoantigen vaccines.** Ugur Sahin, Mainz, Germany

**10:45 a.m.**  
**Beyond tumor antigen immunogenicity: Determinants of protective immunity induced by therapeutic cancer vaccines.** Lelia Delamarre, San Francisco, CA

**11:10 a.m.**  
**Properties of tumor antigens determining induction of immunity.** Nina Bhardwaj, New York, NY
**WEDNESDAY, APRIL 13**

New Orleans Theater B, Convention Center

**CAR T and BiTE: Finally Ready for Solid Tumors?**

Chair: Melissa L. Johnson, Nashville, TN

10:15 a.m. **Introduction.** Melissa L. Johnson, Nashville, TN

10:20 a.m. **BiTE / CD3 bispecific experience in solid tumors: Translational lessons learned.** Dirk Nagorsen, Thousand Oaks, CA

10:45 a.m. **Clinical development of new targets for solid tumor immunotherapy, CAR T and BiTE.** Tanya B. Dorff, Duarte, CA

11:10 a.m. **Not just another irAE: Identification and management of immunotoxicities of bispecifics and CAR-T.** Melissa L. Johnson, Nashville, TN

Room 243-245, Convention Center

**Mechanisms of Cancer Stem Cell Immune Evasion**

Chair: Judith A. Varner, La Jolla, CA

10:45 a.m. **NK cell ligands and leukemia stem cell immune evasion.** Claudia Lengerke, Tübingen, Germany

11:10 a.m. **Evasion of anti-tumor immunity by metastatic stem cells.** Filippo Giancotti, New York, NY

10:20 a.m. **Bidirectional signaling between cancer stem cells and macrophages promote immune evasion.** Judith A. Varner, La Jolla, CA

Room 220-222, Convention Center

**Physical Aspects of Cancer and Physical Sciences of Oncology**

Chair: Claudia Fischbach, Ithaca, NY

10:15 a.m. **Introduction.** Claudia Fischbach, Ithaca, NY

10:20 a.m. **Untangling the connection between stress and metastasis.** Mikala Egeblad, Cold Spring Harbor Laboratory, NY

10:45 a.m. **Aneuploidy and 3D tissue rigidity.** Dennis Discher, Philadelphia, PA

11:10 a.m. **Extracellular matrix as a physical regulator of cancer.** Claudia Fischbach, Ithaca, NY

*Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Regulatory Science and Policy Session
Training the Next Generation of Oncology Leaders

Moderators: Paz Joan Vellanki, Silver Spring, MD; Christopher Chen, Mountain View, CA

Speakers:
Paz Joan Vellanki, Silver Spring, MD
Christopher Chen, Mountain View, CA
Ashkan Emadi, Baltimore, MD
Aakash P. Desai, Rochester, MN
Amanda J. Redig, Cambridge, MA
Dawn K. Aldrich, New York, NY

Plenary Session • 12:00 p.m.–1:25 p.m.

Hall B-C, Convention Center
AACR Annual Meeting 2022 Highlights: Vision for the Future

Chair: Marcia R. Cruz-Correa, San Juan, PR

12:00 p.m.  Introduction. Marcia R. Cruz-Correa, San Juan, PR
12:05 p.m.  Basic and translational research. Danny R. Welch, Kansas City, KS
12:30 p.m.  Prevention, early detection, population sciences, and disparities research. Jennifer A. Doherty, Salt Lake City, UT
12:55 p.m.  Clinical research and clinical trials. Lillian L. Siu, Toronto, ON, Canada
1:20 p.m.  Wrap-up and opportunities for the future. Marcia R. Cruz-Correa, San Juan, PR
**Scholar-in-Training Awards**

The AACR is proud to offer Scholar-in-Training Awards to enable the participation of meritorious early-career scientists at the Annual Meeting 2022. Since its inception in 1986, the AACR Annual Meeting Scholar-in-Training Award program has provided more than 5,000 grants to young investigators and has received support from 67 cancer research foundations, corporations, individuals and other organizations dedicated to the fight against cancer. This year, 16 organizations or individuals generously provided the funding to support this program.

The names and affiliations of the 2022 Scholar-in-Training Award recipients, along with the abstract numbers and titles of their abstracts, are listed below.

**2022 AACR Scholar-in-Training Awards**

The AACR has received and distributed funds to support early-career investigators who will be presenting high quality abstracts in breast cancer research at the AACR Annual Meeting 2022.


**Sarah-Jane Neuberth, MS**, German Cancer Research Center, Heidelberg, Germany. Abstract 652. An androgen receptor-associated transcription factor regulates fatty acid metabolism driving tumor growth in androgen receptor-positive breast cancer.

**Brandon Tan, MS, PhD**, City of Hope, Monrovia, CA. Abstract 2188. The N6-methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer.

**2022 AACR Scholar-in-Training Awards Supported by a Grant from AbbVie**

Early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2022 were generously supported by a grant from AbbVie.

**Aftab Alam, PhD**, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Abstract 2119. KRAS and fungi cooperate to drive IL33 secretion and type 2 immunity in the pancreatic cancer tumor microenvironment.


**Lindsey Carlsen, BS**, Brown University, Providence, RI. Abstract 1231. Prognostic and predictive drug-induced gene signatures for colorectal cancer patients personalized based on p53 status and treatment with FOLFOX, 5-FU, oxaliplatin, or irinotecan.

**Fernando de Miguel, PhD**, Yale University, New Haven, CT. Abstract 1094. SMARCA4-mediated chromatin remodeling regulates osimertinib resistance in EGFR-mutant lung adenocarcinoma.

**Marco Galvez-Nino, MD**, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru. Abstract 509. Tumor inflammation signature (TIS) in residual disease is associated with survival in breast cancer patients with high risk of recurrence.
Martina Ghetti, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori “Dino Amadori”, Meldola, Italy. Abstract 1555. CircPVT1 and linear PVT1 isoforms regulate cell growth, metabolic and DNA damage response related gene signatures in acute myeloid leukemia.

Soma Ghosh, PhD, MD Anderson Cancer Center, Houston, TX. Abstract 1858. Rb deficient HPV+ HNSCC experienced enhanced sensitivity to aurora kinase inhibitors by altering the balance of MAD2 and TRIP13 levels.

Kuldeep Gupta, M Phil, PhD, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 2481. Imaging pancreatic ductal adenocarcinoma using an EphA2 receptor tyrosine kinase binding 68Ga-labeled peptide radiotracer.

Humna Hasan, M Phil, Department of Biological Sciences, Purdue University, West Lafayette, IN. Abstract 1537. Understanding role of uniquely enriched RNAs carried in non-small cell lung cancer derived extracellular vesicles and dynamics of their selective export.

Simon Heeke, PhD, MD Anderson Cancer Center, Houston, TX. Abstract 3473. Use of DNA methylation from tumor and plasma to identify four major small cell lung cancer subtypes with distinct biology and therapeutic vulnerabilities.

Cameron Herberts, BS, University of British Columbia, Vancouver, BC, Canada. Abstract 3625. Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing.

Corbin Jensen, MS, PhD, University of Arizona, Tucson, AZ. Abstract 263. PIM kinase regulates actin dynamics in hypoxia.

Yun Lu, BS, University of Alabama at Birmingham, Hoover, AL. Abstract 2482. Evaluating immune checkpoint blockade treatment efficacy via [89Zr]-CD4 and [89Zr]-CD8 PET imaging in breast cancer mouse models.

Simone Minnie, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. Abstract 1360. CD8 T cells display distinct trajectories of T cell exhaustion in the bone marrow of mice with multiple myeloma.

Rebecca Nash, MPH, Emory University, Atlanta, GA. Abstract 3672. Area-level drivers of the breast cancer mortality race disparity in Georgia.


Michelle Ozaki, BA, Oregon Health and Science University, Portland, OR. Abstract 983. RNA-seq analysis of murine liver to identify breast cancer metastatic potential during liver involution.

Santosh Paidi, MS, PhD, University of California, Berkeley, Berkeley, CA. Abstract 1943. Elucidating early tumor microenvironmental changes due to immunotherapy with label-free Raman spectroscopy and machine learning.

Samantha Perez, PhD, University of Virginia, Charlottesville, VA. Abstract 3591. First in class drug ZB131 shows efficacy in cholangiocarcinoma models.

Zuen Ren, MD, PhD, Albert Einstein College of Medicine, Bronx, NY. Abstract 968. Loss of glutathione peroxidase 2 promotes epithelial to mesenchymal transition and breast cancer metastasis.
TRAVEL AWARDS

Andrea Romanos-Nanclares, MS, PhD, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. Abstract 16. Inflammatory and insulinemic dietary patterns and risk of endometrial cancer: Results from two prospective US cohort studies.


Trine Strandgaard, MS, Aarhus University Hospital, Aarhus N, Denmark. Abstract 1282. Elevated T cell exhaustion and immune cell infiltration is associated with BCG failure in patients with non-muscle invasive bladder cancer.

Timothy Trotter, PhD, Duke University, Durham, NC. Abstract 2451. Dormant mammary tumors resist antigen-specific killing and regulate systemic immunity in association with PTN and DKK3.

Anqi Wang, MPH, University of Southern California, Pasadena, CA. Abstract 1437. Ambient air pollution and risk of prostate cancer: The multiethnic cohort study.

Yanning Wu, MS, Case Western Reserve University, School of Medicine, Cleveland, OH. Abstract 3676. Race-specific methylation profiles and epigenetic age acceleration differentiates estrogen receptor status breast cancer.

Daniel Zabransky, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 3638. Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer.

Jimmy Zhao, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 1728. Single cell RNA-seq analysis reveals a role of pro-inflammatory tumor-associated macrophages in driving prostate cancer progression.

Feng Zhu, PhD, National Cancer Institute, Frederick, MD. Abstract 3044. C. albicans infection mediates upper gastrointestinal tract malignancy independently of Il17a in an APECED-like mouse model.

Nicholas Zorko, MD, PhD, University of Minnesota, Minneapolis, MN. Abstract 2761. FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3.

2022 AACR-American Brain Tumor Association Scholar-in-Training Awards

The American Brain Tumor Association has graciously donated funds to support young investigators who will be presenting high-quality abstracts in brain cancer research for both primary and secondary (metastatic) brain tumors at the AACR Annual Meeting 2022.

Matthew Dankner, BS, Rosalind and Morris Goodman Cancer Institute, Montreal, QC, Canada. Abstract 1569. pSTAT3+ stromal cells drive the invasive growth of brain metastases.

Daniel Doheny, BS, MS, Wake Forest School of Medicine, Winston-Salem, NC. Abstract 2433. Targeting tGLI1 pharmacologically as a new therapeutic strategy for breast cancer brain metastases.
Inbal Greenberg, BS, Tel Aviv University, Bat Yam, Israel. Abstract 266. Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2.

Radhika Mathur, PhD, University of California San Francisco, San Francisco, CA. Abstract 3621. 3D spatial sampling and integrated omics reveal sources and patterning of intratumoral heterogeneity in glioblastoma.

Aram Modrek, MD, PhD, NYU Grossman School of Medicine, New York, NY. Abstract 3622. DNA damage drives DNA methylation and 3D chromatin organization alterations in glioblastoma.

Frederick Varn, MS, PhD, The Jackson Laboratory for Genomic Medicine, Farmington, CT. Abstract 2168. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment.

2022 AACR-Breast Cancer Research Foundation Scholar-in-Training Awards in Memory of Rebecca Scheinkman

The Breast Cancer Research Foundation has graciously donated funds to support young investigators who will be presenting high quality abstracts in breast cancer research at the AACR Annual Meeting 2022. This year, this funding has been given by the Breast Cancer Research Foundation to honor the memory of Rebecca Scheinkman.

Sara Busatto, PhD, Boston Children’s Hospital, Boston, MA. Abstract 2190. Brain-seeking extracellular vesicles derived from metastatic breast cancer cells modulate brain endothelial cell metabolism.

Diana Drago Garcia, MS, Weizmann Institute of Science, Rehovot, Israel. Abstract 991. OVO-like genes are master regulators of the epithelial fate in breast cancer.

2022 AACR-Bristol Myers Squibb Scholar-in-Training Awards

Bristol Myers Squibb has graciously donated funds to support early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2022.

Afaf Abed, MBBS, Edith Cowan University, Caversham, WA, Australia. Abstract 5132. HLA-I homozygosity as a protective biomarker for developing immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy in the first- or second-line setting.

James Black, BA, MBBS, University College London Cancer Institute, London, United Kingdom. Abstract 1603. Genomic transcriptomic evolution in TRACERx lung cancer and metastasis.

Liyun Chen, MS, PhD, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO. Abstract 212. Squamous cell carcinoma antigen counteracts the radiation-induced antitumor response by driving an immune evasion phenotype through STAT signaling.

En Cheng, MD, PhD, Kaiser Permanente Northern California, Oakland, CA. Abstract 682. Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance]).
TRAVEL AWARDS

Michelle Dietzen, BS, MS, University College London Cancer Institute, London, United Kingdom. Abstract 3620. Investigating the role of altered replication timing during tumor evolution in lung and breast cancer.

Amanda Frydendahl, MS, Aarhus University Hospital, Aarhus N, Denmark. Abstract 1959. Sensitive detection of circulating tumor DNA by whole genome sequencing: Validation of MRDetect using serial blood samples from stage III colorectal cancer patients.

Yuanyuan Fu, PhD, University of Hawaii John A. Burns School of Medicine, Honolulu, HI. Abstract 5865. Analysis of RNA sequencing data to advance our understanding of colorectal cancer health disparity in Native Hawaiians.

Ben Jin, MD, Tulane University School of Medicine, New Orleans, LA. Abstract 1313. IL-17RC, but not PLK4 inhibitor centrinone, plays a critical role in the development of skin papilloma and psoriasis in mouse models.

Md Imtiaz Khalil, BS, MS, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA. Abstract 2424. TLK1-MK5 axis modulates actin filaments and focal adhesion components to promote PCa cell migration and invasion.

Homma Khosroyani, BS, Oregon Health and Science University, Portland, OR. Abstract 660. Predicting imatinib responses in exon 18 PDGFRA-mutant GIST.

David Lee, MD, MPH, Massachusetts General Hospital, Boston, MA. Abstract 3651. Obesity, metabolic comorbidities, and lifestyle factors and their association with monoclonal gammopathies in a high-risk screened population: Results of the PROMISE study.

Hong-Tao Li, PhD, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. Abstract 3618. Loss of SETD2 sensitizes kidney cancer cells to DNA methylation inhibitors by inducing viral mimicry and RNA mis-splicing.

Elizabeth Lightbody, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 641. Single-cell RNA sequencing of rare circulating tumor cells in precursor myeloma patients reveals molecular underpinnings of tumor cell circulation.


Akhilesh Mishra, BS, Johns Hopkins University, Baltimore, MD. Abstract 2477. PD-L1 PET quantifies the pharmacodynamic effects of immunotherapy.

Benthe Muntinghe-Wagenaar, MD, University Medical Center Groningen, Groningen, Netherlands. Abstract 666. A phase 1 study to detect adverse events after SBRT and immunotherapy by electronic nose in advanced NSCLC.

Yuki Muroyama, MD, PhD, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA. Abstract 3579. T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade.

Jeffrey Patterson-Fortin, MD, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 1133. Novobiocin-mediated polymerase theta inhibition induces cGAS/STING pathway activation and T-cell infiltration in BRCA-associated cancers.
Evgenii Tcyganov, PhD. The Wistar Institute, Philadelphia, PA. **Abstract 5610.** Targeting Rb1 in experimental pancreatic cancer remodels immune cell landscape and suppresses tumor progression.

Krupa Thakkar, BS, MS. University College London, London, United Kingdom. **Abstract 3043.** Exploring the microbial landscape of NSCLC through TRACERx.

Tomotaka Ugai, MD, PhD. Brigham and Women’s Hospital, Boston, MA. **Abstract 684.** Body mass index throughout adulthood and incidence of colorectal cancer subclassified by T cell, macrophage, and myeloid cell infiltrates in cancer tissue.

Chien-Huan Weng, MS, PhD. Memorial Sloan-Kettering Cancer Center, New York, NY. **Abstract 6150.** Potential role of CD47 in T cell exhaustion program.

Sarah Winter, BS. Queen’s University Belfast, Belfast, United Kingdom. **Abstract 3354.** A gene expression signature of high serum cholesterol and prostate cancer outcomes.

Yasmine Benslimane, BS. McGill University, Montreal, QC, Canada. **Abstract 2515.** Estrogen regulates the immune microenvironment of colorectal cancer liver metastases.

Daniel Boiarsky, MD. Tufts Medical Center, Cambridge, MA. **Abstract 2181.** Genomic correlates of Metastasis in KRAS mutant lung adenocarcinoma.

Marco Campisi, MS. Dana-Farber Cancer Institute, Boston, MA. **Abstract 3874.** Engineered microphysiological systems for testing effectiveness of cell-based cancer immunotherapies in small cell lung cancer.

MeiKuang Chen, PhD. The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1792.** FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance.

Stephen Chong, PhD. Dana-Farber Cancer Institute, Boston, MA. **Abstract 3959.** Targeting BCL2 family protein phosphorylation in venetoclax resistant lymphoid malignancies.

Saikat Chowdhury, MS, PhD. The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1246.** Consensus molecular subtypes (CMS) of colorectal cancer predict anti-EGFR response irrespective of tumor sidedness.

Marika Colombo, DMSc. Istituto di ricerche farmacologiche Mario Negri, IRCCS, Milano, Italy. **Abstract 4025.** Identification of ERK inhibitor-based combinations targeting LKB1-mutated NSCLC.

Jennifer Eng, BA. Oregon Health and Science University, Portland, OR. **Abstract 6149.** Prognostic tumor microenvironment subtypes in triple-negative breast cancer.

---

2022 AACR-Doreen J. Putrah Cancer Research Foundation Scholar-in-Training Awards

These awards are presented to early career investigators of meritorious abstracts to be presented at the AACR Annual Meeting 2022. These awards are made possible through a gracious donation from the Doreen J. Putrah Cancer Research Foundation.

Fawzi Abu Rous, MD. Henry Ford Health System, Detroit, MI. **Abstract 511.** Prognostic relevance of 3q amplification in squamous cell carcinoma of the lung.
TRAVEL AWARDS


Jeffrey How, MD, MPH, MS, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 1248. Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer.

Claire Ihle, BA, University of Colorado Anschutz Medical Campus, Aurora, CO. Abstract 2512. The metastatic breast cancer microenvironment in bone exhibits unique BMP signaling.


Saumya Kasliwal, BS, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 432. Video-based germline testing for individuals with pancreatic ductal adenocarcinoma: Influence of COVID-19 pandemic.

Allison Kirk, BS, MS, St. Jude Children’s Research Hospital, Memphis, TN. Abstract 1383. Characterization of CD8 T cell responses to DNAJB1-PRKACA fusion neoantigens in fibrolamellar carcinoma.

Carmen Kut, MD, PhD, Johns Hopkins, Baltimore, MD. Abstract 1971. Lymphocyte kinetics, frailty and survival outcomes in HNSCC.

Xue Li, PhD, Seoul National University Hospital, Seoul, Republic of Korea. Abstract 904. Neural stem cells of the subventricular zone evolve into tumors around the resection cavity after surgical resection of glioblastoma via the CXCL12/CXCR4 axis.

Shimeng Liu, PhD, Dana Farber Cancer Institute, Boston, MA. Abstract 6147. Immune population changes in mammary adipose tissue during the development of obesity and their influence on triple negative breast cancer progression.

Saloni Malla, B Pharm, University of Toledo, Toledo, OH. Abstract 5659. Development of mitochondrial fission inhibitors in inducing non-apoptotic cell death in triple-negative breast cancer.


Sofia Mastoraki, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 515. Single-cell transcriptomic analysis of HR+/HER2- breast cancer identifies gene signatures that predict outcomes of luminal A and B subtypes.

Soo Park, MD, University of California San Diego, La Jolla, CA. Abstract 1435. Clonal hematopoiesis profiles in breast cancer survivors using error-corrected sequencing.

Sandhya Prabhakaran, MS, PhD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Abstract 5037. Distinct tumor-immune ecologies in NSCLC patients predict progression and define a clinical biomarker of therapy response.

Monali Praharaj, MS, Johns Hopkins School of Medicine, Baltimore, MD. Abstract 2115. Glutamine blockade via prodrug JHU083 reprograms immunosuppressive tumor associated macrophages (TAMs) and drives tumor immunity in urologic cancers.

Jeanny Wang, MBBS, National Institutes of Health, Division of Cancer Epidemiology and Genetics, Bethesda, MD. Abstract 2250. Eosinophil-to-lymphocyte ratio and cancer risk in the UK Biobank.

Chi-Yun Wu, PhD, University of Pennsylvania, Philadelphia, PA. Abstract 5042. Reconstructing the spatial evolution of cancer through subclone detection on copy number profiles in tumor sequencing data.

Haochen Zhang, MS, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 59. Optimization of high-throughput, high-depth, targeted single-cell DNA sequencing to pancreatic ductal adenocarcinoma.

Fen Zhu, PhD, Dana Farber Cancer Institute, Boston, MA. Abstract 5377. Decitabine sensitizes diffuse large B cell lymphoma cells to venetoclax.

2022 AACR-Heyman Family Fund Scholar-in-Training Awards

These awards are presented to early career authors of meritorious abstracts to be presented at the AACR Annual Meeting 2022. These awards are made possible through a gracious donation from the Heyman Family Fund.

Rebecca Caeser, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 90. STAT3-driven MAPK activation represents a therapeutic vulnerability in ASCL1 high SCLC.

Aya Elmarsafawi, MS, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Abstract 1354. Regulation and roles of polyamines in CD8+ T cell fate and function.

Sarah Jensen, BS, Aarhus University Hospital, Aarhus N, Denmark. Abstract 3391. Methylation analysis using TriMeth indicate that asymptomatic colorectal cancers (CRCs) release less circulating tumor DNA (ctDNA) compared to symptomatic cancers.

Jiye Liu, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 5352. Genome-wide CRISPR-cas9 screening identifies KDM6A as a modulator of CD38 expression in multiple myeloma: Therapeutic implications.

2022 AACR-James V. Buzzitta, MD Family Fund Scholar-in-Training Awards

Funds have been graciously donated to the AACR by the James V. Buzzitta, MD Family Fund to recognize outstanding young investigators for their meritorious work in cancer research and to support their attendance at the 2022 AACR Annual Meeting.

Daniel Bronder, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 2164. Chromosomal instability as a mediator of anti-tumor immunity in pancreatic cancer.

TRAVEL AWARDS

2022 AACR-John and Elizabeth Leonard Family Foundation Scholar-in-Training Awards

Funds have been graciously donated to the AACR by the John and Elizabeth Leonard Family Foundation to recognize outstanding young investigators for their meritorious work in cancer research and to support their attendance at the 2022 AACR Annual Meeting.

Nicole Kettner, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 1774. Circulating IL-6, an early biomarker in HR-positive, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors.

John Kwon, BS, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 1330. Role of ENPP1 mediated extracellular cGAMP hydrolysis in cancer metastasis and immune evasion.


John McVey, MD, Hospital of the University of Pennsylvania, Philadelphia, PA. Abstract 1372. Macrophages impair antigen specific CD8+ T cell response against HCC in NAFLD mice.

Minh-Tam Pham, PhD, Johns Hopkins School of Medicine, Baltimore, MD. Abstract 680. Topoisomerase 2 beta facilitates chromatin reorganization during Androgen Receptor induced transcription and contributes to chromoplexy in prostate cancer.

Jason Wong, ScD, National Cancer Institute, Rockville, MD. Abstract 2251. Alu retroelement copy number, leukocyte telomere length, and lung cancer risk in the prospective Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

2022 AACR-John and Joe Warner Fund Scholar-in-Training Awards

Funds have been graciously donated to the AACR by the John and Joe Warner Fund to recognize outstanding young investigators for meritorious work in cholangiocarcinoma research being presented at the 2022 AACR Annual Meeting.

Timothy DiPeri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 2618. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in cholangiocarcinoma with FGFR fusions/rearrangements.


2022 AACR-June L. Biedler Scholar-in-Training Awards

These awards are presented to authors of meritorious abstracts to be presented at the AACR Annual Meeting 2022. These awards are made possible through the Estate of Dr. June L. Biedler. The late Dr. Biedler was a dedicated member of AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.
Lu Han, PhD, Medical University of South Carolina, Charleston, SC. Abstract 3645. The splanchnic mesenchyme is the main tissue origin of fibroblasts in the pancreas during homeostasis and tumorigenesis.

Jennifer Hon, BS, University of Michigan, Ann Arbor, MI. Abstract 2538. Role of Argonaute 2 in regulation of immune microenvironment in pancreatic cancer.

Minh Nguyen, BA, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 1370. Targeting LSD1 rescues MHC-I antigen presentation in small cell lung cancer.

Bobak Parang, MD, PhD, Weill Cornell, New York, NY. Abstract 2378. Methylmalonic acid is elevated in non-small cell lung cancer and promotes drug resistance.

Abhijit Parolia, MS, PhD, University of Michigan, Ann Arbor, MI. Abstract 3592. Targeting SWI/SNF ATPases in enhancer-addicted human cancers.


Guan-Yu Xiao, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 673. The EMT activator ZEB1 initiates polarized secretion of pro-tumorigenic effector proteins to drive lung adenocarcinoma progression.

Maral Adel Fahmideh, MS, PhD, Baylor College of Medicine, Houston, TX. Abstract 1448. Novel specific susceptibility loci identified for pediatric and adult ependymoma in first histology-specific genome-wide association study.

Hongchen Cai, BS, Stanford University, Stanford, CA. Abstract 827. A journey to deconvolute the multifaceted functions and context-dependency of cancer driver genes.

Emily Cybulla, BS, St. Louis University School of Medicine, Saint Louis, MO. Abstract 803. Identifying a RAD18/UBC13-dependent mechanism of replication fork recovery to modulate chemoresponse in BRCA1-deficient cancers.

Muhammed Elhadi, MBBCh, University of Tripoli, Tripoli, Libyan Arab Jamahiriya. Abstract 1999. The impact of the COVID-19 pandemic on 30-day survival in pediatric cancer patients in low, middle, and high-income countries: an international, observational cohort study.

Amal Elhaw, B Pharm, Pittsburgh University, Pittsburgh, PA. Abstract 2445. Orchestrated expression of the atypical Rho-GTPase RHOC mediates multicellular aggregate formation in ovarian cancer.

Marie Hasselluhn, Dr Rer Nat, Columbia University Irving Medical Center, New York, NY. Abstract 3648. Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1.

Joash Joy, M Eng, Barts Cancer Institute, London, United Kingdom. Abstract 693. TGFβ-mediated targeting of the extracellular matrix enhances the migration and cytotoxicity of CAR-T cells in 3D models of ovarian cancer.

2022 AACR-Margaret Foti Foundation Scholar-in-Training Awards

Through a generous gift of the Margaret Foti Foundation, these awards recognize outstanding young investigators for their meritorious work in pediatric, ovarian, pancreatic, or lung cancer research.
Casey Langdon, PhD, St. Jude Children’s Research Hospital, Memphis, TN. Abstract 1667. Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity.

Mingli Li, MD, Beckman Research Institute of City of Hope, Duarte, CA. Abstract 1467. RUVBL1 controls protein synthesis and tumor progression via MYC-dependent EEF1A1 expression.

Bikesh Nirala, PhD, Baylor College of Medicine, Houston, TX. Abstract 1668. Development and characterization of a c-Myc-driven preclinical mouse model of osteosarcoma to investigate the tumor immune microenvironment.

Catherine Pham-Danis, PhD, University of Colorado Anschutz Medical Campus, Aurora, CO. Abstract 3607. A novel adjunctive LAT-activating CAR T (ALA-CART) cell platform demonstrates enhanced antigen sensitivity and eradication of antigen-low leukemia.

Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA. Abstract 2143. Clinicopathologic, genomic and immunophenotypic landscape of ATM mutations in non-small cell lung cancer.


Christian Tegeler, MD, University Hospital of Tübingen, Tübingen, Germany. Abstract 1972. Clinical implications of HLA expression and immunopeptidome-presented tumor antigens in ovarian carcinoma.

Ignacio Vázquez-García, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 2553. Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes.

Meilin Xue, MD, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Abstract 3644. Schwann cells reshape tumor cells and cancer associated fibroblasts in pancreatic ductal adenocarcinoma microenvironment.

Xiyuan Zhang, PhD, National Cancer Institute, Bethesda, MD. Abstract 701. Loss of PRC2 enforces a mesenchymal neural crest stem cell phenotype in NF1-deficient cancer through activation of core transcription factors.

**2022 AACR-Pezcoller Foundation Scholar-in-Training Awards**

The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Ariana Huebner, MS, UCL Cancer Institute, London, United Kingdom. Abstract 3792. TRACERx: Mapping the evolution of metastases in non-small cell lung cancer.

Samvid Kurlekar, MS, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. Abstract 862. Negative cellular outcomes following acute in vivo Vhl inactivation in mice.
**Ferran Nadeu, PhD**, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. **Abstract 3795.** Early seeding of Richter transformation in chronic lymphocytic leukemia.

**Maria Serena Roca, PhD**, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCS, Naples, Italy. **Abstract 1840.** Repurposing of valproic acid and simvastatin in pancreatic cancer: *in vitro* and *in vivo* synergistic antitumor interaction and sensitization to gemcitabine/nab-paclitaxel via inhibition of TGFβ-EMT signaling pathway.

**Vera Thiel, MS**, German Cancer Research Center/Hi-STEM, Heidelberg, Germany. **Abstract 3650.** Trace’n’Seq: Assessing neuronal infiltration and its impact in pancreatic ductal carcinoma.

**2022 AACR-Prostate Cancer Foundation Scholar-in-Training Awards**

The Prostate Cancer Foundation has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious abstracts in prostate cancer research at the AACR Annual Meeting 2022.

**Carolina Gomes Alexandre, MD**, The Johns Hopkins University School of Medicine, Baltimore, MD. **Abstract 653.** Molecular pathology of metastatic prostatic adenocarcinoma treated with bipolar androgen therapy (BAT) reveals a correlation between MYC mRNA and protein.


**Jiaren Zhang, BS**, Weill Cornell Medicine, New York, NY. **Abstract 646.** Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC.

**2022 AACR-Sygnature Discovery Scholar-in-Training Award in Association with the CICR Working Group**

Sygnature Discovery has graciously donated funds to the AACR to support an early-career investigator who will be presenting meritorious work in small molecular drug discovery research at the AACR Annual Meeting 2022.

**Rita Avelar, BS**, University of Michigan, Ann Arbor, MI. **Abstract 3340.** Small molecule mediated stabilization of PP2A modulates the homologous recombination pathway and potentiates DNA damage-induced cell death.

**2022 AACR-WuXi AppTec Scholar-in-Training Awards in association with the CICR Working Group**

WuXi AppTec has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious abstract in biomedical chemistry research at the AACR Annual Meeting 2022.

**Ahmed Abdelaal**, Purdue University, West Lafayette, IN. **Abstract 1482.** Efficient targeting of prostate cancer using ligand conjugated and chemically modified tumor suppressive miRNA.
TRAVEL AWARDS

Shurui Cai, PhD, The Ohio State University, Columbus, OH. Abstract 3325. ERK inhibitor increases cancer stem cell population in NSCLC through Slug-Mediated epithelial-to-mesenchymal transition.


Kelsey Huntington, BS, Brown University, Providence, RI. Abstract 4166. Small-molecule inhibition of glycogen synthase kinase-3 (GSK-3) increases the efficacy of anti-PD-L1 therapy in a murine model of microsatellite stable colorectal cancer (CRC); Therapeutic response correlates with T cell ratios and serum cytokine profiles.

Costanza Lo Cascio, BS, Ivy Brain Tumor Center at Barrow Neurological Institute, Phoenix, AZ. Abstract 349. Pharmacokinetics- and pharmacodynamics-based evaluation of quisinostat as a radiosensitizer in preclinical models of human glioblastoma.


Caitlin O’Connor, PhD, University of Michigan, Ann Arbor, MI. Abstract 3341. Synthetic lethality by targeting ribonucleotide reductase in PP2A deficient uterine serous carcinoma.

Sarah Naomi Olsen, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 681. Targeted MLL-AF9 degradation is phenocopied by combined DOT1L and Menin inhibition.

Zahraa Rahal, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 223. Chronic exposure to waterpipe smoke elicits immunomodulatory and carcinogenic effects in the lung.

2022 Global Scholar-in-Training Awards

The AACR is proud to offer Global Scholar-in-Training Awards (GSITA) to support the participation of meritorious early-career scientists from countries building cancer research capacities who wish to participate in the AACR Annual Meeting 2022. The GSITA program, now in its fourth year, will bring promising scientists from nine countries—Jordan, Nigeria, Peru, India, Colombia, China, Brazil, Serbia, and Argentina—to New Orleans in April.

Zahraa Rahal, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 223. Chronic exposure to waterpipe smoke elicits immunomodulatory and carcinogenic effects in the lung.
Andrea Anampa-Guzmán, Universidad Nacional Mayor de San Marcos, San Fernando Medical school, Lima, Perú, Abstract 3656. Breast cancer care quality in Peru

Titilope Dokunmu, PhD, Covenant University, Ota, Nigeria, Abstract 5850. p53 gene expression and nitric oxide levels after artemisinin-caffeine treatment in breast, lungs and liver of DMBA-induced tumorigenesis

Delfin Lovelina Francis, MDS, All India Institute for Medical Sciences, New Delhi, India, Abstract 2215. Cancer awareness, tobacco use and cessation among Malayali tribes, Yelagiri Hills, Tamil Nadu, India.


Jie Huang, MD, PhD, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China, Abstract 5002. The prognostic relevance and underlying mechanisms of the novel oxygen sensor ADO in cancers

Rahul Kumar, PhD, All India Institute of Medical Sciences, New Delhi, India, Abstract 2277. Evaluation of mutation profile of oncogenic signaling pathway in breast cancer among Indian population

Jude Okoye, PhD, Nnamdi Azikiwe University, Nigeria, Nnewi, Nigeria, Abstract 1496. Circulating mir21 and mir125b in women living with human immunodeficiency virus: Utility of biomarkers for monitoring cervical carcinogenesis

Barbara Paranhos Coelho, PhD, University of Sao Paulo, Sao Paulo, Brazil, Abstract 103. Knockout of cellular prion protein in glioblastoma affects the expression of Wnt signaling genes

Marijana Pavlovic, PhD, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, Abstract 3463. Nischarin agonist rilmenidine inhibits pancreatic ductal adenocarcinoma cell migration and invasion


Xinfeng Wang, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Abstract 5349. Single-cell analysis sheds light on the resistance mechanisms of a novel pan-HER inhibitor, pyrotinib, in non-small cell lung cancer

Anjali Yadav, Indian Institute of Technology Kanpur, Uttar Pradesh, India, Abstract 1542. MALAT1 ablation dismantles homologous recombination repair machinery and sensitizes castrate-resistant prostate cancer cells to PARP inhibitor
TRAVEL AWARDS

2022 AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Awards

The AACR is very pleased to administer this important program, which provides funds for the participation of full-time minority faculty members and faculty members of Minority-Serving Institutions (MSI) at the AACR Annual Meeting 2022. Recipients of this award are scientists who are working at the level of Assistant Professor or above who are engaged in meritorious basic, clinical, or translational cancer research.

Now in its 25th year, this award program has been supported by a generous grant provided by the National Cancer Institute’s Center to Reduce Cancer Health Disparities (CRCHD). The CRCHD works to increase the number of underrepresented minorities participating as competitive NCI/NIH-funded cancer researchers. The Board of Directors of the AACR expresses its appreciation to the CRCHD for its long-term and generous support of faculty members and congratulations to the Minority and Minority Serving Institution Faculty Awardees.

Mario Andres Blanco, PhD, University of Pennsylvania, Philadelphia, PA. Abstract 2960. KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene expression programs.

Matias A. Bustos, PhD, St. John’s Cancer Institute, Santa Monica, CA. Abstract 3233. Interleukin enhancer-binding factor 2 amplification controls mRNA stability and enhances DNA damage response in metastatic melanoma.

Alberto J. Caban-Martinez, DO, MPH, PhD, University of Miami Miller School of Medicine, Coral Gables, FL. Abstract 25. Per- and polyfluoroalkyl substances and obesity in Florida firefighters.

Janaí R. Carr-Asher, PhD, St. John’s Cancer Institute, University of California-Davis, Davis, CA. Abstract 6007. Identification of drivers of soft tissue sarcoma metastasis.

Valery A. Chavez, PhD, University of University of Miami Sylvester Comprehensive Cancer Center, Miami, FL. Abstract 95. In vitro, in vivo and molecular effects of triptolide and minnelide in renal cell.

Sue Anne Chew, PhD, University of Texas Rio Grande Valley, Brownsville, TX. Abstract 1082. The dual delivery of yl5 and metformin in a PLGA scaffold for the treatment of platinum resistant ovarian cancer.

Jayanta Kumar Das, PhD, Florida Memorial University, Miami Gardens, FL. Abstract 5830. Carcinogenic effects of metal and metalloids through epigenetic reprogramming of human bone marrow stem cells: The bioinformatics database analysis.

Yamixa Delgado, BS, PhD, San Juan Bautista School of Medicine, Caguas, Puerto Rico. Abstract 1098. Structure-activity relationship of pentacyclic triterpenes against chemoresistance and metastasis on non-small lung adenocarcinoma cells.

Carlos Joel Diaz Osterman, PhD, Ponce Health Sciences University, Ponce, Puerto Rico. Abstract 2559. Tumor lipogenesis influences macrophage polarization in advanced prostate cancer.
Jorge Gomez-Gutierrez, BS, PhD.
University of Missouri-Columbia, Columbia, MO. **Abstract 3286.** Development and characterization of an oncolytic adenovirus armed with the immune checkpoint stimulator SA-4-IBBL.

Maria Gonzalez-Pons, PhD, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico. **Abstract 2266.** Host genetic susceptibility to COVID-19 and pandemic-associated stressors.

Sonia L. Hernandez, M Phil, PhD, RD, University of Chicago, Chicago, IL. **Abstract 376.** Sonoporationed size selected microbubbles and liposomal doxorubicin additively induce apoptosis in neuroblastoma xenografts.

Tytvette Hillard, PhD, Harper Caner Research, South Bend, IN. **Abstract 2189.** The role of generational obesity on the ovarian metastatic niche. **Oral Presentation.**

Tatiana Hurtado de Mendoza, PhD, UCSD Moores Cancer Center, La Jolla, CA. **Abstract 385.** iRGD mediated delivery of neoantigens to enable immunotherapy in integrin b5-rich tumors.

Jessica Y. Islam, MPH, PhD, Moffitt Cancer Center, Tampa FL. **Abstract 3585.** Disparities in cancer treatment delays or discontinuation among cancer patients diagnosed with SARS-CoV-2 infection: An analysis of the U.S. ASCO COVID-19 and cancer registry. **Oral Presentation.**

Eunkyung Lee, MS, PhD, University of Central Florida, Orlando, FL. **Abstract 3688.** Survival benefit of adjuvant radiotherapy among women with high comorbidity burden and low-risk breast cancer - SEER-MHOS analysis.

Daniel F. Liefwalker, BS, PhD, Oregon Health and Science University, Portland, OR. **Abstract 825.** Evasion of apoptosis in MYC dependent T-ALL through epigenetic control.

Justin Xavier Moore, BA, MPH, PHD, Augusta University, Augusta, GA. **Abstract 5908.** Understanding geographic and racial disparities in mortality from four major cancers in the state of Georgia: A spatial epidemiologic analysis, 1999 – 2019.

Sara Pedron, PhD, University of Illinois at Urbana-Champaign, Urbana, IL. **Abstract 179.** Tumor-driven extracellular matrix remodeling influences therapeutic response. **Abstract 3686.** Differences in disease presentation, and treatment outcomes of neoadjuvant chemotherapy for breast cancer among Hispanics in a minority-serving institution.

Sangeetha Prabhakaran, MD, University of New Mexico, Albuquerque, New NM. **Abstract 3686.** Differences in disease presentation, and treatment outcomes of neoadjuvant chemotherapy for breast cancer among Hispanics in a minority-serving institution.

Francisco Sanchez-Vega, M. Eng, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. **Abstract 3058.** Characterization of the tumor microbiome in patients with locally advanced rectal cancer treated with neoadjuvant therapy.
**TRAVEL AWARDS**

**Lisa Scarton, PhD, RN,** University of Florida, Gainesville, FL. **Abstract 5181.** The association of metformin dose and cancer survival in older adults with advanced cancer: SEER-Medicare analysis.

**Athena Starland-Davenport, PhD,** University of Tennessee Health Science Center, Memphis, TN. **Abstract 3022.** Tryptophan metabolism is associated with obesity and triple negative breast cancer risk in black and white women.

**Justin Taylor, MD,** University of Miami Sylvester Comprehensive Cancer Center, Miami, FL. **Abstract 853.** The biological role and mechanisms of XPO1 R749Q mutation in colon cancer. **Abstract 4067.** Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).

**Juli J. Unternaehrer, PhD,** Loma Linda University, Loma Linda, CA. **Abstract 955.** Detection of Stemness and EMT in response to Radiation in Glioblastoma and Ovarian.

**Enrique Velazquez-Villarreal, MD, MPH, MS, PhD,** Keck School of Medicine of USC, Los Angeles, CA. **Abstract 5749.** Single cell whole genome sequencing to assess tumor heterogeneity in endometrial cancer.

**Mariano S. Viapiano, PhD,** SUNY Upstate Medical University, Syracuse, NY. **Abstract 3167.** The scaffolding protein DLG5 is necessary to maintain Sonic Hedgehog signaling in glioblastoma stem cells and promote tumor growth.

---

**2022 AACR Minority Scholar in Cancer Research Awards**

The AACR is very pleased to administer this important program, which provides funds for the participation of early-career, meritorious minority scientists at the AACR Annual Meeting 2022. Scholars are chosen from both minority institutions and the larger bodies of universities, colleges, and research institutes. They are selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees.

Since its founding in 1985, the Minority Scholar Awards in Cancer Research program has been supported by a generous grant of the National Cancer Institute's Center to Reduce Cancer Health Disparities (CRCHD). The CRCHD works to increase the number of underrepresented minorities participating as competitive NCI/NIH-funded cancer researchers.

For 37 years, the AACR has endeavored through this program to reach out to minority predoctoral and postdoctoral students, trainees, and junior investigators as future cancer researchers. The program was created in an attempt to address the serious problem of lack of minority participation in cancer research by offering young minority students and trainees the opportunity to attend and participate in the Annual Meetings and Special Conferences of the AACR.

The AACR would also like to thank Merck & Co., Inc. for providing additional funding to support young minority investigators.
Aalaa S. Abdallah, BS, MS, Northwestern University Feinberg School of Medicine, Chicago, IL. Abstract 912. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes.

Santiago Acero-Bedoya, BS, MS, University of Chicago, Chicago, IL. Abstract 2100. Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity.

Christopher Andrews, BS, MS, Tuskegee University Montgomery, AL. Abstract 773. Inhibition of ubiquitin receptor ADRM1 for the treatment of metastatic breast cancer.

Alexandra N. Aquino-Acevedo, BS, Ponce Health Sciences University, Ponce, Puerto Rico. Abstract 2543. Chronic stress promotes tumor-associated inflammation in high-grade serous ovarian cancer.

Sarah Asemota, BS, University of Tennessee Health Science Center, Memphis, TN. Abstract 1777. Androgen receptor (AR) agonists inhibit AR- and estrogen-receptor-positive breast cancer.

M. Angela Aznar, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Abstract 3602. Mechanisms of CAR T cell dysfunction and identification of transcription factors that drive the exhaustion phenotype. Oral Presentation.

Heather K. Beasley, BS, MS, Vanderbilt University, Nashville, TN. Abstract 2283. SLC25A46 shows potential as a novel genetic regulator in breast cancer development.

LaKendria K. Brown, MS, Meharry Medical College, Nashville, TN. Abstract 2962. The oncogenic role of epigenetic factor, SNF2L in PCa.

Sediqua Sherese Bufford, MS, Morehouse School of Medicine, Atlanta, GA. Abstract 6141. Understanding the role of gp78 in breast cancer health disparities.

Taaliah Campbell, BS, Clark Atlanta University, Atlanta, GA. Abstract 113. Investigating the role of high mobility group a2 (HMGA2) truncated isoform in promoting oxidative stress in PCa cells.

Alexis E. Carey, BS, Johns Hopkins University School of Public Health, Baltimore, MD. Abstract 2554. Impact of the aged bone marrow on the anti-tumor response to melanoma.

Mayra Carneiro, BS, MS, University of Montreal, Montreal, Canada. Abstract 1361. Crosstalk between peripherally expanded T cells and Tfh-like cells in shaping effector functions of CD8 T cells in ovarian cancer.

Alexander C. Chacon, BS, MD, University of Rochester Medical Center, Rochester, NY. Abstract 254. Dietary fish oil and aspirin to augment anti-PD-1 immunotherapy in metastatic melanoma.

TRAVEL AWARDS

**Ricardo Cordova, BS, MS**, Indiana University of School of Medicine, Indianapolis, IN. **Abstract 3040.** The eIF2 kinase GCN2 controls expression of key amino acid transporters and is critical for prostate cancer growth and progression.

**Luisjesus S. Cruz, BS, MS**, San Diego State University, San Diego, CA. **Abstract 901.** Sox2 and Oct4 activity identify CSC populations in ovarian cancer.

**Ailed M. Cruz-Collazo, MS, PhD**, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico. **Abstract 4065.** Efficacy of the Rac/Cdc42 inhibitor MBQ-167 in combination therapy with Paclitaxel.

**Leslie. Cuellar-Vite, BS**, Case Western Reserve University, Cleveland, OH. **Abstract 2301.** Targeting the MUVB complex or downstream G2/M proteins potentiates CDK4/6 inhibitor efficacy in breast cancer.

**Raquel Santana Da Cruz, PhD**, Georgetown University, Washington, D.C. **Abstract 1429.** DDT induces intergenerational epigenetic inheritance of cancer predisposition in a mouse model.

**Jonelle K. Lee, BS, MS**, University of Maryland-Baltimore, Baltimore, MD. **Abstract 3338.** Concurrent treatment with Pim kinase inhibitor enhances efficacy of FLT3 inhibitors in AML with FLT3-ITD through GSK-3βactivation and GSK-3β-mediated enhanced proteasomal degradation of c-Myc and Mcl-1.

**Catherine C. Elix, PhD**, Loma Linda University, Loma Linda, CA. **Abstract 399.** The glucocorticoid receptor and β-catenin interact in prostate cancer cells and their co-inhibition attenuates stemness and docetaxel resistance.

**Mildred Galvez, BA**, UCLA David Geffen School of Medicine, Los Angeles, CA. **Abstract 1388.** Mutations in transcriptional activators of MHC I antigen presentation, NLRC5 and CIITA, are mutually exclusive and have different effects on melanoma gene transcripts.

**Dana M.A Gant, BS, MS**, North Carolina Central University, Kannapolis, NC. **Abstract 1123.** c-Met downregulation contributes to Metformin-induced inhibition of MDA-MB-468 triple negative breast cancer cells.

**Teklab Gebregiworgis, PhD**, University Health Network, Toronto, Ontario, Canada. **Abstract 670.** Distinct biochemical properties of KRAS Q61H mutant render cancer cells resistant to SHP2 inhibitors. **Oral Presentation.**

**Jovanka Gencel-Augusto, BS, MS**, UT MD Anderson Cancer Center, Houston, TX. **Abstract 829.** p53 dimers elicit tumor suppressive activities through an altered metabolic program.

**Nicole B. Halmai, BS, PhD**, University of California, Davis, Davis, CA. **Abstract 698.** Establishing and characterizing patient derived models from racial/ethnic minority gastric cancer patients to advance cancer precision health equity. **Oral Presentation.**

**Andriana Inkoom, BS**, Florida A&M University, Tallahassee, FL. **Abstract 1746.** Optimizing Gemcitabine efficacy through chemical modification for the treatment of pancreatic cancer using PDX mouse model.

**Kofi K. Khamit-Kush, BA, MS**, Clark Atlanta University, Atlanta, GA. **Abstract 394.** Elevated aryl hydrocarbon receptor and leptin receptor expression correlates with prostate cancer progression and may be associated with obesity-associated leptin-mediated chemoresistance.
Emilee N. Kotnik, BS, Washington University in St. Louis, St. Louis, MO. Abstract 990. Functional genomic screen of kinases in high-grade serous ovarian cancer metastasis.

Shannalee R. Martinez, PhD, Ponce Health Sciences University, Ponce, Puerto Rico. Abstract 2559. Tumor lipogenesis influences macrophage polarization in advanced prostate cancer.

Melayshia McFadden, BS, Morehouse School of Medicine, Atlanta, GA. Abstract 366. Combinatorial effect of fisetin and paclitaxel encapsulated PBM nanoparticles in ovarian cancer therapy.

Lawrence P. McKinney, BS, MPH, Morehouse School of Medicine, Atlanta, GA. Abstract 2701. Multivariate transcriptome analysis identifies networks and key drivers of metastatic castration-resistant prostate cancer.

Matthew A. Murray, BS, Yale University, New Haven, CT. Abstract 294. Exploiting mutant PPM1D-induced metabolic defects with nanoparticle-encapsulated NAMPT inhibitors.

Sha’Kayla K. Nunez, BS, MS, Morehouse School of Medicine, Atlanta, GA. Abstract 2285. Co-expressed gene networks in CRC CMS1 subtype.

Mabel G. Oquendo-Perez, BS, MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX. Abstract 676. ZEB1 acetylation regulates dimerization and protein stability to promote lung adenocarcinoma progression and metastasis. Oral Presentation.

THERON PALMER, BS, John Hopkins University School of Medicine, Baltimore, MD. Abstract 2728. Characterization of splicing-derived neoantigens using splicemutr shows their independence from TMB and potential as a biomarker for immunotherapy response.

Cristina Paz, MS, University of Wisconsin-Madison, Madison, WI. Abstract 3152. IFN-gamma stimulated cryopreserved mesenchymal stromal cells for treatment of radiation induced xerostomia.

Jaileene Perez-Morales, PhD, H. Lee Moffitt Cancer Center, Temple Terrace, FL. Abstract 3218. Radiomic biomarkers to optimize treatment decision and predict patient outcomes in serous ovarian carcinoma.

Catherine M. Pichardo, BA, MA University of Illinois at Chicago, Chicago, IL. Abstract 32. Patterns of segregation among diverse Hispanic/Latino adults- implications for cancer prevention.

Gonzalo M. Pinero, PhD, Icahn School of Medicine at Mount Sinai, New York, NY. Abstract 1340. The role of chemokines CCL8 and CCL12 in diffuse intrinsic pontine gliomas.

Stephanie Pitts, BA, John Hopkins University School of Medicine, Baltimore, MD. Abstract 678. Identification of an E3 ligase regulating the catalytic subunit of RNA polymerase I. Oral Presentation.

Gabriel Prado, BS, University of Florida, Gainesville, FL. Abstract 3719. Loss of Kmt2c, of the COMPASS-like complex, cooperates with oncogenic signaling in cancer.

Alvaro Quintanal-Villalonga, BDS, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 658. AKT pathway as a therapeutic target to constrain lineage plasticity leading to histological transdifferentiation. Oral Presentation.

Enrique I. Ramos, PhD, Texas Tech University Health Sciences Center El Paso, El Paso, TX. Abstract 3372. Comprehensive analysis of estrogen-regulated testis specific IncRNAs in breast cancer.
TRAVEL AWARDS

Laura Reyes Uribe, MD, UT MD Anderson Cancer Center, Houston, TX. Abstract 721. Epigenetic intervention in the prevention of Lynch Syndrome Colorectal Cancer.

Angelina Requa, BS, PhD, Wake Forest University School of Medicine, Winston-Salem, NC. Abstract 1039. TrkA and JAK2-STAT3 pathway crosstalk promotes breast cancer stem cells in HER2-enriched and triple-negative breast cancers.

Leslimar Rios Colon, PhD, North Carolina Central University, Durham, NC. Abstract 5822. Leptin modulated microRNA-628-5p targets Jagged1 and inhibits prostate cancer hallmarks.

Evelyn S. Sanchez Hernandez, BS, Loma Linda University, Loma Linda, CA. Abstract 2348. Contribution of the GR/LEDGFp75 axis to prostate cancer chemoresistance.

Mitzy J. Santiago Rosario, BS, MS University of Puerto Rico, San Juan, Puerto Rico. Abstract 2348. Contribution of the GR/LEDGFp75 axis to prostate cancer chemoresistance.

Robert Schauner, BA, Case Western Reserve University School of Medicine, Cleveland, OH. Abstract 4080. New platform for novel biomarker discovery using single-cell RNA sequencing on pediatric acute myeloid leukemia samples.

Marcus Tunde Smith, BS, Meharry Medical College, Nashville, TN. Abstract 3266. The KDM5 inhibitor PBIT reduces proliferation of castration-resistant prostate cancers via the induction of senescence.

Zulaida M. Soto Vargas, BS, Purdue University, West Lafayette, IN. Abstract 1581. Uncovering mechanisms of biogenesis and secretion of small extracellular vesicles in non small cell lung cancer (NSCLC).

Lizeth I. Tamayo, BA, MPH, University of Chicago, Chicago, IL. Abstract 1440. Identifying inherited genetic variation that impacts individuals’ ability to metabolize arsenic and susceptibility to toxicity.

Kristi Tredway, BA, MA, PhD, John Hopkins University, Baltimore, MD. Abstract 3679. A qualitative analysis of coping with genetically exacerbated risk of breast and ovarian cancers among medically-underserved women with BRCA1/2 mutation.


Jason A. White, MS, Tuskegee University, Montgomery, AL. Abstract 1507. Tumor only analysis of whole exome sequencing from a multi-institutional Nigerian prostate cancer cohort reveals DNA repair genes associated with African ancestry.

Tyler J. Woodard, MD, M.Ed, Washington University School of Medicine, St. Louis, MO. Abstract 795. Entinostat restores responsiveness to Olaparib in ID8, TP53, and ID8, TP53, BRCA2 mouse ovarian cancer cell lines.

Maryl J. Wright, BS, Tulane University School of Medicine, New Orleans, LA. Abstract 3831. Utilizing decellularized triple-negative breast cancer patient-derived tumor models as drug testing platforms.

Corey D. Young, BS, MS, Morehouse School of Medicine, Atlanta, GA. Abstract 2950. Coexpression networks of miRNAs and gene transcripts coinciding with lung adenocarcinoma progression and survival.
2022 AACR Women in Cancer Research Scholar Awards

The AACR is pleased to administer this important program, which provides funds for the participation of early-career, meritorious scientists at the AACR Annual Meeting 2022. Scholars are selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees.

Alicia-Marie J. Conway, MBChB. CRUK Manchester Institute, Macclesfield, United Kingdom. Abstract 2808. cfDNA multi-omics profiling and tissue of origin predictions in cancers of unknown primary.

Melody Di Bona, PhD. Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 1589. Unraveling the mechanisms underlying micronuclear rupture, a seminal event in cancer progression.

Li Han, PhD. City of Hope Beckman Research Institute, Duarte, CA. Abstract 3617. METTL16 drives leukemogenesis and maintains leukemia stem cell self-renewal via reprogramming BCAA metabolism. Oral Presentation.

Taghreed Hirz, PhD. Harvard Medical School, Boston, MA. Abstract 2510. An atlas of single-cell and spatial transcriptomics reveals alterations that correlate with human prostate cancer progression.

Deborah Im, BS. University of Southern California, Los Angeles, CA. Abstract 5151. Potential of aqueous humor as a liquid biopsy for uveal melanoma.


Meaghan K. McGeary, BA, M Phil. Yale Graduate School of Arts and Sciences, New Haven, CT. Abstract 1380. Setdb1-loss reactivates ERV expression and interferon signaling to induce immune-mediated melanoma clearance.

Margaret S. Pichardo, MPH, MD, PhD. Howard University, Washington, DC. Abstract 739. Adherence to the lifestyle guidelines among Hispanic/Latino adults vary by physical activity measures.

Jinhua Wu, PhD. Children’s Hospital of Philadelphia, Philadelphia, PA. Abstract 5268. The spectrum of FGFR mutations in pediatric and young adult solid tumor.

AACR-Undergraduate Scholar Awards

The AACR is pleased to announce the recipients of 2022 AACR-Undergraduate Scholar Awards. The primary purpose of these awards is to inspire young science students at the undergraduate level to enter the field of cancer research. The AACR is committed to promoting the education and training of the next generation of dedicated scientists and to facilitating and nurturing their careers in cancer research or cancer related biomedical science. In 2022, the AACR is celebrating 25 years of this award program and continues to
TRAVEL AWARDS

generously provide the funding for these awards. The Board of Directors would like to congratulate this year’s awardees.

2021-2022

Anamika Basa, Washington University in St. Louis, Scottsdale, AZ.

Cort B. Breuer, Cornell University, Wellesley, MA.


Suhas K. Etigunta, University of North Carolina at Chapel Hill, Chapel, NC. Abstract 3507. β-Hydroxy-β-methylbutyrate (HMB) sensitizes murine pancreatic ductal adenocarcinoma (PDAC) to immunotherapy.

Aditi Gnanasekar, University of California, San Diego, La Jolla, CA. Abstract 3528. Influence of obesity-associated intra-tumor microbes on exacerbating cancer severity.

Seayoung Lee, Duke University Durham, NC.

Jane (Minh Ngoc) Pham, Cape Breton University, Sydney, Nova Scotia, Canada.

Suchet Taori, University of Virginia, Charlottesville, VA. Abstract 4205. Staged anti-PD-1 therapy with intratumoral recombinant calreticulin improves anti-tumor immunity and survival in glioblastoma mouse models.

Enrique Trevino, University of Florida, College of Medicine, Gainesville, FL.


2022-2023

Ritu Dave, Washington University in St. Louis, St. Louis, MO. Abstract 168. DDR2 regulates angiogenesis via HSP-90 modulation in ovarian cancer.

Anabella Maria D. Galang, Cornell University, Naples, FL.

Akshay Govindan, Washington University in St. Louis, Saint Louis, MO.

Charlene Mansour, University of Alabama at Birmingham, Birmingham, AL.

Caitlin R. McCabe, Cornell University, Ithaca, NY.


Julia A. Pena, University of Texas at Austin, Austin, TX.


Eric G. Sun, Yale University, New Haven, CT.

Afi H. Tageddji, University of Louisville, Louisville, KY. Abstract 4037. The effects of n-acetyltransferase 1 gene knockout on the cytotoxicity of pyrimidine biosynthesis inhibitors in human breast cancer cells.
Gain actionable insights to accelerate the next generation of precision medicines in oncology

Your multi-omics partner from bench to market

Biomarker Experts
Spatial tissue testing and immuno-oncology expertise to uncover critical biomarkers that may drive effective decision-making

Unique Database
Extensive genomic data based on a whole-transcriptome approach to accelerate your clinical research and identify biomarker signatures

Diagnostic Providers
IVD expertise, CLIA laboratories and global commercial presence to develop, manufacture and distribute your CDx

VISIT US IN-PERSON AND ONLINE AT AACR: BOOTH # 3305
NEW!
A subscription offering for our comprehensive database of biomarkers that are linked to clinical outcome data to help guide your drug development programs

WHY VERACYTE?
• 100+ projects with biopharma companies supporting clinical evidence in oncology
• Deep immuno-oncology expertise
• Global presence

To learn more, contact biopharma@veracyte.com
veracyte.com

Scan the QR code to book a demo today
Shine A Light.

Don't miss Pfizer's presentation in the Patient Partnership in Research Spotlight Theater on Monday, April 11 from 12:30 – 1:30pm CDT.

Leading experts illuminate:

• How and why HCPs can partner with their patients in oncology
• The spectrum and status of patient partnership in oncology research and what it can provide in terms of clinical value
• Key opportunities in this area and next steps for the research community

Introduction and Objectives

An Emerging Science – Making the Case for Patient-Partnered Research: Dr. Neal Shore, MD

Chief Medical Officer, Surgical Oncology and Urology, GenesisCare, US
Medical Director, Carolina Urologic Research Center
Urologist, Atlantic Urology Clinics

A Collaborative Journey – Roadblocks and Opportunities: Sarah Krüg, MS

CEO, Health Collaboratory
Executive Director, CANCER101

Incorporating the Patient Perspective: Tom Bognanno

Patient Expert
Member, Board of Directors, ZERO The End to Prostate Cancer

Panel Q&A and Close